Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists

ABSTRACT

The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a Divisional of U.S. patent application Ser. No.15/776,933, filed May 17, 2018, now allowed, which is the 371 NationalStage of International Application No. PCT/US2016/065504, filed Dec. 8,2016, which claims priority to U.S. Provisional Patent Application U.S.Ser. No. 62/265,885, filed Dec. 10, 2015, hereby incorporated byreference in their entireties.

BACKGROUND OF THE INVENTION

The present invention relates to novel piperidinone compounds, which areformyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1)receptor agonists, compositions containing them, and methods of usingthem, for example, for the treatment of atherosclerosis, heart failure,chronic obstructive pulmonary disease (COPD), and related diseases.

Formyl peptide receptor 2 (FPR2) belongs to a small group ofseven-transmembrane domain, G protein-coupled receptors that areexpressed mainly by mammalian phagocytic leukocytes and are known to beimportant in host defense and inflammation. FPR2 shares significantsequence homology with FPR1 and FPR3. Collectively, these receptors binda number of structurally diverse agonists, including N-formyl andnonformyl peptides which act as chemo attractants and activatephagocytes. The endogenous peptide Annexin A1 and its N-terminalfragments also bind human FPR1 and FPR2. Importantly, eicosanoid lipoxinA4, which belongs to a class of small pro-resolution mediators (SPMs),has been identified as a specific agonist for FPR2 (Ye R D., et al.,Pharmacol. Rev., 2009, 61, 119-61).

Endogenous FPR2 pro-resolution ligands, such as lipoxin A₄ and AnnexinA1 bind to the receptor triggering a wide array of cytoplasmaticcascades such as Gi coupling, Ca²⁺ mobilization and β-arrestinrecruitment. Activation of FPR2 by lipoxin A₄ modifies the effects ofpeptidic agonists, such as serum amyloid A (SAA), and has alternativeeffects on phosphorylation pathways depending on the cell type. Lipoxinsregulate components of both innate and adaptive immune systems includingneutrophils, macrophages, T-, and B-cells. In neutrophils, lipoxinsmodulate movement, cytotoxicity and life span. In macrophages, lipoxinsprevent apoptosis and enhance efferocytosis. In most inflammatory cells,lipoxins also down-regulate expression of several pro-inflammatorycytokines, such as IL-6, IL-1β and IL-8 as well as up-regulateexpression of anti-inflammatory cytokine IL-10 (Chandrasekharan J A,Sharma-Walia N, J. Inflamm. Res., 2015, 8, 181-92). The primary effectsof lipoxin on neutrophils and macrophages are termination ofinflammation and initiation of resolution of inflammation. The latter isprimarily responsible for enhancing anti-fibrotic wound healing andreturning of the injured tissue to homeostasis (Romano M., et al., Eur.J. Pharmacol., 2015, 5, 49-63).

Chronic inflammation is part of the pathway of pathogenesis of manyhuman diseases and stimulation of resolution pathways with FPR2 agonistsmay have both protective and reparative effects. Ischaemia-reperfusion(I/R) injury is a common feature of several diseases associated withhigh morbidity and mortality, such as myocardial infarction and stroke.Non-productive wound healing associated with cardiomyocyte death andpathological remodeling resulting from ischemia-reperfusion injury leadsto scar formation, fibrosis, and progressive loss of heart function.FPR2 modulation is proposed to enhance myocardial wound healing postinjury and diminish adverse myocardial remodeling (Kain V., et al., J.Mol. Cell. Cardiol., 2015, 84, 24-35). In addition, FPR2 pro-resolutionagonists, in the central nervous system, may be useful therapeutics forthe treatment of a variety of clinical I/R conditions, including strokein brain (Gavins F N., Trends Pharmacol. Sci., 2010, 31, 266-76) and I/Rinduced spinal cord injury (Liu Z Q., et al., Int. J. Clin. Exp. Med.,2015, 8, 12826-33).

In addition to beneficial effects of targeting the FPR2 receptor withnovel pro-resolution agonists for treatment of I/R induced injurytherapeutic, utility of these ligands can also be applied to otherdiseases. In the cardiovascular system both the FPR2 receptor and itspro-resolution agonists were found to be responsible foratherogenic-plaque stabilization and healing (Petri M H., et al.,Cardiovasc. Res., 2015, 105, 65-74; and Fredman G., et al., Sci. Trans.Med., 2015, 7(275); 275ra20). FPR2 agonists also have been shown to bebeneficial in preclinical models of chronic inflammatory human diseases,including: infectious diseases, psoriasis, dermatitis, occularinflammation, sepsis, pain, metabolic/diabetes diseases, cancer, COPD,asthma and allergic diseases, cystic fibrosis, acute lung injury andfibrosis, rheumatoid arthritis and other joint diseases, Alzheimer'sdisease, kidney fibrosis, and organ transplantation (Romano M., et al.,Eur. J. Pharmacol., 2015, 5, 49-63, Perrett, M., et al., Trends inPharm. Sci., 2015, 36, 737-755).

DESCRIPTION OF THE INVENTION

The invention encompasses compounds of formula I, which are formylpeptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1)receptor agonists, compositions containing them, and methods of usingthem, for example, in the treatment of atherosclerosis, heart failure,chronic obstructive pulmonary disease (COPD), and related diseases.

One aspect of the invention is a compound of formula I

where:

Ar¹ is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl,furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl,oxazolyl, thiazolyl, triazinyl, oxadiazolyl, thiadiazolyl, orbenzodioxyl, and is substituted with 1-3 substituents selected fromcyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, and SO₂R⁶;

Ar² is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, or pyrazinyl, and issubstituted with 0-3 substituents selected from cyano, halo, alkyl,haloalkyl, alkoxy, and haloalkoxy;

Ar³ is aryl or heteroaryl, and is substituted with 0-3 substituentsselected from cyano, halo, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl,(NR¹R²)alkyl, (CO₂R³)alkyl, (CONR⁴R⁵)alkyl, (SO₂R⁶)alkyl, hydroxy,alkoxy, haloalkoxy, cycloalkoxy, NR¹R², CO₂R³, CONR⁴R⁵, SO₂R⁶, oxo,aryl, and heteroaryl;

R¹ is hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, orhaloalkylsulfonyl;

R² is hydrogen or alkyl;

or NR¹R² taken together is selected from azetidinyl, pyrrolidinyl,piperidinyl, piperazinyl, and morpholinyl, and is substituted with 0-3substituents selected from halo, alkyl, haloalkyl, alkoxy, andhaloalkoxy; and

R³ is alkyl or haloalkyl;

R⁴ is hydrogen, alkyl, or (R⁷R⁸N)alkyl;

R⁵ is hydrogen or alkyl;

or NR⁴R⁵ taken together is selected from azetidinyl, pyrrolidinyl,piperidinyl, piperazinyl, and morpholinyl, and is substituted with 0-3substituents selected from halo, alkyl, haloalkyl, alkoxy, andhaloalkoxy;

R⁶ is alkyl or R⁷R⁸N;

R⁷ is hydrogen or alkyl;

R⁸ is hydrogen or alkyl;

or NR⁷R⁸ taken together is selected from azetidinyl, pyrrolidinyl,piperidinyl, piperazinyl, and morpholinyl, and is substituted with 0-3substituents selected from halo, alkyl, haloalkyl, alkoxy, andhaloalkoxy; and

X is hydrogen, halo, hydroxy, or alkoxy;

or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a compound of formula I where:

Ar¹ is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl,furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl,oxazolyl, thiazolyl, triazinyl, oxadiazolyl, thiadiazolyl, orbenzodioxyl, and is substituted with 1-3 substituents selected fromcyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, and SO₂R⁶;

Ar² is phenyl or pyridinyl substituted with 0-3 substituents selectedfrom cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;

Ar³ is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl,pyridinonyl, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl,isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazinyl, oxadiazolyl,thiadiazolyl, or benzodioxyl and is substituted with 0-3 substituentsselected from cyano, halo, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl,(NR¹R²)alkyl, hydroxy, alkoxy, haloalkoxy, cycloalkoxy, NR¹R², CO₂R³,CONR⁴R⁵, and SO₂R⁶;

R¹ is hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, orhaloalkylsulfonyl;

R² is hydrogen or alkyl;

or NR¹R² taken together is selected from azetidinyl, pyrrolidinyl,piperidinyl, piperazinyl, and morpholinyl, and is substituted with 0-3substituents selected from halo, alkyl, haloalkyl, alkoxy, andhaloalkoxy;

R³ is hydrogen or alkyl;

R⁴ is hydrogen, alkyl, or (R⁷R⁸N)alkyl;

R⁵ is hydrogen or alkyl;

or NR⁴R⁵ taken together is selected from azetidinyl, pyrrolidinyl,piperidinyl, piperazinyl, and morpholinyl, and is substituted with 0-3substituents selected from halo, alkyl, haloalkyl, alkoxy, andhaloalkoxy;

R⁶ is alkyl or R⁷R⁸N;

R⁷ is hydrogen or alkyl;

R⁸ is hydrogen or alkyl;

or NR⁷R⁸ taken together is selected from azetidinyl, pyrrolidinyl,piperidinyl, piperazinyl, and morpholinyl, and is substituted with 0-3substituents selected from halo, alkyl, haloalkyl, alkoxy, andhaloalkoxy; and

X is hydrogen, halo, hydroxy, or alkoxy;

or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a compound of formula I where Ar¹ isphenyl, pyridinyl, pyridazinyl, thiazolyl, or benzodioxoyl and issubstituted with 1-3 substituents selected from cyano, halo, alkyl,haloalkyl, alkoxy, haloalkoxy, and alkylthio; Ar² is phenyl or pyridinyland is substituted with 0-3 substituents selected from cyano and halo;Ar³ is phenyl, pyridinyl, pyrimidinyl, pyridinonyl, thienyl, pyrazolyl,isoxazolyl, benzodioxoyl, and is substituted with 0-3 substituentsselected from cyano, halo, alkyl, haloalkyl, hydroxyalkyl, (NR¹R²)alkyl,alkoxy, haloalkoxy, NR¹R², CO₂R³, CONR⁴R⁵, and SO₂R⁶.

Another aspect of the invention is a compound of formula I where Ar¹ isphenyl or pyridinyl and is substituted with 1-3 substituents selectedfrom halo, alkyl, haloalkyl, alkoxy, haloalkoxy or alkylthio.

Another aspect of the invention is a compound of formula I where Ar¹ isphenyl or pyridinyl and is -1,4-substituted with 1 halo, alkyl,haloalkyl, alkoxy, haloalkoxy or alkylthio substituent with respect tothe nitrogen attached to Ar¹ and also substituted with 0-2 fluorosubstituents.

Another aspect of the invention is a compound of formula I where Ar² isphenyl or pyridinyl and is substituted with 0-3 substituents selectedfrom cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy.

Another aspect of the invention is a compound of formula I where Ar² is-1,4-substituted with respect to the nitrogen and the Ar³ to which it isattached.

Another aspect of the invention is a compound of formula I where Ar² isphenyl or pyridinyl and is -1,4-substituted with respect to the nitrogenand the Ar³ to which it is attached and is substituted with 0-3substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, andhaloalkoxy.

Another aspect of the invention is a compound of formula I where Ar² isphenyl or pyridinyl and is -1,4-substituted with respect to the nitrogenand the Ar³ to which it is attached and is substituted with 0-3substituents selected from cyano and halo.

Another aspect of the invention is a compound of formula I where Ar³ isphenyl, pyridinyl, pyrimidinyl, pyridinonyl, thienyl, pyrazolyl,isoxazolyl, benzodioxoyl, and is substituted with 0-3 substituentsselected from cyano, halo, alkyl, haloalkyl, hydroxyalkyl, (NR¹R²)alkyl,alkoxy, haloalkoxy, NR¹R², CO₂R³, CONR⁴R⁵, and SO₂R⁶.

Another aspect of the invention is a compound of formula I where Ar³ isphenyl, pyridinyl, pyrimidinyl, pyridinonyl, thienyl, pyrazolyl,isoxazolyl, benzodioxoyl, and is substituted with 0-3 substituentsselected from cyano, halo, alkyl, haloalkyl, hydroxyalkyl, (NR¹R²)alkyl,alkoxy, haloalkoxy, NR¹R², CO₂R³, CONR⁴R⁵, and SO₂R⁶.

Another aspect of the invention is a compound of formula I where Ar³ isphenyl or pyridinyl and is substituted with 0-3 substituents selectedfrom cyano, halo, alkyl, haloalkyl, hydroxyalkyl, (NR¹R²)alkyl, alkoxy,haloalkoxy, NR¹R², CO₂R³, CONR⁴R⁵, and SO₂R⁶.

Another aspect of the invention is a compound of formula I where X ishydrogen.

Another aspect of the invention is a compound of formula I where X ishalo or hydroxy.

For a compound of Formula I, the scope of any instance of a variablesubstituent, including R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, X, Ar¹, Ar², andAr³ can be used independently with the scope of any other instance of avariable substituent. As such, the invention includes combinations ofthe different aspects.

Unless specified otherwise, these terms have the following meanings.“Alkyl” means a straight or branched alkyl group composed of 1 to 6carbons. “Alkenyl” means a straight or branched alkyl group composed of2 to 6 carbons with at least one double bond. “Alkynyl” means a straightor branched alkyl group composed of 2 to 6 carbons with at least onetriple bond. “Cycloalkyl” means a monocyclic ring system composed of 3to 7 carbons. Terms with a hydrocarbon moiety (e.g. alkoxy) includestraight and branched isomers for the hydrocarbon portion. “Halo”includes fluoro, chloro, bromo, and iodo. “Haloalkyl” and “haloalkoxy”include all halogenated isomers from monohalo to perhalo “Aryl” means amonocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbonatoms, or a bicyclic fused ring system wherein one or both of the ringsis aromatic. Bicyclic fused ring systems consist of a phenyl group fusedto a four- to seven-membered aromatic or non-aromatic carbocyclic ring.Representative examples of aryl groups include but are not limited tophenyl, indanyl, indenyl, naphthyl, and tetrahydronaphthyl. “Heteroaryl”means a 5 to 7 membered monocyclic or 8 to 11 membered bicyclic aromaticring system with 1-5 heteroatoms independently selected from nitrogen,oxygen, and sulfur. Where a bonding attachment location is notspecified, the bonding may be attached at any appropriate location asunderstood by practitioners in the art. Combinations of substituents andbonding patterns are only those that result in stable compounds asunderstood by practitioners in the art. Parenthetic and multiparentheticterms are intended to clarify bonding relationships to those skilled inthe art. For example, a term such as ((R)alkyl) means an alkylsubstituent further substituted with the substituent R.

Heteroaryl includes N-substituted pyridinonyl:

The invention includes all pharmaceutically acceptable salt forms of thecompounds. Pharmaceutically acceptable salts are those in which thecounter ions do not contribute significantly to the physiologicalactivity or toxicity of the compounds and as such function aspharmacological equivalents. These salts can be made according to commonorganic techniques employing commercially available reagents. Someanionic salt forms include acetate, acistrate, besylate, bromide,chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride,hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate,phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Somecationic salt forms include ammonium, aluminum, benzathine, bismuth,calcium, choline, diethylamine, diethanolamine, lithium, magnesium,meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium,tromethamine, and zinc.

Some of the compounds of the invention exist in stereoisomeric formsincluding the structure below with the indicated carbon. The inventionincludes all stereoisomeric forms of the compounds including enantiomersand diastereomers. Methods of making and separating stereoisomers areknown in the art. The invention includes all tautomeric forms of thecompounds. The invention includes atropisomers and rotational isomers.

The invention is intended to include all isotopes of atoms occurring inthe compounds. Isotopes include those atoms having the same atomicnumber but different mass numbers. By way of general example and withoutlimitation, isotopes of hydrogen include deuterium and tritium. Isotopesof carbon include ¹³C and ¹⁴C. Isotopically-labeled compounds of theinvention can generally be prepared by conventional techniques known tothose skilled in the art or by processes analogous to those describedherein, using an appropriate isotopically-labeled reagent in place ofthe non-labeled reagent otherwise employed. Such compounds may have avariety of potential uses, for example as standards and reagents indetermining biological activity. In the case of stable isotopes, suchcompounds may have the potential to favorably modify biological,pharmacological, or pharmacokinetic properties.

Biological Methods

N-formyl peptide receptors (FPRs) are a family of chemo attractantreceptors that facilitate leukocyte response during inflammation. FPRsbelong to the seven-transmembrane G protein-coupled receptor superfamilyand are linked to inhibitory G-proteins (Gi). Three family members(FPR1, FPR2 and FPR3) have been identified in humans and arepredominantly found in myeloid cells with varied distribution and havealso been reported in multiple organs and tissues. After agonistbinding, the FPRs activate a multitude of physiological pathways, suchas intra cellular signaling transduction, Ca²⁺ mobilization andtranscription. The family interacts with a diverse set of ligands thatincludes proteins, polypeptides and fatty acid metabolites whichactivate both pro-inflammatory and pro-resolution downstream responses.

The FPR2 receptor binds multiple ligands to invoke both inflammatory andanti-inflammatory responses. Inflammation mediator release by FPR2 hasbeen reported to be promoted by endogenous protein ligands such as Serumamyloid A (SAA) and Amyloid β (1-42), whereas resolution of inflammationis induced by ligands that include arachidonic acid metabolites, lipoxinA4 (LXA4) and Epi-lipoxin (ATL), and a docosahexenoic acid metabolite,resolvin D1 (RvD1). The pro-resolving fatty acid metabolites mediateinhibition and resolution of inflammation through the FPR2 receptor bystimulating phagocytosis of apototic neutrophils by macrophages. Removalof the apototic neutrophils induce the release of cytokines thatactivate pro-resolution pathways.

The FPR1 receptor was originally isolated as a high affinity receptorfor N-Formylmethionine containing peptides, such asN-Formylmethionine-leucyl-phenylalanine (FMLP). The protein directsmammalian phagocytic and blood leukocyte cells to sites of invadingpathogens or inflamed tissues and activates these cells to killpathogens or to remove cellular debris.

FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture offorskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μMfinal) were added to 384-well Proxiplates (Perkin-Elmer) pre-dotted withtest compounds in DMSO (1% final) at final concentrations in the rangeof 0.020 nM to 100 μM. Chinese Hamster Ovary cells (CHO) overexpressinghuman FPR1 or human FPR2 receptors were cultured in F-12 (Ham's) mediumsupplemented with 10% qualified FBS, 250 μg/ml zeocin and 300 μg/mlhygromycin (Life Technologies). Reactions were initiated by adding 2,000human FPR2 cells per well or 4,000 human FPR1 cells per well inDulbecco's PBS (with calcium and magnesium) (Life Technologies)supplemented with 0.1% BSA (Perkin-Elmer). The reaction mixtures wereincubated for 30 min at room temperature. The level of intracellularcAMP was determined using the HTRF HiRange cAMP assay reagent kit(Cisbio) according to manufacturer's instruction. Solutions of cryptateconjugated anti-cAMP and d2 flurorophore-labelled cAMP were made in asupplied lysis buffer separately. Upon completion of the reaction, thecells were lysed with equal volume of the d2-cAMP solution and anti-cAMPsolution. After a 1-h room temperature incubation, time-resolvedfluorescence intensity was measured using the Envision (Perkin-Elmer) at400 nm excitation and dual emission at 590 nm and 665 nm. A calibrationcurve was constructed with an external cAMP standard at concentrationsranging from 1 μM to 0.1 pM by plotting the fluorescent intensity ratiofrom 665 nm emission to the intensity from the 590 nm emission againstcAMP concentrations. The potency and activity of a compound to inhibitcAMP production was then determined by fitting to a 4-parametriclogistic equation from a plot of cAMP level versus compoundconcentrations.

The examples disclosed below were tested in the FPR2 and FPR1 cAMP assaydescribed above and found having FPR2 and/or FPR1 agonist activity. Arange of IC₅₀ values of ≤1 μM (1000 nM) in one of the assays wasobserved. Table 1 below lists EC₅₀ values in the FPR2 and FPR1 cAMPassays measured for the following examples.

TABLE 1 hFPR2 cAMP2 hFPR1 cAMP Example EC50 (uM) EC50 (uM) 15 0.00840.20 16 0.0093 0.39 17 0.010 0.17 26 0.38 0.21 27 0.40 0.95 28 0.56 1.236 0.0097 0.28 47 0.33 1.6 48 0.56 0.93 49 0.85 2.1 58 0.0092 0.28 660.00032 0.10 76 0.00081 0.010 77 0.00068 0.0088 78 0.00089 0.042 820.011 0.014 86 0.00014 0.032 125 0.0090 0.33 129 0.0094 0.17 139 0.0100.15 145 0.00036 0.015 166 0.0080 0.33 174 0.45 0.90 175 0.52 2.6 1760.78 1.2 177 0.84 1.7 183 0.00046 0.00056 184 0.0081 1.5 188 0.000130.025 197 0.00076 0.22 199 0.00028 0.14

The following Examples were tested in the hFPR2 Assay described aboveand found having hFPR2 agonist activity with EC₅₀ values of ≤0.005 μM (5nM): 1, 4, 5, 6, 7, 8, 9, 10, 11, 12, 29, 30, 31, 33, 51, 54, 56, 57,61, 67, 68, 69, 70, 72, 79, 80, 81, 88, 91, 93, 98, 105, 106, 107, 108,109, 111, 112, 113, 115, 116, 118, 121, 122, 133, 136, 137, 138, 141,143, 146, 150, 151, 152, 154, 155, 163, 164, 165, 168, 171, 172, 173,182, 186, 187, 190, 191, 194, 196, 202, 206, 207, and 210.

The following Examples were tested in the hFPR2 Assay described aboveand found having hFPR2 agonist activity with EC₅₀ values between 0.005μM and 0.040 μM: 2, 13, 14, 18, 19, 20, 32, 34, 35, 37, 38, 39, 52, 55,59, 63, 64, 71, 73, 74, 83, 84, 85, 89, 92, 96, 97, 102, 103, 104, 110,114, 119, 120, 123, 124, 128, 131, 132, 135, 140, 142, 149, 156, 158,167, 169, 178, 185, 192, 193, 195, 198, 200, 201, 203, 204, 205, 208,and 209.

The following Examples were tested in the hFPR2 Assay described aboveand found having hFPR2 agonist activity with EC₅₀ values between 0.04 μMand 1 μM: 3, 21, 22, 23, 24, 25, 40, 41, 42, 43, 44, 45, 46, 50, 53, 60,62, 65, 75, 87, 90, 94, 95, 99, 100, 101, 117, 126, 127, 130, 134, 144,147, 148, 157, 159, 160, 161, 162, 170, 179, 180, 181, and 189.

Pharmaceutical Compositions and Methods of Use

The compounds of the present invention may be administered to mammals,preferably humans, for the treatment of a variety of conditions anddisorders including atherosclerosis, heart failure, lung diseasesincluding asthma, COPD, and cystic fibrosis; neuroinflammatory diseasesincluding multiple sclerosis, Alzheimer's disease, and stroke; andchronic inflammatory diseases such as inflammatory bowel disease,rheumatoid arthritis, psoriasis, sepsis, and kidney fibrosis.

Unless otherwise specified, the following terms have the statedmeanings. The term “subject” refers to any human or other mammalianspecies that could potentially benefit from treatment with a FPR2 and/orFPR1 agonist as understood by practioners in this field. Some subjectsinclude human beings of any age with risk factors for cardiovasculardisease. Common risk factors include age, sex, weight, family history,sleep apnea, alcohol or tobacco use, physical inactivity arrthymia orsigns of insulin resistance such as acanthosis nigricans, hypertension,dyslipidemia, or polycystic ovary syndrome (PCOS). The term “patient”means a person suitable for therapy as determined by practitioners inthe field. “Treating” or “treatment” cover the treatment of a patient orsubject as understood by practitioners in this field. “Preventing” or“prevention” cover the preventive treatment (i.e., prophylaxis and/orrisk reduction) of a subclinical disease-state in a patient or subjectaimed at reducing the probability of the occurrence of a clinicaldisease-state as understood by practitioners in this field. Patients areselected for preventative therapy based on factors that are known toincrease risk of suffering a clinical disease state compared to thegeneral population. “Therapeutically effective amount” means an amountof a compound that is effective as understood by practitioners in thisfield.

Another aspect of the invention are pharmaceutical compositionscomprising a therapeutically effective amount of a compound of formula Iin combination with a pharmaceutical carrier.

Another aspect of the invention are pharmaceutical compositionscomprising a therapeutically effective amount of a compound of formula Iin combination with at least one other therapeutic agent and apharmaceutical carrier.

“Pharmaceutical composition” means a composition comprising a compoundof the invention in combination with at least one additionalpharmaceutically acceptable carrier. A “pharmaceutically acceptablecarrier” refers to media generally accepted in the art for the deliveryof biologically active agents to animals, in particular, mammals,including, i.e., adjuvant, excipient or vehicle, such as diluents,preserving agents, fillers, flow regulating agents, disintegratingagents, wetting agents, emulsifying agents, suspending agents,sweetening agents, flavoring agents, perfuming agents, anti-bacterialagents, anti-fungal agents, lubricating agents and dispensing agents,depending on the nature of the mode of administration and dosage forms.

Pharmaceutically acceptable carriers are formulated according to anumber of factors well within the purview of those of ordinary skill inthe art. These include, without limitation: the type and nature of theactive agent being formulated; the subject to which the agent-containingcomposition is to be administered; the intended route of administrationof the composition; and the therapeutic indication being targeted.Pharmaceutically acceptable carriers include both aqueous andnon-aqueous liquid media, as well as a variety of solid and semi-soliddosage forms. Such carriers can include a number of differentingredients and additives in addition to the active agent, suchadditional ingredients being included in the formulation for a varietyof reasons, e.g., stabilization of the active agent, binders, etc., wellknown to those of ordinary skill in the art. Descriptions of suitablepharmaceutically acceptable carriers, and factors involved in theirselection, are found in a variety of readily available sources such as,for example, Allen, L. V., Jr. et al., Remington: The Science andPractice of Pharmacy (2 Volumes), 22nd Edition, Pharmaceutical Press(2012).

Particularly when provided as a single dosage unit, the potential existsfor a chemical interaction between the combined active ingredients. Forthis reason, when the compound of the present invention and a secondtherapeutic agent are combined in a single dosage unit they areformulated such that although the active ingredients are combined in asingle dosage unit, the physical contact between the active ingredientsis minimized (that is, reduced). For example, one active ingredient maybe enteric coated. By enteric coating one of the active ingredients, itis possible not only to minimize the contact between the combined activeingredients, but also, it is possible to control the release of one ofthese components in the gastrointestinal tract such that one of thesecomponents is not released in the stomach but rather is released in theintestines. One of the active ingredients may also be coated with amaterial that affects a sustained-release throughout thegastrointestinal tract and also serves to minimize physical contactbetween the combined active ingredients. Furthermore, thesustained-released component can be additionally enteric coated suchthat the release of this component occurs only in the intestine. Stillanother approach would involve the formulation of a combination productin which the one component is coated with a sustained and/or entericrelease polymer, and the other component is also coated with a polymersuch as a low viscosity grade of hydroxypropyl methylcellulose (HPMC) orother appropriate materials as known in the art, in order to furtherseparate the active components. The polymer coating serves to form anadditional barrier to interaction with the other component.

Another aspect of the invention is a method for treating heart diseasecomprising administering a therapeutically effective amount of acompound of formula I to a patient.

Another aspect of the invention is a method for treating heart diseasewherein the heart disease is selected from the group consisting ofangina pectoris, unstable angina, myocardial infarction, heart failure,acute coronary disease, acute heart failure, chronic heart failure, andcardiac iatrogenic damage.

Another aspect of the invention is a method for treating heart diseasewherein the treatment is post myocardial infarction.

Another aspect of the invention is a method for treating heart diseasecomprising administering a therapeutically effective amount of acompound of formula I to a patient in conjuction with other therapeuticagents.

The compounds of this invention can be administered by any suitablemeans, for example, orally, such as tablets, capsules (each of whichincludes sustained release or timed release formulations), pills,powders, granules, elixirs, tinctures, suspensions (includingnanosuspensions, microsuspensions, spray-dried dispersions), syrups, andemulsions; sublingually; bucally; parenterally, such as by subcutaneous,intravenous, intramuscular, or intrasternal injection, or infusiontechniques (e.g., as sterile injectable aqueous or non-aqueous solutionsor suspensions); nasally, including administration to the nasalmembranes, such as by inhalation spray; topically, such as in the formof a cream or ointment; or rectally such as in the form ofsuppositories. They can be administered alone, but generally will beadministered with a pharmaceutical carrier selected on the basis of thechosen route of administration and standard pharmaceutical practice.

The dosage regimen for the compounds of the present invention will, ofcourse, vary depending upon known factors, such as the pharmacodynamiccharacteristics of the particular agent and its mode and route ofadministration; the species, age, sex, health, medical condition, andweight of the recipient; the nature and extent of the symptoms; the kindof concurrent treatment; the frequency of treatment; the route ofadministration, the renal and hepatic function of the patient, and theeffect desired.

By way of general guidance, the daily oral dosage of each activeingredient, when used for the indicated effects, will range betweenabout 0.01 to about 5000 mg per day, preferably between about 0.1 toabout 1000 mg per day, and most preferably between about 0.1 to about250 mg per day. Intravenously, the most preferred doses will range fromabout 0.01 to about 10 mg/kg/minute during a constant rate infusion.Compounds of this invention may be administered in a single daily dose,or the total daily dosage may be administered in divided doses of two,three, or four times daily.

Dosage forms (pharmaceutical compositions) suitable for administrationmay contain from about 1 milligram to about 2000 milligrams of activeingredient per dosage unit. In these pharmaceutical compositions theactive ingredient will ordinarily be present in an amount of about0.1-95% by weight based on the total weight of the composition. Atypical capsule for oral administration contains at least one of thecompounds of the present invention (250 mg), lactose (75 mg), andmagnesium stearate (15 mg). The mixture is passed through a 60 meshsieve and packed into a No. 1 gelatin capsule. A typical injectablepreparation is produced by aseptically placing at least one of thecompounds of the present invention (250 mg) into a vial, asepticallyfreeze-drying and sealing. For use, the contents of the vial are mixedwith 2 mL of physiological saline, to produce an injectable preparation.

The compounds of the present invention may be employed in combinationwith other suitable therapeutic agents useful in the treatment of theaforementioned diseases or disorders including: anti-atheroscleroticagents, anti-dyslipidemic agents, anti-diabetic agents,anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-thromboticagents, anti-retinopathic agents, anti-neuropathic agents,anti-nephropathic agents, anti-ischemic agents, anti-hypertensiveagents, anti-obesity agents, anti-hyperlipidemic agents,anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents,anti-restenotic agents, anti-pancreatic agents, lipid lowering agents,anorectic agents, memory enhancing agents, anti-dementia agents,cognition promoting agents, appetite suppressants, agents for treatingheart failure, agents for treating peripheral arterial disease, agentsfor treating malignant tumors, and anti-inflammatory agents.

The compounds of the invention may be used with at least one of thefollowing heart failure agents selected from loop diuretics, Angiotensinconverting enzyme (ACE) inhibitors, Angiotensin II receptor blockers(ARBs), angiotensin receptor-neprilysin inhibitors (ARNI), betablockers, mineralocorticoid receptor antagonists, nitroxyl donors, RXFP1agonists, APJ agonists and cardiotonic agents. These agents include, butare not limited to furosemide, bumetanide, torsemide,sacubitrial-valsartan, thiazide diruetics, captopril, enalapril,lisinopril, carvedilol, metopolol, bisoprolol, serelaxin,spironolactone, eplerenone, ivabradine, candesartan, eprosartan,irbestarain, losartan, olmesartan, telmisartan, and valsartan.

The compounds of the present invention may be employed in combinationwith at least one of the following therapeutic agents in treatingatherosclerosis: anti-hyperlipidemic agents, plasma HDL-raising agents,anti-hyperchol esterolemic agents, cholesterol biosynthesis inhibitors(such as HMG CoA reductase inhibitors), LXR agonist, probucol,raloxifene, nicotinic acid, niacinamide, cholesterol absorptioninhibitors, bile acid sequestrants (such as anion exchange resins, orquaternary amines (e.g., cholestyramine or colestipol)), low densitylipoprotein receptor inducers, clofibrate, fenofibrate, benzofibrate,cipofibrate, gemfibrizol, vitamin B₆, vitamin B₁₂, anti-oxidantvitamins, β-blockers, anti-diabetes agents, angiotensin II antagonists,angiotensin converting enzyme inhibitors, platelet aggregationinhibitors, fibrinogen receptor antagonists, aspirin and fibric acidderivatives.

The compounds of the present invention may be employed in combination atleast one of the following therapeutic agents in treating cholesterolbiosynthesis inhibitor, particularly an HMG-CoA reductase inhibitor.Examples of suitable HMG-CoA reductase inhibitors include, but are notlimited to, lovastatin, simvastatin, pravastatin, fluvastatin,atorvastatin, and rosuvastatin.

The compounds of the invention may be used in combination with at leastone of the following anti-diabetic agents depending on the desiredtarget therapy. Studies indicate that diabetes and hyperlipidemiamodulation can be further improved by the addition of a second agent tothe therapeutic regimen. Examples of anti-diabetic agents include, butare not limited to, sulfonylureas (such as chlorpropamide, tolbutamide,acetohexamide, tolazamide, glyburide, gliclazide, glynase, glimepiride,and glipizide), biguanides (such as metformin), thiazolidinediones (suchas ciglitazone, pioglitazone, troglitazone, and rosiglitazone), andrelated insulin sensitizers, such as selective and non-selectiveactivators of PPARα, PPARβ and PPARγ; dehydroepiandrosterone (alsoreferred to as DHEA or its conjugated sulphate ester, DHEA-SO₄);anti-glucocorticoids; TNFα inhibitors; dipeptidyl peptidase IV (DPP4)inhibitor (such as sitagliptin, saxagliptin), GLP-1 agonists or analogs(such as exenatide), α-glucosidase inhibitors (such as acarbose,miglitol, and voglibose), pramlintide (a synthetic analog of the humanhormone amylin), other insulin secretagogues (such as repaglinide,gliquidone, and nateglinide), insulin, as well as the therapeutic agentsdiscussed above for treating atherosclerosis.

The compounds of the invention may be used in combination with at leastone of the following anti-obesity agents selected fromphenylpropanolamine, phentermine, diethylpropion, mazindol,fenfluramine, dexfenfluramine, phentiramine, β₃-adrenoreceptor agonistagents; sibutramine, gastrointestinal lipase inhibitors (such asorlistat), and leptins. Other agents used in treating obesity orobesity-related disorders include neuropeptide Y, enterostatin,cholecytokinin, bombesin, amylin, histamine H₃ receptors, dopamine D₂receptor modulators, melanocyte stimulating hormone, corticotrophinreleasing factor, galanin and gamma amino butyric acid (GABA).

The compounds of the present invention are also useful as standard orreference compounds, for example as a quality standard or control, intests or assays involving the FPR2. Such compounds may be provided in acommercial kit, for example, for use in pharmaceutical researchinvolving FPR2 activity. For example, a compound of the presentinvention could be used as a reference in an assay to compare its knownactivity to a compound with an unknown activity. This would ensure theexperimenter that the assay was being performed properly and provide abasis for comparison, especially if the test compound was a derivativeof the reference compound. When developing new assays or protocols,compounds according to the present invention could be used to test theireffectiveness. The compounds of the present invention may also be usedin diagnostic assays involving FPR2.

The present invention also encompasses an article of manufacture. Asused herein, article of manufacture is intended to include, but not belimited to, kits and packages. The article of manufacture of the presentinvention, comprises: (a) a first container; (b) a pharmaceuticalcomposition located within the first container, wherein the composition,comprises a first therapeutic agent, comprising a compound of thepresent invention or a pharmaceutically acceptable salt form thereof;and, (c) a package insert stating that the pharmaceutical compositioncan be used for the treatment of dyslipidemias and the sequelae thereof.In another embodiment, the package insert states that the pharmaceuticalcomposition can be used in combination (as defined previously) with asecond therapeutic agent for the treatment of dyslipidemias and thesequelae thereof. The article of manufacture can further comprise: (d) asecond container, wherein components (a) and (b) are located within thesecond container and component (c) is located within or outside of thesecond container. Located within the first and second containers meansthat the respective container holds the item within its boundaries. Thefirst container is a receptacle used to hold a pharmaceuticalcomposition. This container can be for manufacturing, storing, shipping,and/or individual/bulk selling. First container is intended to cover abottle, jar, vial, flask, syringe, tube (e.g., for a cream preparation),or any other container used to manufacture, hold, store, or distribute apharmaceutical product. The second container is one used to hold thefirst container and, optionally, the package insert. Examples of thesecond container include, but are not limited to, boxes (e.g., cardboardor plastic), crates, cartons, bags (e.g., paper or plastic bags),pouches, and sacks. The package insert can be physically attached to theoutside of the first container via tape, glue, staple, or another methodof attachment, or it can rest inside the second container without anyphysical means of attachment to the first container. Alternatively, thepackage insert is located on the outside of the second container. Whenlocated on the outside of the second container, it is preferable thatthe package insert is physically attached via tape, glue, staple, oranother method of attachment. Alternatively, it can be adjacent to ortouching the outside of the second container without being physicallyattached. The package insert is a label, tag, marker, etc. that recitesinformation relating to the pharmaceutical composition located withinthe first container. The information recited will usually be determinedby the regulatory agency governing the area in which the article ofmanufacture is to be sold (e.g., the United States Food and DrugAdministration). Preferably, the package insert specifically recites theindications for which the pharmaceutical composition has been approved.The package insert may be made of any material on which a person canread information contained therein or thereon. Preferably, the packageinsert is a printable material (e.g., paper, plastic, cardboard, foil,adhesive-backed paper or plastic, etc.) on which the desired informationhas been formed (e.g., printed or applied).

Chemistry Methods

Abbreviations as used herein, are defined as follows: “1×” for once,“2×” for twice, “3×” for thrice, “° C.” for degrees Celsius, “aq” foraqueous, “Col” for column, “eq” for equivalent or equivalents, “g” forgram or grams, “mg” for milligram or milligrams, “L” for liter orliters, “mL” for milliliter or milliliters, “L” for microliter ormicroliters, “N” for normal, “M” for molar, “nM” for nanomolar, “mol”for mole or moles, “mmol” for millimole or millimoles, “min” for minuteor minutes, “h” for hour or hours, “rt” for room temperature, “RT” forretention time, “ON” for overnight, “atm” for atmosphere, “psi” forpounds per square inch, “conc.” for concentrate, “aq” for “aqueous”,“sat” or “sat'd” for saturated, “MW” for molecular weight, “mw” or“awave” for microwave, “mp” for melting point, “Wt” for weight, “MS” or“Mass Spec” for mass spectrometry, “ESI” for electrospray ionizationmass spectroscopy, “HR” for high resolution, “HRMS” for high resolutionmass spectrometry, “LCMS” for liquid chromatography mass spectrometry,“HPLC” for high pressure liquid chromatography, “RP HPLC” for reversephase HPLC, “TLC” or “tlc” for thin layer chromatography, “NMR” fornuclear magnetic resonance spectroscopy, “nOe” for nuclear Overhausereffect spectroscopy, “¹H” for proton, “δ” for delta, “s” for singlet,“d” for doublet, “t” for triplet, “q” for quartet, “m” for multiplet,“br” for broad, “Hz” for hertz, and “α”, “β”, “R”, “S”, “E”, and “Z” arestereochemical designations familiar to one skilled in the art.

Ac Acetic AcOH acetic acid ACN (or acetonitrile MeCN) APF aminophenylfluorescein BINAP 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl BISPINBis(pinacolato)diboron Bn benzyl Boc tert-butyl carbonyl Boc₂ODi-tert-butyl dicarbonate Bu butyl dba dibenzylideneacetone (Pd₂(dba)₃)CMBP cyanomethylenetributylphosphorane DCM dichloromethane DEAD diethylazodicarboxylate DIAD diisopropyl azodicarboxylate DiamideN,N,N′,N′-Tetramethylazodicarbonamide(1,1′-Azobis(N,N-dimethylformamide)) DIEA diisopropylethylamine DMAP4-dimethylaminopyridine DME Dimethoxyethane DMF dimethylformamide DMSOdimethyl sulfoxide dppf 1,1′-bis(diphenylphosphino)ferrocene(DtBPF)PdCl₂ 1.1′-bis(di-tert-butylphosphino)ferrocene palladiumdichloride Et ethyl EtOH ethanol EtOAc ethyl acetate HATU2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3- tetramethyluroniumhexafluorophosphate HBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate i-Bu isobutyl i-Pr isopropyl LAHlithium aluminum hydride Me methyl MeOH methanol NMM N-methylmorpholineNMP N-Methylpyrrolidone PCC pyridinium chlorochromate Ph phenyl Prpropyl RT or rt Room temperature t-Bu tert-butyl TBDMS-Clt-butyldimethylchlorosilane TBDMS t-butyldimethylsilyl TBDPSt-butyldiphenylsilyl TBDPS-Cl t-butyldiphenylchlorosilane TEATriethylamine TFA Trifluoroacetic acid THF tetrahydrofuran TMADN,N,N′,N′-Tetramethylazodicarbonamide(1,1′-Azobis(N,N-dimethylformamide)) Ts tosyl

The compounds of this invention can be made by various methods known inthe art including those of the following schemes and in the specificembodiments section. The structure numbering and variable numberingshown in the synthetic schemes are distinct from, and should not beconfused with, the structure or variable numbering in the claims or therest of the specification. The variables in the schemes are meant onlyto illustrate how to make some of the compounds of this invention.

The disclosure is not limited to the foregoing illustrative examples andthe examples should be considered in all respects as illustrative andnot restrictive, and all changes which come within the meaning and rangeof equivalency of the claims are therefore intended to be embraced.

It will also be recognized that another major consideration in theplanning of any synthetic route in this field is the judicious choice ofthe protecting group used for protection of the reactive functionalgroups present in the compounds described in this invention. Anauthoritative account describing the many alternatives to the trainedpractitioner is Greene, T. W. et al., Protecting Groups in OrganicSynthesis, 4th Edition, Wiley (2007)).

Compounds having the general Formula (I): wherein A, B and C are definedabove as Ar¹, Ar² and Ar³, respectively, can be prepared by thefollowing one or more of the synthetic Schemes.

1-Arylpiperidinone compounds of this invention wherein rings A, B and Care substituted phenyl rings can be prepared by the general route shownin Scheme 1, starting from a suitably protected 3-aminopiperidin-2-one1a, where PG is a protecting group such as Boc or Cbz. Copper-catalyzedcoupling of 1a to a substituted iodobenzene 1b or other suitable haloaryl or heteroaryl compound in a suitable solvent such as butanol ordioxane, in the presence of a base such as potassium carbonate and asuitable ligand such as N,N′-dimethylethylenediamine, can afford1-phenylpiperidinones 1c. Additional methods for this transformationinclude other variations of Ullmann, Goldberg, and Buchwaldcopper-catalyzed amidation or Buchwald Pd-catalyzed amidation dependingon the nature of ring B, using methods known to one skilled in the artfor these types of couplings (see for example Yin & Buchwald OrganicLett. 2000, 2, 1101; Klapers et al. JACS, 2001, 123, 7727; Klapars etal. JACS, 2002, 124, 7421; Yin & Buchwald JACS. 2002, 124, 6043;Kiyomor, Madoux & Buchwald, Tet. Lett., 1999, 40, 2657). Subsequentpalladium-catalyzed coupling of 1c to a suitably substituted phenylboronic acid 1d, or analogous boronate or trifluoroborate reagent, canprovide the biaryl compound 1e. Removal of the Boc or Cbz protectinggroup from 1e, followed by condensation of the resulting free amine witha suitably substituted phenyl isocyanate, 1g or 4-nitrophenylphenylcarbamate 1h can provide ureas 1f. Suitable isocyanates or4-nitrophenylcarbamates are either commercially available or can bereadily obtained from the corresponding aniline by methods known to oneskilled in the art. Alternately, the ureas 1f can be obtained bytreatment of the deprotected 3-aminopiperidinone intermediate with4-nitrophenylchloroformate to form the carbamate, followed bycondensation with a appropriately substituted aniline 1j. It will alsobe recognized by one skilled in the art that additional compounds ofthis invention wherein rings A, B or C are heteroaryl rings, such aspyridine, pyrimidine, thiazole, etc., can also be prepared using themethods outlined in Scheme 1 by substituting the appropriate heteroaryliodide or bromine for 1b, heteroarylboronic acid or boronate for 1d andheteroaryl amine, isocyanate or p-nitrophenylcarbamate for 1e.

Alternatively as described in Scheme 2, compounds of this invention canbe prepared from intermediate 1c by first deprotecting the amine andforming the urea linkage to ring A using the conditions described abovefor the conversion of 1e to 1f to provide compounds 2a. Compound 2a canthen be coupled with an appropriate boronic acid or boronate underPd-catalysis conditions as shown in Scheme 1 for the transformation of1c to 1e.

Additionally, compounds of this invention can be prepared fromintermediate 2a by conversion to boronate 3b using iridium-catalyzed C—Hborylation according to the method of Suzuki and Miyaura followed bycoupling of the resulting pinacolatoboron species with aryl orheteroaryl halides using palladium or copper catalyzed processes toprovide compounds 1f.

Other features of the invention will become apparent in the course ofthe following descriptions of exemplary embodiments that are given forillustration of the invention and are not intended to be limitingthereof.

The following methods were used in the exemplified Examples, exceptwhere noted otherwise. Purification of intermediates and final productswas carried out via either normal or reverse phase chromatography.Normal phase chromatography was carried out using prepacked SiO₂cartridges eluting with either gradients of hexanes and ethyl acetate orDCM and MeOH unless otherwise indicated. Reverse phase preparative HPLCwas carried out using C18 columns with UV 220 nm or prep LCMS detectioneluting with gradients of Solvent A (90% water, 10% MeOH, 0.1% TFA) andSolvent B (10% water, 90% MeOH, 0.1% TFA) or with gradients of Solvent A(95% water, 5% ACN, 0.1% TFA) and Solvent B (5% water, 95% ACN, 0.1%TFA) or with gradients of Solvent A (95% water, 2% ACN, 0.1% HCOOH) andSolvent B (98% ACN, 2% water, 0.1% HCOOH) or with gradients of Solvent A(95% water, 5% ACN, 10 mM NH₄OAc) and Solvent B (98% ACN, 2% water, 10mM NH₄OAc) or with gradients of Solvent A (98% water, 2% ACN, 0.1%NH₄OH) and Solvent B (98% ACN, 2% water, 0.1% NH₄OH).

LC/MS Methods Employed in Characterization of Examples. Reverse phaseanalytical HPLC/MS was performed on a Waters Acquity system coupled witha Waters MICROMASS® ZQ Mass Spectrometer.

Method A: Linear gradient of 0 to 100% B over 3 min, with 0.75 min holdtime at 100% B;

-   -   UV visualization at 220 nm    -   Column: Waters BEH C18 2.1×50 mm    -   Flow rate: 1.0 mL/min    -   Solvent A: 0.1% TFA, 95% water, 5% acetonitrile    -   Solvent B: 0.1% TFA, 5% water, 95% acetonitrile

Method B: Linear gradient of 0 to 100% B over 3 min, with 0.75 min holdtime at 100% B;

-   -   UV visualization at 220 nm    -   Column: Waters BEH C18 2.1×50 mm    -   Flow rate: 1.0 mL/min    -   Solvent A: 10 mM ammonium acetate, 95% water, 5% acetonitrile    -   Solvent B: 10 mM ammonium acetate, 5% water, 95% acetonitrile

Analytical HPLC: Methods Employed in Characterization of Examples

Products were analyzed by reverse phase analytical HPLC: carried out ona Shimadzu Analytical HPLC: system running Discovery VP software.RT=retention time.

Method A:SunFire C18 column (3.5 m C18, 3.0×150 mm). Gradient elution(1.0 mL/min) from 10-100% Solvent B over 12 min and then 100% Solvent Bfor 3 min was used. Solvent A is 95% water, 5% acetonitrile, 0.05% TFAand Solvent B is 5% water, 95% acetonitrile, 0.05% TFA, UV 220 nm.

Method B: XBridge Phenyl column (3.5 m C18, 3.0×150 mm). Gradientelution (1.0 mL/min) from 10-100% Solvent B over 12 min and then 100%Solvent B for 3 min was used. Solvent A is 95% water, 5% acetonitrile,0.05% TFA and Solvent B is 5% water, 95% acetonitrile, 0.05% TFA, UV 220nm.

Method C: Ascentis Express C18, 2.1×50 mm, 2.7-μm particles; Solvent A:95% water, 5% acetonitrile, 0.05% TFA; Solvent B: 95% acetonitrile, 5%water, 0.1% TFA; Temperature: 50° C.; Gradient: 0-100% B over 4 minutes,then a 1-minute hold at 100% B; Flow: 1.1 mL/min.

Method D: Ascentis Express C18, 2.1×50 mm, 2.7-μm particles; Solvent A:95% water, 5% acetonitrile with 10 mM ammonium acetate; Solvent B: 95%acetonitrile, 5% water with 10 mM ammonium acetate; Temperature: 50° C.;Gradient: 0-100% B over 4 minutes, then a 1-minute hold at 100% B; Flow:1.1 mL/min.

Method E: Ascentis Express C18, 2.1×50 mm, 2.7-μm particles; Solvent A:95% water, 5% acetonitrile, 0.05% TFA; Solvent B: 95% acetonitrile, 5%water, 0.1% TFA; Temperature: 50° C.; Gradient: 0-100% B over 3 minutes,then a 1-μminute hold at 100% B; Flow: 1.1 mL/min.

Method F: Ascentis Express C18, 2.1×50 mm, 2.7-μm particles; Solvent A:95% water, 5% acetonitrile with 10 mM ammonium acetate; Solvent B: 95%acetonitrile, 5% water with 10 mM ammonium acetate; Temperature: 50° C.;Gradient: 0-100% B over 3 minutes, then a 1-minute hold at 100% B; Flow:1.1 mL/min.

Method G: SunFire C18 column (3.5 μm C18, 3.0×150 mm). Gradient elution(1.0 mL/min) from 10-100% Solvent B over 25 min and then 100% Solvent Bfor 5 min was used. Solvent A is 95% water, 5% acetonitrile, 0.05% TFAand Solvent B is 5% water, 95% acetonitrile, 0.05% TFA, UV 220 nm.

Method H: XBridge Phenyl column (3.5 μm C18, 3.0×150 mm). Gradientelution (1.0 mL/min) from 10-100% Solvent B over 25 min and then 100%Solvent B for 5 min was used. Solvent A is 95% water, 5% acetonitrile,0.05% TFA and Solvent B is 5% water, 95% acetonitrile, 0.05% TFA, UV 220nm.

Method I: SunFire C18 column (3.5 m, 4.6×150 mm). Gradient elution (1.0mL/min) from 10-100% Solvent B over 12 min and then 100% Solvent B for 3min was used.

Solvent A is 95% water, 5% acetonitrile, 0.05% TFA and Solvent B is 5%water, 95% acetonitrile, 0.05% TFA, UV 220 nm.

Method J: XBridge Phenyl column (3.5 m, 4.6×150 mm). Gradient elution(1.0 mL/min) from 10-100% Solvent B over 12 min and then 100% Solvent Bfor 3 min was used. Solvent A is 95% water, 5% acetonitrile, 0.05% TFAand Solvent B is 5% water, 95% acetonitrile, 0.05% TFA, UV 220 nm.

Method K: SunFire C18 column (3.5 m, 4.6×150 mm). Gradient elution (1.0mL/min) from 10-100% Solvent B over 25 min and then 100% Solvent B for 5min was used.

Solvent A is 95% water, 5% acetonitrile, 0.05% TFA and Solvent B is 5%water, 95% acetonitrile, 0.05% TFA, UV 220 nm.

Method L: XBridge Phenyl column (3.5 am, 4.6×150 mm). Gradient elution(1.0 mL/min) from 10-100% Solvent B over 25 min and then 100% Solvent Bfor 5 min was used. Solvent A is 95% water, 5% acetonitrile, 0.05% TFAand Solvent B is 5% water, 95% acetonitrile, 0.05% TFA, UV 220 nm

Method M: SunFire C18 column (3.5 am, 4.6×150 mm). Gradient elution (1.0mL/min) from 10-100% Solvent B over 18 min and then 100% Solvent B for 5min was used.

Solvent A is 95% water, 5% acetonitrile, 0.05% TFA and Solvent B is 5%water, 95% acetonitrile, 0.05% TFA, UV 220 nm.

Method N: XBridge Phenyl column (3.5 μm, 4.6×150 mm). Gradient elution(1.0 mL/min) from 10-100% Solvent B over 18 min and then 100% Solvent Bfor 5 min was used. Solvent A is 95% water, 5% acetonitrile, 0.05% TFAand Solvent B is 5% water, 95% acetonitrile, 0.05% TFA, UV 220 nm.

SFC and Chiral Purity Methods

Method I: Chiralpak AD-H, 250×4.6 mm, 5.0-μm particles; % CO2: 60%, % Cosolvent: 40% {0.2% DEA IN IPA:A CN(1:1)}, Total Flow: 4.0 g/min, BackPressure: 100 bars, Temperature: 25° C., UV: 218 nm.

Method II: Chiralpak OD-H, 250×4.6 mm, 5.0-μm particles; % CO2: 60%, %Co solvent: 40% {0.2% DEA IN IPA:A CN(1:1)}, Total Flow: 4.0 g/min, BackPressure: 104 bars, Temperature: 24.9° C., UV: 287 nm.

Method III: Chiralpak OJ-H, 250×4.6 mm, 5.0-μm particles; % CO2: 60%, %Co-solvent: 30%(0.3% DEA in Methanol), Total Flow: 4.0 g/min, BackPressure: 101 bars, Temperature: 23.6° C., UV: 272 nm.

Method IV: Chiralpak AS-H, 250×4.6 mm, 5.0-μm particles; % CO2: 60%, %Co-solvent: 40%(0.3% DEA in Methanol), Total Flow: 4.0 g/min, BackPressure: 102 bars, Temperature: 25.4° C., UV: 272 nm.

Method V: Chiralcel OJ-H, 250×4.6 mm, 5.0-μm particles; % CO2: 60%, %Co-solvent: 40%(0.2% DEA in Methanol), Total Flow: 4.0 g/min, BackPressure: 102 bars, Temperature: 24.6° C., UV: 272 nm.

Method VI: Luxcellulose-2, 250×4.6 mm, 5.0-μm particles; % CO2: 60%, %Co-solvent: 35%(0.2% DEA in Methanol), Total Flow: 3.0 g/min, BackPressure: 101 bars, Temperature: 23.6° C., UV: 260 nm.

Method VII: Chiralcel AS-H, 250×4.6 mm, 5.0-μm particles; % CO2: 60%, %Co-solvent: 40%(0.2% DEA in Methanol), Total Flow: 4.0 g/min, BackPressure: 101 bars, Temperature: 24.4° C., UV: 270 nm.

Method VIII: Chiralpak IC, 250×4.6 mm, 5.0-μm particles; % CO2: 60%, %Co-solvent: 40%(0.2% DEA in Methanol), Total Flow: 4.0 g/min, BackPressure: 101 bars, Temperature: 24.4° C., UV: 270 nm.

Method IX: COLUMN: chiralpakF (250×4.6 mm), 5 micron, MOBILE PHASE:−0.2% DEA in ETHANOL, FLOW: 1.0 ml\min.

Method X: COLUMN: LUX AMYLOSE 2 (250×4.6 mm), 5 micron, MOBILE PHASE:0.2% DEA in n-HEXANE:ETHANOL:5:95, FLOW:1.0 ml\min.

Method XI: COLUMN: CHIRALCEL OD-H (250×4.6 mm), 5 micron, MOBILE PHASE:−0.2% DEA in n-HEXANE:ETHANOL:70:30, FLOW:1.0 ml\min.

Method XII: COLUMN: CHIRAL PAK ID 250×4.6 mm), 5 micron, MOBILE PHASE:−0.1% DEA in METHANOL, FLOW: 1.0 ml\min.

NMR Employed in Characterization of Examples. ¹H NMR spectra wereobtained with Bruker or JEOL® Fourier transform spectrometers operatingat frequencies as follows: ¹H NMR: 400 MHz (Bruker or JEOL®) or 500 MHz(Bruker or JEOL®). ¹³C NMR: 100 MHz (Bruker or JEOL®). Spectra data arereported in the format: chemical shift (multiplicity, couplingconstants, number of hydrogens). Chemical shifts are specified in ppmdownfield of a tetramethylsilane internal standard (6 units,tetramethylsilane=0 ppm) and/or referenced to solvent peaks, which in ¹HNMR spectra appear at 2.49 ppm for CD₂HSOCD₃, 3.30 ppm for CD₂HOD, 1.94for CD₃CN, and 7.24 ppm for CHCl₃, and which in ¹³C NMR spectra appearat 39.7 ppm for CD₃SOCD₃, 49.0 ppm for CD₃OD, and 77.0 ppm for CDCl₃.All ¹³C NMR spectra were proton decoupled.

Intermediate 1:(R)-1-(1-(4-bromophenyl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

Intermediate 1a: tert-butyl(R)-(1-(4-bromophenyl)-2-oxopiperidin-3-yl)carbamate

In a 1 L sealed tube, to a solution of (R)-tert-butyl(2-oxopiperidin-3-yl)carbamate (23 g, 110 mmol) in 1,4-dioxane (300 mL)was added 1,4-dibromobenzene (28 g, 120 mmol), potassium phosphatetribasic (34 g, 160 mmol), cuprous iodide (8.2 g, 43 mmol),N,N′-dimethylethylenediamine (4.7 ml, 43 mmol). The reaction mixture waspurged with Argon for 10-15 minutes and then heated to 60° C. forovernight. The reaction mixture was diluted with ethyl acetate (250 mL)and washed with brine solution (200 mL). The organic layer was driedover Na₂SO₄ and concentrated to produce the crude product. The crudecompound was purified through 330 gm Silica column and was eluted withethylacetate:pet-ether (40:60) to achieve off white solids of tert-butyl(1-(4-bromophenyl)-2-oxopiperidin-3-yl)carbamate (20 gm). Chiral SFCanalysis of the purified product showed ˜10% epimerization. The compoundwas then purified via SFC to afford Intermediate 1a (15 gm, 40 mmol, 38%yield) as a white solid. MS(ESI) m/z: 369.0/371.0 (M+H). ¹H NMR (400MHz, CDCl₃): δ ppm 7.48 (d, J=4.8 Hz, 2H), 7.11 (d, J=4.8 Hz, 2H), 5.48(br-s, 1H), 4.25-4.18 (m, 1H), 3.70-3.62 (m, 2H), 2.60-2.52 (m, 1H),2.08-1.95 (m, 2H), 1.74-1.64 (m, 1H), 1.43 (s, 9H). [α]_(D) ²⁵ (c=0.1,MeOH): +30.0. Chiral Purity (SFC): 99.9%, retention time=4.15 min (timeof Peak-01 (0.105%)=3.03 min & Retention time of Peak-02 (99.9%)=4.15min; Co-Solvent: 0.2% DEA in Methanol; Column: Whelk-01 (R,R)(250×4.6)mm 5 u; Column Temperature: 24.5; Total Flow: 3; CO2 Flow Rate: 1.8;Co-Solvent Flow Rate: 1.2; Co-Solvent % 40; Back Pressure 100.)

Preparative SFC Conditions: Column/dimensions: Whelk(R,R) (250×30) mm, 5u; CO₂%: 70%; Co-solvent %: 30% of (0.2% DEA in methanol); Total Flow:120 g/min; Back Pressure: 100 bar; Temperature: 30° C.; UV: 240 nm.Retention time of Peak-01=3.20 min & Retention time of Peak-02=4.60 min;

Intermediate 1b: (R)-3-amino-1-(4-bromophenyl)piperidin-2-onehydrochloride

To a cooled solution of Intermediate 1a (400 mg, 1.1 mmol) in1,4-dioxane (10 mL) was added 4N HCl in 1,4-dioxane (5.2 mL) and stirredat rt for two hours. The solvent was evaporated and the residue wasdried under reduced pressure to obtain a gummy solid.

The solid was further triturated with diethyl ether (2×20 mL) and driedto afford Intermediate 1b (300 mg, 0.98 mmol, 91% yield) as a off whitesolid. MS(ESI) m/z: 271.0 (M+H). ¹H NMR (400 MHz, DMSO-d₆): δ 8.36 (br.s., 3H), 7.65-7.60 (m, 2H), 7.32-7.26 (m, 2H), 4.06-3.99 (m, 1H),3.77-3.68 (m, 1H), 3.64-3.58 (m, 1H), 2.28-2.24 (m, 1H), 2.06-1.96 (m,2H), 1.96-1.85 (m, 1H).

Intermediate 1

To a cooled solution of Intermediate 1b(R)-3-amino-1-(4-bromophenyl)piperidin-2-one (300 mg, 1.1 mmol) in THF(10 mL) were added TEA (0.47 mL, 3.3 mmol) and1-isocyanato-4-(trifluoromethyl)benzene (210 mg, 1.1 mmol) and thereaction mixture was stirred at rt for 15 hours. The mixture wasconcentrated under reduced pressure to get the crude compound which wastriturated with diethyl ether to afford Intermediate 1 (450 mg, 0.99mmol, 88% yield) as a light brown solid. MS(ESI) m/z: 458.0 (M+H). ¹HNMR (400 MHz, DMSO-d₆): δ 9.28 (s, 1H), 7.62-7.55 (m, 6H), 7.31-7.26 (m,2H), 6.71 (d, J=6.5 Hz, 1H), 4.37-4.23 (m, 1H), 3.75-3.59 (m, 2H),2.29-2.25 (m, 1H), 2.03-1.93 (m, 2H), 1.87-1.75 (m, 1H).

Intermediate 2:(S)-1-(1-(4-bromophenyl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

(S)-3-amino-1-(4-bromophenyl)piperidin-2-one was synthesized in ananalogous way to Intermediate 1b. To a cooled solution of(S)-3-amino-1-(4-bromophenyl)piperidin-2-one hydrochloride (300 mg, 1.1mmol) in THF (10 mL) were added TEA (0.39 mL, 2.8 mmol) and1-isocyanato-4-(trifluoromethyl)benzene (210 mg, 1.1 mmol) and thereaction mixture was stirred at rt for 15 hours. The mixture wasconcentrated under reduced pressure to yield the crude compound whichwas triturated with diethyl ether to afford Intermediate 2 (300 mg, 0.66mmol, 59% yield) as a off white solid. MS(ESI) m/z: 459.0 (M+H). ¹H NMR(400 MHz, DMSO-d₆): δ 9.21 (s, 1H), 7.64-7.54 (m, 6H), 7.29 (d, J=9.0Hz, 2H), 6.67 (d, J=7.0 Hz, 1H), 4.38-4.28 (m, 1H), 3.75-3.60 (m, 2H),2.36-2.22 (m, 1H), 2.05-1.91 (m, 2H), 1.87-1.73 (m, 1H).

Intermediate 3:(R)-1-(1-(4-bromophenyl)-2-oxopiperidin-3-yl)-3-(4-chlorophenyl)urea

To a cooled solution of (R)-3-amino-1-(4-bromophenyl)piperidin-2-one(350 mg, 1.3 mmol) in THF (10 mL) were added TEA (0.45 mL, 2.6 mmol) and1-chloro-4-isocyanatobenzene (200 mg, 1.3 mmol) and the reaction mixturewas stirred at RT for 15 hours. The mixture was concentrated underreduced pressure to give the crude product which was triturated withdiethyl ether to afford Intermediate 3 (400 mg, 0.95 mmol, 72% yield) asa light brown solid. MS(ESI) m/z: 423.0 (M+H). ¹H NMR (400 MHz, DMSO-d6)δ 8.90 (s, 1H), 7.58 (d, J=9.0 Hz, 2H), 7.42 (d, J=8.5 Hz, 2H), 7.27(dd, J=8.5, 6.0 Hz, 4H), 6.54 (d, J=6.5 Hz, 1H), 4.37-4.24 (m, 1H),3.75-3.58 (m, 2H), 2.31-2.22 (m, 1H), 2.04-1.93 (m, 2H), 1.85-1.72 (m,1H).

Intermediate 4:((R)-1-(2-oxo-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

To a solution of Intermediate 1 (1.0 g, 2.2 mmol) in 1,4-dioxane (10 mL)were added BISPIN (0.84 g, 3.3 mmol) and potassium acetate (0.43 g, 4.4mmol). The reaction mixture was purged with nitrogen for 5 min andcharged with Pd(dppf)Cl₂.DCM adduct (0.18 g, 0.22 mmol). The reactionmixture was again purged with nitrogen for 3 min and heated at 60° C.for 16 h. The reaction mixture was cooled, filtered through a celitepad, and washed with ethyl acetate (50 mL). The filtrate wasconcentrated under reduced pressure and the crude compound was purifiedby column chromatography to afford Intermediate 4 (0.70 g, 1.4 mmol, 64%yield) as a pale brown solid. MS(ESI) m/z: 504 (M+H); ¹H NMR (400 MHz,DMSO-d₆) δ 9.2 (s, 1H), 7.73-7.65 (m, 2H), 7.63-7.53 (m, 4H), 7.36-7.28(m, 2H), 6.71-6.63 (m, 1H), 4.40-4.30 (m, 1H), 3.78-3.61 (m, 2H),2.36-2.24 (m, 1H), 2.04-1.93 (m, 2H), 1.86-1.73 (m, 1H), 1.29 (s, 12H).

Intermediate 5:(R)-1-(4-chlorophenyl)-3-(2-oxo-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-3-yl)urea

To a solution of Intermediate 3 (0.50 g, 1.2 mmol) in 1,4-dioxane (10mL) were added BISPIN (0.45 g, 1.8 mmol) and potassium acetate (0.23 g,2.4 mmol). The reaction mixture was purged with nitrogen for 5 min andcharged with Pd(dppf)Cl₂.DCM adduct (0.097 g, 0.12 mmol). The reactionmixture was again purged with nitrogen for 3 min and heated at 60° C.for 16 h. The reaction mixture was cooled, filtered through a celitepad, and washed with ethyl acetate (50 mL×2). The filtrate wasconcentrated under reduced pressure and the crude compound was purifiedby column chromatography to afford Intermediate 5 (0.50 g, 1.1 mmol, 90%yield) as a pale brown solid. MS(ESI) m/z: 470.2 (M+H); ¹H NMR (400 MHz,DMSO-d₆): δ 8.90 (s, 1H), 7.91 (s, 2H), 7.68 (d, J=8.5 Hz, 2H), 7.33 (d,J=8.5 Hz, 2H), 7.26 (d, J=9.0 Hz, 2H), 6.57-6.51 (m, 1H), 4.36-4.27 (m,1H), 3.77-3.62 (m, 2H), 2.35-2.24 (m, 1H), 2.04-1.93 (m, 2H), 1.83-1.71(m, 1H), 1.29 (s, 12H).

Intermediate 6: tert-butyl(R)-(1-(5-bromopyridin-2-yl)-2-oxopiperidin-3-yl)carbamate Intermediate7: tert-butyl (S)-(1-(5-bromopyridin-2-yl)-2-oxopiperidin-3-yl)carbamateIntermediate 8: tert-butyl(R)-(1-(6-iodopyridin-3-yl)-2-oxopiperidin-3-yl)carbamate Intermediate9: tert-butyl (S)-(1-(6-iodopyridin-3-yl)-2-oxopiperidin-3-yl)carbamate

To a solution containing tert-butyl (2-oxopiperidin-3-yl)carbamate (4.0g, 19 mmol) in dry DMF (10 mL) were added 5-bromo-2-iodopyridine (5.3 g,19 mmol) and potassium phosphate, tribasic (7.9 g, 37 mmol). Thereaction mixture was purged with nitrogen for 30 min and charged withcopper(I) iodide (0.36 g, 1.9 mmol) and N,N′-dimethylethylenediamine(0.33 g, 3.7 mmol). The reaction mixture was again purged with nitrogenfor 10 min and heated at 60° C. for 15 h. The reaction mixture wascooled, filtered through a celite pad, washed with ethyl acetate (50 mL)and the filtrate was concentrated under reduced pressure. The crudecompound was purified by column chromatography to afford 2.3 g of aracemic mixture which was further subjected to enantiomeric separationusing Supercritical fluid chromatography (SFC) (method I) to provide theIntermediates 7-10, as single enantiomers.

Intermediate 7 (1.5 g, 4.1 mmol, 22% yield). MS(ESI) m/z: 372 (M+H); ¹HNMR (400 MHz, CDCl₃): δ 8.44 (dd, J=2.3, 0.8 Hz, 1H), 7.85-7.81 (m, 1H),7.81-7.76 (m, 1H), 5.48 (br. s., 1H), 4.47-4.33 (m, 2H), 3.75-3.66 (m,1H), 2.61-2.56 (m, 1H), 2.07-1.98 (m, 2H), 1.70-1.62 (m, 1H), 1.48 (s,9H); The absolute stereochemistry of Intermediate 7 was confirmed bysingle molecule crystal structure.

Intermediate 8 (0.90 g, 2.4 mmol, 13% yield). MS(ESI) m/z: 372 (M+H); δ8.44 (dd, J=2.3, 0.8 Hz, 1H), 7.85-7.81 (m, 1H), 7.81-7.76 (m, 1H), 5.48(br. s., 1H), 4.47-4.33 (m, 2H), 3.75-3.66 (m, 1H), 2.61-2.56 (m, 1H),2.07-1.98 (m, 2H), 1.70-1.62 (m, 1H), 1.48 (s, 9H).

Intermediate 9 (1.9 g, 4.6 mmol, 24% yield). MS(ESI) m/z: 418 (M+H); ¹HNMR (400 MHz, CDCl₃): δ 8.59 (dd, J=2.3, 0.8 Hz, 1H), 7.95 (dd, J=8.8,2.3 Hz, 1H), 7.75 (dd, J=8.8, 0.8 Hz, 1H), 5.49 (br. s., 1H), 4.47-4.33(m, 2H), 3.73-3.66 (m, 1H), 2.63-2.53 (m, 1H), 2.07-1.98 (m, 2H),1.70-1.60 (m, 1H), 1.48 (s, 9H).

Intermediate 10 (2.2 g, 5.3 mmol, 28% yield) MS(ESI) m/z: 418 (M+H); ¹HNMR (400 MHz, CDCl₃): δ 8.59 (dd, J=2.3, 0.8 Hz, 1H), 7.95 (dd, J=8.8,2.3 Hz, 1H), 7.75 (dd, J=8.8, 0.8 Hz, 1H), 5.49 (br. s., 1H), 4.47-4.33(m, 2H), 3.73-3.66 (m, 1H), 2.63-2.53 (m, 1H), 2.07-1.98 (m, 2H),1.70-1.60 (m, 1H), 1.48 (s, 9H).

Example 1.1-(4-chlorophenyl)-3-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)urea

Example 1A. tert-butyl(1-(4-chloro-2-fluorophenyl)-2-oxopiperidin-3-yl)carbamate

A mixture of 4-chloro-2-fluoro-1-iodobenzene (5.3 g, 21 mmol),tert-butyl (2-oxopiperidin-3-yl)carbamate (2.0 g, 9.3 mmol),N,N′-dimethyl-1,2-ethanediamine (0.25 g, 2.8 mmol), CuI (0.89 g, 4.7mmol) and K₂CO₃ (6.5 g, 47 mmol) in n-BuOH (20 mL) was degassed withnitrogen and heated to 100° C. overnight. The cooled reaction mixturewas filtered through a pad of celite and washed with EtOAc. The reactionsolution was concentrated and the residue was diluted with EtOAc, washedwith saturated aqueous NH₄Cl solution, followed by brine. The organicswere dried over MgSO₄ and concentrated to give the crude product. Thecrude product was purified by column chromatography to give the titlecompound, (1.2 g, 37% yield). Partial racemization of the stereocenterwas observed. MS (ESI) m/z 343.1 (M+H).

Example 1B. tert-butyl(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)carbamate

A mixture of Example 1A (150 mg, 0.44 mmol),(2-(methylsulfonyl)phenyl)boronic acid (260 mg, 1.3 mmol), Na₂CO₃ (230mg, 2.2 mmol) andchloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)(47 mg, 0.066 mmol) in toluene (2.0 mL), EtOH (2.0 mL) and H₂O (0.20 mL)was purged with argon and heated by microwave irradiation for 1 hr at150° C. in a sealed vial. The reaction mixture was concentrated andpurified by column chromatography to give Example 1B (160 mg, 79% yield.MS (ESI) m/z 463.2 (M+H).

Example 1C.3-amino-1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)piperidin-2-one

To a solution of Example 1B (160 mg, 0.35 mmol) in CH₂Cl₂ (5.0 mL) wasadded HCl in dioxane (0.87 mL, 3.5 mmol). After stirring for 6 h at rt,the reaction mixture was concentrated to give the crude product (125 mg,99%.) MS (ESI) m/z 363.1 (M+H).

Example 1

To a solution of Example 1C (30 mg, 0.075 mmol)) in DMF (1.0 mL) wasadded 1-chloro-4-isocyanatobenzene (12 mg, 0.075 mmol) and Et₃N (0.11mL, 0.75 mmol). After stirring for 1 h at rt, the reaction mixture wasfiltered, and the product was purified by reverse phase preparative HPLCto give the title compound, (55 mg, 60% yield). MS (ESI) m/z 516.1(M+H). ¹H NMR (500 MHz, DMSO-d6) δ 12.50 (s, 1H), 8.25 (d, J=7.8 Hz,1H), 8.05-7.63 (m, 9H), 7.16-6.97 (m, 3H), 6.72 (d, J=7.4 Hz, 1H),4.33-4.10 (m, 1H), 4.04-3.84 (m, 2H), 2.35 (t, J=9.0 Hz, 1H), 2.18 (d,J=9.8 Hz, 2H), 2.04-1.86 (m, 1H). Analytical HPLC: RT=1.74 min (MethodB).

Example 2.1-(5-chloropyridin-2-yl)-3-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)urea

To a solution of 5-chloropyridin-2-amine (10 mg, 0.078 mmol) in DCM(0.50 mL) was added pyridine (0.025 ml, 0.31 mmol). After stirring for 5min, 4-nitrophenyl chloroformate (17 mg, 0.086 mmol) was added, and themixture was stirred at rt overnight. To the reaction mixture was added1C (28 mg, 0.078 mmol), followed by TEA (0.050 mL), and the reactionmixture was stirred overnight. The reaction mixture was concentrated togive the crude product, which was purified by reverse phase preparativeHPLC to provide the title compound (19 mg, 46% yield. MS(ESI) m/z 517.0(M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.47 (s, 1H), 8.22 (d, J=2.3 Hz, 1H),8.10 (d, J=7.8 Hz, 1H), 8.01 (br. s., 1H), 7.84-7.75 (m, 2H), 7.75-7.66(m, 1H), 7.58 (d, J=8.8 Hz, 1H), 7.51-7.42 (m, 2H), 7.36 (d, J=11.0 Hz,1H), 7.28 (d, J=8.0 Hz, 1H), 4.51-4.35 (m, 1H), 3.80-3.56 (m, 2H), 2.90(s, 3H), 2.33 (dd, J=11.6, 5.8 Hz, 1H), 2.03 (d, J=5.5 Hz, 2H),1.89-1.83 (m, 1H). Analytical HPLC: RT=1.60 min (Method A).

Example 3.4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxamide

Example 3A.1-(1-(4-chlorophenyl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

Example 3A was synthesized from 1-chloro-4-iodobenzene using theprocedures described in Examples 1A and 1C. 1. MS (ESI) m/z 412.3 (M+H).

Example 3

To a solution of Example 3A (25 mg, 0.061 mmol),(2-carbamoylphenyl)boronic acid (30 mg, 0.18 mmol) and CsF (46 mg, 0.30mmol) in CH₃CN (1.3 mL) and H₂O (0.20 mL) was addeddichlorobis(tricyclohexylphosphine) palladium(II) (9.0 mg, 0.012 mmol).The reaction mixture was purged with nitrogen and heated by microwaveirradiation for 0.5 hr at 150° C. in a sealed vial. The reaction mixturewas filtered, and the product was purified via preparative reverse phaseHPLC to give the title compound, (2.1 mg, 6.7% yield.) MS (ESI) m/z497.3 (M+H). ¹H NMR (500 MHz, DMSO-d6) δ 9.26 (s, 1H), 7.71 (br. s.,1H), 7.61-7.53 (m, 3H), 7.49-7.23 (m, 9H), 6.74 (d, J=6.7 Hz, 1H),4.42-4.30 (m, 1H), 3.72 (d, J=14.4 Hz, 1H), 3.52 (br. s., 1H), 2.28 (br.s., 1H), 2.00 (br. s., 2H), 1.82 (br. s., 1H). Analytical HPLC: RT=1.649min (Method B).

The following are additional Examples, prepared using the methodsdescribed above or modifications thereof known to one skilled in theart, of the compounds of Formula (I) of the present invention.

Examples 4-30 below were similarly prepared using the general proceduresdescribed for Example 1.

Example 4.4′-(3-(3-(4-chlorophenyl)ureido)-2-oxopiperidin-1-yl)-[1,1′-biphenyl]-2-carboxamide

MS(ESI) m/z 462.9 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.94 (s, 1H), 7.71(s, 1H), 7.54-7.23 (m, 13H), 6.58 (d, J=6.6 Hz, 1H), 4.42-4.25 (m, 1H),3.83-3.60 (m, 2H), 2.34-2.20 (m, 1H), 2.05-1.92 (m, 2H), 1.90-1.69 (m,1H). Analytical HPLC: RT=1.48 min (Method B).

Example 5.1-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(p-tolyl)urea

MS(ESI) m/z 495.9 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.60 (s, 1H), 8.08(m, 1H), 7.77 (m, 1H), 7.69 (m, 1H), 7.50-7.39 (m, 2H), 7.33 (d, J=11.0Hz, 1H), 7.29-7.20 (m, 3H), 7.03 (d, J=8.1 Hz, 2H), 6.46 (d, J=7.2 Hz,1H), 4.39-4.27 (m, 1H), 3.66 (m, 2H), 2.88 (s, 3H), 2.25 (d, J=6.9 Hz,1H), 2.20 (s, 3H), 2.05-1.95 (m, 2H), 1.83 (m, 1H). Analytical HPLC:RT=1.61 min (Method B).

Example 6.4′-(3-(3-(4-chlorophenyl)ureido)-2-oxopiperidin-1-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxamide

MS(ESI) m/z 481.1 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.91 (s, 1H), 7.83(s, 1H), 7.56-7.38 (m, 8H), 7.34-7.19 (m, 4H), 6.59 (d, J=7.0 Hz, 1H),4.40-4.28 (m, 1H), 3.69 -3.49 (m, 2H), 2.27 (d, J=6.3 Hz, 1H), 2.06-1.96(m, 2H), 1.83 (m, 1H). Analytical HPLC: RT=1.59 min (Method B).

Example 7.4′-(2-oxo-3-(3-(p-tolyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-Carboxamide

MS(ESI) m/z 443 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.67 (s, 1H), 7.74(br. s., 1H), 7.54-7.23 (m, 11H), 7.04 (d, J=8.2 Hz, 2H), 6.48 (d, J=6.8Hz, 1H), 4.36-4.22 (m, 1H), 3.78-3.63 (m, 1H), 2.27 (m, 5H), 1.98 (m,2H), 1.85-1.66 (m, 1H). Analytical HPLC: RT=1.39 min (Method B).

Example 8.1-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(methylthio)phenyl)urea

MS(ESI) m/z 528.1 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.74 (s, 1H), 8.09(d, J=7.7 Hz, 1H), 7.77 (t, J=7.4 Hz, 1H), 7.69 (t, J=7.7 Hz, 1H),7.50-7.39 (m, 2H), 7.35 (m, 3H), 7.26 (d, J=8.1 Hz, 1H), 7.17 (d, J=8.5Hz, 2H), 6.52 (d, J=7.0 Hz, 1H), 4.39-4.27 (m, 1H), 3.65-3.55 (m, 2H),2.88 (s, 3H), 2.39 (s, 3H), 2.26 (m, 1H), 2.08-1.96 (m, 2H), 1.84 (m,1H). Analytical HPLC: RT=1.65 min (Method B).

Example 9.1-(1-(3-fluoro-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(p-tolyl)urea

MS(ESI) m/z 418.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.63 (s, 1H),7.84-7.35 (m, 8H), 7.27 (d, J=8.2 Hz, 2H), 7.04 (d, J=8.1 Hz, 2H), 6.49(d, J=6.9 Hz, 1H), 4.42-4.27 (m, 1H), 3.74-3.60 (m, 1H), 3.57-3.45 (m,1H), 2.29 (m, 1H), 2.21 (s, 3H), 2.01 (m, 2H), 1.82 (m, 1H). AnalyticalHPLC: RT=2.06 min (Method B).

Example 10.3-{1-[2-fluoro-4-(2-oxo-1,2-dihydropyridin-1-yl)phenyl]-2-oxopiperidin-3-yl}-1-[4-(trifluoromethyl)phenyl]urea

MS(ESI) m/z 488.8 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.18 (s, 1H),7.76-7.44 (m, 8H), 7.30 (d, J=8.2 Hz, 1H), 6.72 (d, J=7.2 Hz, 1H), 6.51(d, J=9.2 Hz, 1H), 6.37 (t, J=6.6 Hz, 1H), 4.45-4.28 (m, 1H), 3.80-3.64(m, 2H), 2.26 (d, J=5.3 Hz, 1H), 2.02 (m, 2H), 1.87 (m, 1H). AnalyticalHPLC: RT=1.55 min (Method B).

Example 11.1-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 550.1 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.19 (s, 1H), 8.11(d, J=7.7 Hz, 1H), 7.78 (t, J=7.3 Hz, 1H), 7.71 (t, J=7.6 Hz, 1H),7.64-7.55 (m, 4H), 7.51-7.44 (m, 2H), 7.37 (d, J=11.0 Hz, 1H), 7.29 (d,J=7.9 Hz, 1H), 6.73 (d, J=6.9 Hz, 1H), 4.44-4.32 (m, 1H), 3.78-3.62 (m,2H), 2.90 (s, 3H), 2.31 (m, 1H), 2.04 (m, 2H), 1.93-1.79 (m, 1H).Analytical HPLC: RT=1.86 min (Method A).

Example 12.1-(4-chlorophenyl)-3-{1-[2-fluoro-4-(2-oxo-1,2-dihydropyridin-1-yl)phenyl]-2-oxopiperidin-3-yl}urea

MS(ESI) m/z 455.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.87 (s, 1H), 7.65(d, J=5.5 Hz, 1H), 7.57-7.37 (m, 5H), 7.32-7.17 (m, 3H), 6.59 (d, J=7.0Hz, 1H), 6.50 (s, 1H), 6.37 (t, J=6.4 Hz, 1H), 4.56-4.29 (m, 1H),3.85-3.62 (m, 2H), 2.26 (m, 5.6 Hz, 1H), 2.02 (m, 2H), 1.85 (m, 1H).Analytical HPLC: RT=1.47 min (Method A).

Example 13.1-(4-chlorophenyl)-3-(1-(3-fluoro-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)urea

MS(ESI) m/z 438.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.90 (s, 1H),7.81-7.38 (m, 10H), 7.32-7.21 (m, 2H), 6.59 (d, J=6.9 Hz, 1H), 4.40-4.27(m, 1H), 3.67-3.41 (m, 2H), 2.28 (d, J=6.2 Hz, 1H), 2.07-1.96 (m, 2H),1.84 (m, 1H). Analytical HPLC: RT=2.02 min (Method A).

Example 14.1-(4-ethylphenyl)-3-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)urea

MS(ESI) m/z 510.3 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.63 (s, 1H), 8.10(m, 1H), 7.78 (m, 1H), 7.70 (m, 1H), 7.51-7.41 (m, 2H), 7.37 (d, J=10.9Hz, 1H), 7.29 (d, J=7.9 Hz, 3H), 7.06 (d, J=8.2 Hz, 2H), 6.48 (m, 1H),4.42-4.28 (m, 1H), 3.76-3.60 (m, 2H), 2.90 (s, 3H), 2.60 (m, 2H), 2.29(m, 1H), 2.02 (m, 2H), 1.82 (m, 1H), 1.14 (t, J=7.5 Hz, 3H). AnalyticalHPLC: RT=1.79 min (Method B).

Example 15.1-(4-ethylphenyl)-3-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)urea

MS(ESI) m/z 400.9 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.92 (s, 1H), 8.68(s, 1H), 8.58 (d, J=4.1 Hz, 1H), 8.11 (d, J=7.9 Hz, 1H), 7.76 (d, J=8.3Hz, 2H), 7.60-7.41 (m, 3H), 7.29 (d, J=8.2 Hz, 2H), 7.04 (d, J=8.0 Hz,2H), 6.49 (d, J=6.6 Hz, 1H), 4.56-4.17 (m, 1H), 3.89-3.64 (m, 2H), 2.30(dd, J=11.9, 5.8 Hz, 1H), 2.22 (s, 3H), 2.06-1.96 (m, 2H), 1.86-1.68 (m,1H). Analytical HPLC: RT=1.47 min (Method B).

Example 16.1-(4-chlorophenyl)-3-(2-oxo-1-(4-(pyridin-3-yl)phenyl)piperidin-3-yl)urea

MS(ESI) m/z 421.1 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.93 (s, 2H), 8.59(s, 1H), 8.11 (d, J=7.8 Hz, 1H), 7.76 (d, J=8.3 Hz, 2H), 7.55-7.39 (m,5H), 7.27 (d, J=8.7 Hz, 2H), 6.58 (d, J=6.8 Hz, 1H), 4.39-4.20 (m, 1H),3.82-3.62 (m, 2H), 2.29 (m, 5.8 Hz, 1H), 2.04-1.96 (m, 2H), 1.85-1.67(m, 1H). Analytical HPLC: RT=1.56 min (Method B).

Example 17.1-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-methoxyphenyl)urea

MS(ESI) m/z 511.8 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.53 (s, 1H), 8.10(d, J=7.8 Hz, 1H), 7.78 (t, J=7.4 Hz, 1H), 7.70 (t, J=7.6 Hz, 1H),7.50-7.41 (m, 2H), 7.36 (d, J=10.9 Hz, 1H), 7.29 (d, J=8.7 Hz, 3H), 6.82(d, J=8.8 Hz, 2H), 6.42 (d, J=6.9 Hz, 1H), 4.42-4.28 (m, 1H), 3.75-3.60(m, 4H), 3.48-3.34 (m, 2H), 2.90 (s, 3H), 2.28 (m, 1H), 2.02 (m, 2H),1.83 (m, 1H). Analytical HPLC: RT=1.46 min (Method B).

Example 18.3′-fluoro-4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxamide

MS(ESI) m/z 515.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.20 (s, 1H), 7.83(s, 1H), 7.59 (s, 4H), 7.51-7.38 (m, 6H), 7.34-7.21 (m, 2H), 6.71 (d,J=6.8 Hz, 1H), 4.42-4.24 (m, 1H), 3.76-3.48 (m, 2H), 2.30 (m, 1H), 2.02(m, 2H), 1.85 (m, 1H). Analytical HPLC: RT=1.73 min (Method B).

Example 19.1-(4-chloro-3-fluorophenyl)-3-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)urea

MS(ESI) m/z 534.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.12 (s, 1H), 8.09(d, J=7.8 Hz, 1H), 7.85-7.59 (m, 3H), 7.51-7.24 (m, 5H), 7.08 (d, J=8.1Hz, 1H), 6.68 (d, J=7.1 Hz, 1H), 4.42-4.28 (m, 1H), 3.63 (m., 2H), 2.89(s, 3H), 2.26 (m, 1H), 2.02 (m, 2H), 1.91-1.54 (m, 1H). Analytical HPLC:RT=1.93 min (Method B).

Example 20.4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-3-carboxamide

MS(ESI) m/z 497.3 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.24 (s, 1H),8.21-8.11 (m, 2H), 7.83 (d, J=7.5 Hz, 2H), 7.74 (d, J=8.2 Hz, 2H),7.65-7.52 (m, 5H), 7.41 (d, J=7.7 Hz, 3H), 6.75 (d, J=6.6 Hz, 1H),4.40-4.21 (m, 1H), 3.71 (br. s., 2H), 2.26 (m, 1H), 2.00 (m, 2H), 1.84(m, 1H). Analytical HPLC: RT=1.68 min (Method B).

Example 21.1-(6-chloropyridin-3-yl)-3-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)urea

MS(ESI) m/z 517.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.12 (s, 1H), 8.41(d, J=2.4 Hz, 1H), 8.11 (d, J=7.9 Hz, 1H), 7.95 (dd, J=8.7, 2.6 Hz, 1H),7.83-7.67 (m, 2H), 7.51-7.24 (m, 5H), 6.77 (d, J=7.0 Hz, 1H), 4.45-4.23(m, 1H), 3.75-3.56 (m, 2H), 2.91 (s, 3H), 2.40-2.26 (m, 1H), 2.03 (m,2H), 1.91-1.79 (m, 1H). Analytical HPLC: RT=1.64 min (Method A).

Example 22.1-(1-(3-fluoro-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 472.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.22 (s, 1H), 7.72(d, J=7.5 Hz, 2H), 7.65-7.54 (m, 6H), 7.51-7.28 (m, 3H), 6.74 (d, J=6.8Hz, 1H), 4.44-4.30 (m, 1H), 3.73-3.58 (m, 2H), 2.31 (m, 1H), 2.03 (m,2H), 1.86 (m, 1H). Analytical HPLC: RT=2.18 min (Method B).

Example 23.1-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(methylsulfonyl)phenyl)urea

MS(ESI) m/z 560.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.34 (s, 1H), 8.10(d, J=7.8 Hz, 1H), 7.85-7.58 (m, 6H), 7.52-7.42 (m, 2H), 7.38-7.22 (m,2H), 6.79 (d, J=7.1 Hz, 1H), 4.46-4.29 (m, 1H), 3.82-3.46 (m, 2H), 3.12(s, 3H), 2.95-2.85 (m, 3H), 2.29 (d, J=6.1 Hz, 1H), 2.04 (br. s., 2H),1.89 (s, 1H). Analytical HPLC: RT=1.46 min (Method B).

Example 24.1-(4-cyanophenyl)-3-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)urea

MS(ESI) m/z 507.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.53 (s, 1H), 8.10(d, J=7.8 Hz, 1H), 7.78 (t, J=7.4 Hz, 1H), 7.70 (t, J=7.6 Hz, 1H),7.50-7.41 (m, 2H), 7.36 (d, J=10.9 Hz, 1H), 7.29 (d, J=8.7 Hz, 3H), 6.82(d, J=8.8 Hz, 2H), 6.42 (d, J=6.9 Hz, 1H), 4.42-4.28 (m, 1H), 3.75-3.60(m, 2H), 2.90 (s, 3H), 2.28 (m, 1H), 2.02 (m, 2H), 1.83 (m, 1H).Analytical HPLC: RT=1.57 min (Method B).

Example 25.1-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethoxy)phenyl)urea

MS(ESI) m/z 566.3 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.96 (s, 1H), 8.10(d, J=7.8 Hz, 1H), 7.78 (t, J=7.4 Hz, 1H), 7.70 (t, J=7.7 Hz, 1H),7.54-7.42 (m, 4H), 7.37 (d, J=10.9 Hz, 1H), 7.28 (d, J=7.4 Hz, 1H), 7.23(d, J=8.7 Hz, 2H), 6.60 (d, J=6.9 Hz, 1H), 4.42-4.31 (m, 1H), 3.76-3.59(m, 2H), 2.90 (s, 3H), 2.30 (m, 1H), 2.02 (m, 2H), 1.92-1.76 (m, 1H).Analytical HPLC: RT=1.88 min (Method A).

Example 26.1-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(5-methylthiazol-2-yl)urea

MS(ESI) m/z 502.8 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.11 (d, J=7.9 Hz,1H), 7.83-7.69 (m, 2H), 7.51-7.42 (m, 2H), 7.39-7.25 (m, 2H), 7.08-6.93(m, 2H), 4.47-4.23 (m, 1H), 3.69 (m, 2H), 2.90 (s, 3H), 2.29 (s, 4H),2.04 (m, 2H), 1.89-1.78 (m, 2H). Analytical HPLC: RT=1.32 min (MethodA).

Example 27.1-(6-chloropyridazin-3-yl)-3-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)urea

MS(ESI) m/z 518.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.96 (s, 1H),8.22-7.98 (m, 2H), 7.88-7.63 (m, 4H), 7.51-7.39 (m, 2H), 7.32-7.18 (m,2H), 4.67-4.32 (m, 1H), 3.69 (br. s., 2H), 2.89 (s, 3H), 2.31 (m, 1H),2.04 (m, 2H), 1.89 (m, 1H). Analytical HPLC: RT=1.46 min (Method A).

Example 28.1-(1-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-fluorophenyl)urea

MS(ESI) m/z 500 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.76 (s, 1H), 8.09(d, J=7.7 Hz, 1H), 7.77 (m, 1H), 7.69 (m, 1H), 7.50-7.41 (m, 2H),7.41-7.30 (m, 3H), 7.26 (d, J=8.0 Hz, 1H), 7.06 (m, 2H), 6.51 (d, J=7.1Hz, 1H), 4.40-4.28 (m, 1H), 3.67-3.52 (m, 2H), 2.89 (s, 3H), 2.31-2.20(m, 1H), 2.07-1.96 (m, 2H), 1.84 (m, 1H). Analytical HPLC: RT=1.54 min(Method B).

Example 29.2′-fluoro-4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxamide

MS(ESI) m/z 515 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.30 (s, 1H), 7.70(br. s., 1H), 7.63-7.11 (m, 12H), 6.77 (d, J=6.7 Hz, 1H), 4.50-4.30 (m,1H), 3.75 (d, J=19.2 Hz, 2H), 2.38-2.20 (m, 1H), 2.06-1.94 (m, 2H),1.88-1.73 (m, 1H). Analytical HPLC: RT=1.64 min (Method A).

Example 30.4′-(3-(3-(4-chlorophenyl)ureido)-2-oxopiperidin-1-yl)-2′-fluoro-[1,1′-biphenyl]-2-carboxamide

MS(ESI) m/z 481 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.97 (s, 1H), 7.72(s, 1H), 7.59-7.10 (m, 12H), 6.59 (d, J=6.8 Hz, 1H), 4.44-4.31 (m, 1H),3.85-3.67 (m, 2H), 2.27 (m, 1H), 1.99 (m, 2H), 1.80 (m, 1H). AnalyticalHPLC: RT=1.63 min (Method A).

Examples 31-53 were similarly prepared using the procedures describedabove for Example 2 or 3.

Example 31.1-(1-(2′-fluoro-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 472.3 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.19 (s, 1H),7.73-7.49 (m, 7H), 7.40 (d, J=7.9 Hz, 3H), 7.32-7.19 (m, 2H), 6.70 (d,J=6.8 Hz, 1H), 4.42-4.23 (m, 1H), 3.86-3.72 (m, 2H), 2.33-2.19 (m, 1H),2.00 (m, 2H), 1.84 (m, 1H). Analytical HPLC: RT=2.14 min (Method B).

Example 32.1-(1-(4-(2-fluoropyridin-3-yl)phenyl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 473 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.22 (s, 1H),8.32-8.04 (m, 2H), 7.75-7.55 (m, 6H), 7.49-7.32 (m, 3H), 6.71 (d, J=6.9Hz, 1H), 4.48-4.29 (m, 1H), 3.82-3.62 (m, 1H), 3.61-3.48 (m, 1H), 2.29(m, 1H), 2.07-1.92 (m, 2H), 1.88-1.64 (m, 1H). Analytical HPLC: RT=1.91min (Method B).

Example 33.1-(1-(2′-cyano-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 479.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.23 (s, 1H), 7.94(d, J=7.7 Hz, 1H), 7.83-7.74 (m, 1H), 7.68-7.54 (m, 8H), 7.48 (d, J=8.3Hz, 2H), 6.72 (d, J=6.9 Hz, 1H), 4.45-4.25 (m, 1H), 3.92-3.68 (m, 2H),2.28 (d, J=6.0 Hz, 1H), 2.10-1.97 (m, 2H), 1.65 (s, 1H). AnalyticalHPLC: RT=1.89 min (Method A).

Example 34. methyl4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxylate

MS(ESI) m/z 512 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.21 (s, 1H), 7.73(d, J=7.6 Hz, 1H), 7.63-7.55 (m, 5H), 7.50-7.25 (m, 6H), 6.69 (d, J=6.6Hz, 1H), 4.42-4.24 (m, 1H), 3.75 (d, J=5.5 Hz, 2H), 3.60 (s, 3H), 2.29(d, J=5.4 Hz, 1H), 1.79 (m, 2H), 1.44-1.07 (m, 1H). Analytical HPLC:RT=2.09 min (Method A).

Example 35.1-(2-oxo-1-(4-(pyridin-3-yl)phenyl)piperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 455.1 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.23 (s, 1H), 8.89(s, 1H), 8.57 (d, J=4.0 Hz, 1H), 8.09 (d, J=7.8 Hz, 1H), 7.76 (d, J=8.2Hz, 2H), 7.63-7.32 (m, 7H), 6.71 (d, J=6.8 Hz, 1H), 4.44-4.31 (m, 1H),3.81-3.68 (m, 1H), 3.60-3.42 (m, 1H), 2.30 (m, 1H), 2.00 (m, 2H),1.90-1.76 (m, 1H). Analytical HPLC: RT=1.37 min (Method A).

Example 36.1-(1-([1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 454.3 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.21 (s, 1H),7.74-7.55 (m, 8H), 7.50-7.32 (m, 5H), 6.70 (d, J=6.7 Hz, 1H), 4.44-4.28(m, 1H), 3.81-3.54 (m, 2H), 2.28 (d, J=6.8 Hz, 1H), 2.09-1.95 (m, 2H),1.88-1.72 (m, 1H). Analytical HPLC: RT=2.12 min (Method A).

Example 37.1-(1-(3′-fluoro-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 472.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.20 (s, 1H), 7.72(d, J=8.3 Hz, 2H), 7.62-7.36 (m, 9H), 7.18 (t, J=8.0 Hz, 1H), 6.70 (d,J=6.9 Hz, 1H), 4.40-4.20 (m, 1H), 3.78-3.56 (m, 2H), 2.28-2.22 (m, 1H),2.04-1.94 (m, 2H), 1.84 (m, 1H). Analytical HPLC: RT=2.1 min (Method).

Example 38.1-(2-oxo-1-(4-(pyridin-4-yl)phenyl)piperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 454.9 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.19 (s, 1H), 8.61(d, J=5.0 Hz, 2H), 7.82 (d, J=8.4 Hz, 2H), 7.72 (d, J=5.6 Hz, 2H), 7.58(s, 4H), 7.45 (d, J=8.4 Hz, 2H), 6.70 (d, J=7.1 Hz, 1H), 4.44-4.30 (m,1H), 3.83-3.66 (m, 2H), 2.26 (m, 1H), 2.05-1.95 (m, 2H), 1.85 (m, 1H).Analytical HPLC: RT=1.67 min (Method B).

Example 39.1-(1-(4′-fluoro-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 472 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.22 (s, 1H),7.81-7.52 (m, 8H), 7.39 (d, J=8.2 Hz, 2H), 7.29 (t, J=8.7 Hz, 2H), 6.70(d, J=6.7 Hz, 1H), 4.47-4.28 (m, 1H), 3.82-3.59 (m, 2H), 2.38-2.21 (m,1H), 2.00 (m, 2H), 1.84 (m, 1H). Analytical HPLC: RT=2.04 min (MethodA).

Example 40. methyl3-fluoro-4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxylate

MS(ESI) m/z 530.4 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.38 (s, 1H),7.70-7.53 (m, 5H), 7.42-7.29 (m, 6H), 6.90 (d, J=6.7 Hz, 1H), 4.45-4.29(m, 1H), 3.86-3.71 (m, 1H), 3.67-3.37 (m, 4H), 2.11-1.62 (m, 3H),1.41-1.05 (m, 1H). Analytical HPLC: RT=2.15 min (Method B).

Example 41.1-(1-(4-(2-ethoxy-5-fluoropyridin-4-yl)phenyl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 517.3 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.24 (s, 1H), 8.21(s, 1H), 7.75-7.55 (m, 6H), 7.46 (d, J=8.4 Hz, 2H), 6.98 (d, J=5.3 Hz,1H), 6.73 (d, J=6.8 Hz, 1H), 4.45-4.25 (m, 3H), 3.91-3.68 (m, 2H),3.54-3.41 (m, 3H), 2.38-2.25 (m, 1H), 2.00 (m, 2H), 1.85 (m, 1H).Analytical HPLC: RT=2.17 min (Method B).

Example 42.4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxylicacid

MS(ESI) m/z 498.1 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.51 (s, 1H),7.78-7.53 (m, 5H), 7.47-7.17 (m, 7H), 6.99 (d, J=6.1 Hz, 1H), 4.43-4.24(m, 1H), 3.75-3.57 (m, 2H), 2.29 (d, J=5.8 Hz, 1H), 1.98 (d, J=6.1 Hz,2H), 1.86-1.63 (m, 1H). Analytical HPLC: RT=1.92 min (Method A).

Example 43.1-(1-(3′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 532.1 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.23 (s, 1H), 8.13(s, 1H), 8.03 (s, 1H), 7.90 (d, J=7.8 Hz, 1H), 7.77-7.69 (m, 3H), 7.58(s, 4H), 7.45 (d, J=8.4 Hz, 2H), 6.74 (d, J=7.0 Hz, 1H), 4.33 (d, J=11.6Hz, 1H), 3.88-3.66 (m, 2H), 3.26 (s, 3H), 2.26 (d, J=5.8 Hz, 1H),2.09-1.94 (m, 2H), 1.82 (s, 1H). Analytical HPLC: RT=1.78 min (MethodB).

Example 44.1-(1-(4-(2-methylpyridin-3-yl)phenyl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 468.9 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.24 (s, 1H), 8.66(d, J=4.8 Hz, 1H), 8.11 (d, J=7.7 Hz, 1H), 7.69 (t, J=6.4 Hz, 1H),7.61-7.34 (m, 8H), 6.73 (d, J=6.7 Hz, 1H), 4.48-4.33 (m, 1H), 3.85-3.70(m, 2H), 2.66-2.54 (s, 3H), 2.29 (m, 1H), 2.01 (m, 2H), 1.87 (m, 1H).Analytical HPLC: RT=1.9 min (Method B).

Example 45.1-(1-(4-(3-methylpyridin-4-yl)phenyl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 469.1 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.28 (s, 1H),8.62-8.37 (m, 2H), 7.71-7.52 (m, 4H), 7.45 (d, J=2.3 Hz, 4H), 7.26 (d,J=4.8 Hz, 1H), 6.76 (d, J=6.6 Hz, 1H), 4.42-4.29 (m, 1H), 3.86-3.66 (m,2H), 2.28 (m, 4H), 2.01 (m, 2H), 1.90-1.77 (m, 1H). Analytical HPLC:RT=1.76 min (Method B).

Example 46.1-(1-(4′-cyano-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 479.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.24 (s, 1H),8.03-7.86 (m, 4H), 7.78 (d, J=8.3 Hz, 2H), 7.65-7.53 (m, 4H), 7.46 (d,J=8.3 Hz, 2H), 6.73 (d, J=6.7 Hz, 1H), 4.47-4.28 (m, 1H), 3.81-3.62 (m,1H), 3.55-3.32 (m, 1H), 2.32-2.21 (m, 1H), 2.09-1.97 (m, 2H), 1.92-1.64(m, 1H). Analytical HPLC: RT=2 min (Method A).

Example 47.1-(1-(4-(4-methylpyridin-3-yl)phenyl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 468.9 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.26 (s, 1H),8.55-8.37 (m, 2H), 7.59 (s, 4H), 7.49-7.40 (m, 4H), 7.26 (d, J=4.8 Hz,1H), 6.74 (d, J=6.5 Hz, 1H), 4.44-4.25 (m, 1H), 3.82-3.71 (m, 1H),3.71-3.50 (m, 1H), 2.28 (s, 3H), 2.01 (m, 2H), 1.89-1.56 (m, 2H).Analytical HPLC: RT=1.83 min (Method B).

Example 48.4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-4-carboxamide

MS(ESI) m/z 497.1 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.24 (s, 1H), 8.05(br. s., 1H), 7.96 (d, J=8.0 Hz, 2H), 7.83-7.72 (m, 4H), 7.68-7.54 (m,4H), 7.47-7.35 (m, 3H), 6.72 (d, J=6.6 Hz, 1H), 4.46-4.33 (m, 1H),3.88-3.65 (m, 2H), 2.30 (m, 1H), 2.01 (m, 2H), 1.84 (m, 1H). AnalyticalHPLC: RT=1.61 min (Method B).

Example 49.1-(1-(4′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 532 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.59 (br. s., 1H),8.09-7.94 (m, 4H), 7.80 (d, J=8.3 Hz, 2H), 7.70-7.43 (m, 6H), 7.10 (br.s., 1H), 4.41-4.28 (m, 1H), 3.94-3.63 (m, 2H), 2.63-2.49 (s, 3H),2.32-2.22 (m, 1H), 2.02 (m, 2H), 1.90-1.77 (m, 1H). Analytical HPLC:RT=1.71 min (Method A).

Example 50.2′-cyano-5-fluoro-N-methyl-4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxamide

MS(ESI) m/z 554 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 8.15 (d, J=4.6 Hz,1H), 7.87 (d, J=8.2 Hz, 2H), 7.66 (d, J=8.2 Hz, 2H), 7.55 (dd, J=8.4,6.0 Hz, 1H), 7.35-7.23 (m, 1H), 7.20 (dd, J=9.8, 2.1 Hz, 1H), 7.10 (d,J=8.5 Hz, 1H), 6.99-6.79 (m, 2H), 6.32 (s, 2H), 4.32 (d, J=7.3 Hz, 1H),3.14 (d, J=6.4 Hz, 2H), 2.58 (d, J=4.6 Hz, 3H) 2.03-1.59 (m, 4H).Analytical HPLC: RT=1.74 min (Method A).

Example 51.5-fluoro-N-methyl-4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxamide

MS(ESI) m/z 528.8 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.22 (s, 1H), 8.15(d, J=4.6 Hz, 1H), 7.59 (s, 4H), 7.49-7.09 (m, 7H), 6.69 (d, J=6.8 Hz,1H), 4.44-4.24 (m, 1H), 3.86-3.53 (m, 2H), 2.88 (s, 3H), 2.28 (dd,J=12.1, 5.7 Hz, 1H), 2.07-1.94 (m, 2H), 1.86-1.69 (m, 1H). AnalyticalHPLC: RT=1.69 min (Method B).

Example 52.1-(1-(2′-(morpholine-4-carbonyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 567.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.22 (s, 1H),7.68-7.26 (m, 12H), 6.81-6.59 (m, 1H), 4.34 (br. s., 1H), 3.74-3.49 (m,2H), 3.31-3.05 (m, 2H), 3.00-2.87 (m, 2H), 2.80-2.63 (m, 2H), 2.42 (d,J=11.4 Hz, 1H), 2.28 (d, J=5.8 Hz, 1H), 2.08-1.95 (m, 2H), 1.89-1.72 (m,2H). Analytical HPLC: RT=1.88 min (Method B).

Example 53.1-(1-(4-(2-methoxypyridin-3-yl)phenyl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

MS(ESI) m/z 484.9 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.21 (s, 1H),8.26-8.10 (m, 1H), 7.85-7.72 (m, 1H), 7.66-7.52 (m, 6H), 7.35 (d, J=8.4Hz, 2H), 7.15-6.94 (m, 1H), 6.77-6.63 (m, 1H), 4.40-4.25 (m, 1H), 3.87(s, 3H), 3.73-3.58 (m, 2H), 2.31-2.21 (m, 1H), 2.10-1.96 (m, 2H),1.87-1.68 (m, 1H). Analytical HPLC: RT=2.01 min (Method B).

Example 54.N-methyl-4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxamide

Example 54A. methyl4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxylate

Example 54A was synthesized from Example 3A and2-(methoxycarbonyl)phenyl)boronic acid in a route similar to thatdescribed in preparing Example 3. MS (ESI) m/z 512.5 (M+H).

Example 54B.4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxylicacid

To a solution of Example 54A (100 mg, 0.20 mmol) in THF (1.0 mL), MeOH(1.0 mL) and H₂O (0.20 mL) was added LiOH—H₂O (41 mg, 0.98 mmol). Thereaction mixture was stirred overnight at RT. The reaction solution wasdiluted with EtOAc and IN HCl, the layers were separated, and theaqueous layer extracted with EtOAc (2×). The combined extracts werewashed with brine, dried over Na₂SO₄, and concentrated to give the crudeproduct (80 mg, 0.16 mmol). MS (ESI) m/z 498.4 (M+H).

Example 54

A mixture of Example 54B (40 mg, 0.080 mmol), methanamine (0.015 mL,0.40 mmol), HATU (61 mg, 0.16 mmol) and Et₃N (0.11 mL, 0.80 mmol) in DMF(1.0 mL) was stirred at RT for 5 h. The reaction solution was filteredand the product was purified via reverse phase prep HPLC to give thetitle compound, (2.0 mg, 0.0038 mmol). MS (ESI) m/z 511.0 (M+H). ¹H NMR(500 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.18-8.07 (m, 1H), 7.61 (m, 5H), 7.36(m, 7H), 6.86-6.65 (m, 1H), 4.46-4.31 (m, 1H), 3.81-3.63 (m, 2H), 3.16(m, 1H), 2.59 (s, 3H), 2.37-2.24 (m, 1H), 2.01 (m, 2H). Analytical HPLC:RT=1.649 min (Method A).

Example 55.N,N-dimethyl-4′-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)-[1,1′-biphenyl]-2-carboxamide

Example 55 was synthesized using the procedures described in Example 54.MS(ESI) m/z 525.2 (M+H). ¹H NMR (500 MHz, DMSO-d₆) δ 9.58 (s, 1H),7.79-7.29 (m, 12H), 7.10 (d, J=6.4 Hz, 1H), 4.46-4.28 (m, 1H), 3.80-3.57(m, 2H), 2.79 (s, 3H), 2.47 (s, 3H), 2.27 (d, J=6.1 Hz, 1H), 2.00 (m,2H), 1.91-1.76 (m, 1H). Analytical HPLC: RT=1.76 min (Method A).

Example 56.4′-(3-(3-(4-chlorophenyl)ureido)-2-oxopiperidin-1-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide

Example 56A.4′-(3-((tert-butoxycarbonyl)amino)-2-oxopiperidin-1-yl)-[1,1′-biphenyl]-2-carboxylicacid

Example 56A was prepared from 1-chloro-4-iodobenzene and 2-boronobenzoicacid in a route similar to that described in preparing Example 1A andExample 1B. MS (ESI) m/z 411.3 (M+H).

Example 56B. tert-butyl(1-(2′-(methylcarbamoyl)-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)carbamate

Example 56B was prepared from Example 56A using the amide couplingconditions described in preparing Example 4. MS (ESI) m/z 424.3 (M+H).

Example 56C.4′-(3-amino-2-oxopiperidin-1-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide

Example 56C was prepared from Example 56B using deprotection conditionsdescribed in preparing Example 1C. MS (ESI) m/z 324.1 (M+H).

Example 56 was prepared from Example 5C and 1-chloro-4-isocyanatobenzeneusing conditions described in preparing Example 1. MS (ESI) m/z 477.4(M+H).

Example 57:(R)-1-(1-(4-(2-fluoropyridin-3-yl)phenyl)-2-oxopiperidin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea

To a solution of Intermediate 1 in 1,4-dioxane (2 mL) were addedpotassium phosphate, tribasic (23 mg, 0.13 mmol) and(2-fluoropyridin-3-yl)boronic acid (11 mg, 0.079 mmol). The reactionmixture was purged with nitrogen for 5 min and charged withPd(dppf)Cl₂.DCM adduct (5.4 mg, 6.6 μmol). The reaction mixture wasagain purged with nitrogen for 3 min and heated at 60° C. for 15 h. Themixture was cooled, filtered through celite pad and the filtrate wasconcentrated under reduced pressure to yield the crude product which waspurified by reverse phase chromatography to afford the title compound(11 mg, 34%, 0.023 mmol) as a off white solid. MS(ESI) m/z: 473.1 (M+H);¹H NMR (400 MHz, DMSO-d₆): δ 9.22 (s, 1H), 8.25 (d, J=5.14 Hz, 1H),8.18-8.11 (m, 1H), 7.68-7.56 (m, 6H), 7.51-7.44 (m, 3H), 6.70 (d, J=6.60Hz, 1H), 4.41-4.34 (m, 1H), 3.82-3.68 (m, 2H), 2.35-2.28 (m, 1H),2.06-1.98 (m, 2H), 1.89-1.79 (m, 1H). Analytical HPLC: RT=2.08 min,(Method F).

The following examples in Table 2 were made by using analogousprocedures to those shown in Example 57 from Intermediates 1-3 using theappropriate boronic acids.

TABLE 2 HPLC Method, LCMS RT (M + (min.) & Ex Structure H)+ Purity 1HNMR  58

484.2 Method E, RT = 1.80 min, 97.6% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 7.64- 7.54 (m, 5H), 7.44-7.29 (m, 6H), 7.24 (dd, J = 7.5, 1.5Hz, 1H), 6.69 (d, J = 6.5 Hz, 1H), 5.14 (t, J = 5.3 Hz, 1H), 4.45-4.30(m, 3H), 3.83-3.68 (m, 2H), 2.37-2.27 (m, 1H), 2.09-1.96 (m, 2H),1.89-1.75 (m, 1H)  59

484.2 Method E, RT = 2.12 min, 96.3% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 7.64- 7.54 (m, 4H), 7.52-7.46 (m, 2H), 7.38-7.27 (m, 4H), 7.12(d, J = 7.5 Hz, 1H), 7.06-6.99 (m, 1H), 6.69 (d, J = 7.0 Hz, 1H),4.39-4.30 (m, 1H), 3.80- 3.66 (m, 5H), 2.36-2.30 (m, 1H), 2.06-1.95 (m,2H), 1.89-1.72 (m, 1H)  60

498.2 Method E, RT = 1.79 min, 98% ¹H NMR (400 MHz, DMSO- d₆): δ 9.50(br. s., 1H), 7.65-7.50 (m, 5H), 7.46- 7.27 (m, 6H), 6.99 (d, J = 6.0Hz, 1H), 6.72 (br. s., 1H), 6.31-6.30 (m, 1H), 4.41-4.28 (m, 1H), 3.75-3.64 (m, 2H), 2.29 (m, 1H), 2.05-1.94 (m, 2H), 1.88- 1.73 (m, 1H)  61

497.1 Method F, RT = 1.811 min, 99.2% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 7.69 (s, 1H), 7.63-7.55 (m, 4H), 7.51-7.29 (m, 9H), 6.69 (d, J= 6.60 Hz, 1H), 4.39-4.33 (s, 1H), 3.79-3.69 (m, 2H), 2.36-2.28 (m, 1H),2.05- 1.97 (m, 2H), 1.87-1.75 (m, 1H).  62

455.2 Method F, RT = 1.664 min, 99.8% ¹H NMR (400 MHz, DMSO- d₆): δ 9.26(s, 1H), 8.83 (d, J = 6.40 Hz, 2H), 8.15 (d, J = 6.40 Hz, 2H), 8.00 (d,J = 8.40 Hz, 2H), 7.63-7.59 (m, 4H), 7.55 (d, J = 8.80 Hz, 2H), 6.74 (d,J = 6.80 Hz, 1H), 4.42-4.36 (m, 1H), 3.84-3.71 (m, 2H), 2.33- 2.27 (m,1H), 2.06-1.99 (m, 2H), 1.90-1.82 (m, 1H).  63

473.1 Method F, RT = 2.072 min, 95.2% ¹H NMR (400 MHz, DMSO- d₆): δ 9.21(s, 1H), 7.65- 7.55 (m, 4 H), 7.42 (s, 4 H), 6.68 (d, J = 6.85 Hz, 1H),4.40-4.30 (m, 1H), 3.80-3.67 (m, 2H), 2.42 (s, 3H), 2.34-2.29 (m, 1H),2.24 (s, 3H), 1.95-2.05 (m, 2H), 1.90-1.76 (m, 1H).  64

458.1 Method F, RT = 1.858 min, 99.1% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 8.13 (s, 1H), 7.86 (s, 1H), 7.54- 7.64 (m, 6H), 7.28 (d, J =8.56 Hz, 2H), 6.68 (d, J = 6.60 Hz, 1H), 4.38-4.29 (m, 1H), 3.86 (s,3H), 3.76-3.61 (m, 2H), 2.31 (m, 1H), 2.03-1.94 (m, 2H), 1.86-1.74 (m,1H).  65

486.0 Method F, RT = 2.284 min, 99.5% ¹H NMR (400 MHz, DMSO- d₆): δ8.94-8.91 (m, 1H) 7.46-7.38 (m, 6H) 7.30- 7.24 (m, 2H) 6.90-6.83 (m, 2H)6.59-6.54 (m, 1H) 4.38-4.29 (m, 1H) 4.06-4.03 (s, 3H) 3.80- 3.66 (m, 2H)2.35-2.24 (m, 1H) 2.05-1.96 (m, 2H) 1.88-1.74 (m, 1H)  66

547.2 Method F, RT = 1.83 min, 96.8% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 7.65- 7.56 (m, 3H), 7.53-7.47 (m, 2H), 7.46-7.32 (m, 7H), 6.70(d, J = 7.0 Hz, 1H), 6.27 (s, 1H), 4.42- 4.31 (m, 1H), 3.82-3.67 (m,2H), 2.73 (s, 3H), 2.33- 2.28 (m, 1H), 2.01 (m, 2H), 1.84 (m, 1H).  67

484.2 Method F, RT = 1.804 min, 98.6% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 7.65- 7.54 (m, 5H), 7.45-7.30 (m, 6H), 7.28-7.21 (m, 1H), 6.70(d, J = 6.5 Hz, 1H), 5.18-5.11 (m, 1H), 4.45-4.31 (m, 3H), 3.83- 3.68(m, 2H), 2.32-2.27 (m, 1H), 2.06-1.97 (m, 2H), 1.89-1.78 (m, 1H)  68

484.2 Method E, RT = 2.132 min, 94.5% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 7.64- 7.55 (m, 4H), 7.52-7.46 (m, 2H), 7.38-7.28 (m, 4H), 7.12(d, J = 8.5 Hz, 1H), 7.03 (td, J = 7.5, 1.0 Hz, 1H), 6.69 (d, J = 7.0Hz, 1H), 4.39-4.29 (m, 1H), 3.80-3.67 (m, 5H), 2.32- 2.26 (m, 1H), 2.05-1.97 (m, 2H), 1.83 (m, 1H)  69

468.2 Method E, RT = 2.227 min, 98.4% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 7.64- 7.54 (m, 4H), 7.41-7.34 (m, 4H), 7.32-7.18 (m, 4H), 6.70(d, J = 7.0 Hz, 1H), 4.41-4.30 (m, 1H), 3.83-3.66 (m, 2H), 2.32- 2.27(m, 1H), 2.26 (s, 3H), 2.05-1.96 (m, 2H), 1.84 (m, 1H)  70

522.2 Method F, RT = 2.25 min, 96.6% ¹H NMR (400 MHz, METHANOL-d₄): δ7.78 (d, J = 8.0 Hz, 1H), 7.67-7.62 (m, 1H), 7.60-7.50 (m, 5H),7.41-7.33 (m, 5H), 4.45 (dd, J = 11.5, 6.0 Hz, 1H), 3.92-3.73 (m, 2H),2.47-2.37 (m, 1H), 2.19- 2.09 (m, 2H), 2.05-1.92 (m, 1H)  71

498.2 Method F, RT = 1.286 min, 94.9% ¹H NMR (400 MHz, METHANOL-d₄): δ7.67 (d, J = 6.5 Hz, 1H), 7.60-7.51 (m, 4H), 7.51-7.43 (m, 3H),7.41-7.30 (m, 4H), 4.45 (dd, J = 11.5, 6.0 Hz, 1H), 3.88-3.70 (m, 2H),2.48-2.37 (m, 1H), 2.17- 2.08 (m, 2H), 1.98 (m, 1H)  72

511.2 Method F, RT = 1.712 min, 93.5% ¹H NMR (400 MHz, DMSO- d₆): δ 9.31(s, 1H), 7.65- 7.53 (m, 5H), 7.47-7.24 (m, 8H), 6.80 (d, J = 7.0 Hz,1H), 4.42-4.29 (m, 1H), 3.73 (tq, J = 12.1, 6.0 Hz, 2H), 2.33-2.25 (m,1H), 2.06-1.95 (m, 2H), 1.88-1.76 (m, 4H).  73

456.2 Method E, RT = 1.532 min, 97.5% ¹H NMR (400 MHz, DMSO- d₆): δ9.24-9.14 (m, 3H), 7.88-7.82 (m, 2H), 7.65- 7.54 (m, 4H), 7.52-7.45 (m,2H), 6.70 (d, J = 7.0 Hz, 1H), 6.26 (s, 1H), 4.36 (m, 1H), 3.75 (d, J =16.6 Hz, 2H), 2.32 (m, 1H), 2.01 (m, 2H), 1.84 (m, 1H)  74

498.2 Method F, RT = 2.064 min, 91.9% ¹H NMR (400 MHz, DMSO- d₆): δ 9.21(s, 1H), 7.66- 7.54 (m, 6H), 7.39-7.32 (m, 2H), 7.26 (d, J = 1.5 Hz,1H), 7.16 (dd, J = 8.3, 1.8 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.69 (d,J = 6.5 Hz, 1H), 6.06 (s, 2H), 4.40-4.29 (m, 1H), 3.71 (dt, J = 16.6,6.5 Hz, 2H), 2.29 (m, 1H), 2.07-1.94 (m, 2H), 1.82 (m, 1H)  75

499.2 Method E, RT = 1.975 min, 97.8% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 8.48 (d, J = 2.5 Hz, 1H), 8.05- 7.98 (m, 1H), 7.72-7.64 (m,2H), 7.63-7.55 (m, 4H), 7.43-7.36 (m, 2H), 6.92-6.85 (m, 1H), 6.69 (d, J= 6.5 Hz, 1H), 4.41- 4.29 (m, 3H), 3.81-3.64 (m, 2H), 2.32-2.27 (m, 1H),2.07-1.96 (m, 2H), 1.88-1.74 (m, 1H), 1.37- 1.30 (m, 3H)  76

445.2 Method C, RT = 1.85 min, 96.9% ¹H NMR (400 MHz, DMSO- d₆): δ 8.92(s, 1H), 7.98- 7.92 (m, 1H), 7.84-7.75 (m, 1H), 7.67-7.54 (m, 4H),7.51-7.39 (m, 4H), 7.29-7.23 (m, 2H), 6.56 (d, J = 6.8 Hz, 1H), 4.41-4.30 (m, 1H), 3.84-3.65 (m, 2H), 2.31-2.24 (m, 1H), 2.05-1.94 (m, 2H),1.88-1.73 (m, 1H)  77

450.2 Method D, RT = 1.67 min, 98.1% ¹H NMR (400 MHz, DMSO- d₆): δ 8.93(s, 1H), 7.57 (d, J = 7.6 Hz, 1H), 7.47-7.31 (m, 8H), 7.30-7.21 (m, 3H),6.57 (d, J = 6.6 Hz, 1H), 5.14 (t, J = 5.4 Hz, 1H), 4.42 (d, J = 5.1 Hz,2H), 4.38-4.27 (m, 1H), 3.82-3.66 (m, 2H), 2.29 (m, 1H), 2.04-1.96 (m,2H), 1.87-1.75 (m, 1H)  78

481.1 Method E, RT = 1.708 min, 100.0% ¹H NMR (400 MHz, DMSO- d₆): δ8.92-8.87 (m, 1H) 7.80-7.76 (m, 1H) 7.53- 7.36 (m, 8 H) 7.35-7.24 (m, 4H) 6.60-6.55 (m, 1H) 4.39-4.31 (m, 1H) 3.68-3.60 (m, 2H) 2.35- 2.26 (m,1H) 2.05-1.97 (m, 2H) 1.88-1.76 (m, 1H)  79

450.4 Method C, RT = 2.007 min, 96.3% 1H NMR (400 MHz, DMSO-d₆): δ 8.93(s, 1H), 7.52-7.40 (m, 4H), 7.38- 7.23 (m, 6H), 7.12 (d, J = 7.3 Hz,1H), 7.03 (td, J = 7.5, 1.0 Hz, 1H), 6.56 (d, J = 6.4 Hz, 1H), 4.37-4.26(m, 1H), 3.78 (s, 3H), 3.76- 3.66 (m, 2H), 2.29 (m, 1H), 2.05-1.95 (m,2H), 1.85-1.75 (m, 1H)  80

498.2 Method D, RT = 1.673 min, 94.5% ¹H NMR (400 MHz, DMSO- d₆): δ 8.96(s, 1H), 8.10 (d, J = 9.3 Hz, 1H), 7.81-7.73 (m, 1H), 7.72-7.64 (m, 1H),7.47-7.37 (m, 7H), 7.27 (d, J = 8.8 Hz, 2H), 6.60 (d, J = 6.8 Hz, 1H),4.35 (d, J = 11.7 Hz, 1H), 3.84-3.69 (m, 2H), 2.82 (s, 3H), 2.32-2.23(m, 1H), 2.00 (m, 2H), 1.83 (m, 1H)  81

434.2 Method D, RT = 2.12 min, 96.8% ¹H NMR (400 MHz, DMSO- d₆): δ 8.92(s, 1H), 7.46- 7.40 (m, 2H), 7.39-7.32 (m, 4H), 7.31-7.17 (m, 6H), 6.56(d, J = 6.6 Hz, 1H), 4.38-4.27 (m, 1H), 3.79-3.66 (m, 2H), 2.31- 2.26(m, 1H), 2.25 (s, 3H), 2.03-1.94 (m, 2H), 1.86- 1.72 (m, 1H)  82

489.1 Method D, RT = 2.173 min, 96.9% ¹H NMR (400 MHz, DMSO- d₆): δ 8.93(s, 1H), 7.62- 7.56 (m, 2H), 7.48-7.39 (m, 5H), 7.32-7.23 (m, 4H), 6.56(d, J = 6.8 Hz, 1H), 4.40-4.30 (m, 1H), 3.84-3.69 (m, 2H), 2.32- 2.26(m, 1H), 2.05-1.96 (m, 2H), 1.87-1.74 (m, 1H)  83

481.2 Method D, RT = 2.097 min, 97.1% ¹H NMR (400 MHz, DMSO- d₆): δ 8.92(s, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.56-7.48 (m, 2H), 7.46-7.38 (m, 2H),7.35-7.23 (m, 4H), 6.55 (d, J = 6.6 Hz, 1H), 6.48 (d, J = 8.1 Hz, 1H),4.38-4.26 (m, 1H), 3.90 (d, J = 1 Hz, 6H), 3.77- 3.63 (m, 2H), 2.28 (m,1H), 2.03-1.94 (m, 2H), 1.86- 1.72 (m, 1H)  84

464.1 Method C, RT = 1.658 min, 97.6% ¹H NMR (400 MHz, DMSO- d₆): δ 9.01(s, 1H), 7.63 (br. s., 1H), 7.51 (br. s., 1H), 7.47-7.31 (m, 8H),7.30-7.23 (m, 2H), 6.64 (d, J = 6.6 Hz, 1H), 4.39- 4.28 (m, 1H),3.77-3.66 (m, 2H), 2.33-2.25 (m, 1H), 2.05-1.94 (m, 2H), 1.86-1.71 (m,1H)  85

451.2 Method C, RT = 1.537 min, 96.8% ¹H NMR (400 MHz, DMSO- d₆): δ 8.93(s, 1H), 8.24 (dd, J = 5.5, 0.6 Hz, 1H), 7.85-7.78 (m, 2H), 7.49- 7.41(m, 4H), 7.34 (dd, J = 5.5, 1.6 Hz, 1H), 7.31- 7.24 (m, 2H), 7.13 (dd, J= 1.6, 0.6 Hz, 1H), 6.58 (d, J = 6.6 Hz, 1H), 4.40-4.30 (m, 1H), 3.91(s, 3H), 3.82- 3.66 (m, 2H), 2.32-2.23 (m, 1H), 2.07-1.94 (m, 2H),1.88-1.75 (m, 1H)  86

513.1 Method D, RT = 1.705 min, 97.4% ¹H NMR (400 MHz, DMSO- d₆): δ 9.19(s, 1H), 7.76 (d, J = 8.6 Hz, 2H), 7.72-7.47 (m, 10H), 6.83 (d, J = 6.8Hz, 1H), 4.64-4.53 (m, 1H), 4.07-3.92 (m, 2H), 2.96 (s, 3H), 2.58-2.51(m, 1H), 2.25 (m, 2H), 2.06 (m, 1H)  87

423.9 Method F, RT = 1.975 min, 100.0% ¹H NMR (400 MHz, DMSO- d₆): δ8.92-8.88 (m, 1H), 7.61-7.54 (m, 2H), 7.45- 7.39 (m, 2H), 7.31-7.24 (m,4 H), 6.57-6.51 (m, 1H), 4.35-4.26 (m, 1H), 3.75-3.59 (m, 2H), 2.31-2.21 (m, 1H), 2.02-1.92 (m, 2H), 1.85-1.71 (m, 1H).  88

477.2 Method D, RT = 1.565 min, 97.8% ¹H NMR (400 MHz, DMSO- d₆): δ 9.32(s, 1H), 8.96 (s, 1H), 7.49-7.22 (m, 12H), 6.64-6.55 (m, 1H), 4.40- 4.29(m, 1H), 3.74 (dq, J = 12.0, 6.1 Hz, 2H), 2.30 (m, 1H), 2.07-1.96 (m,2H), 1.91 (s, 3H), 1.87-1.73 (m, 1H)  89

422.2 Method D, RT = 1.369 min, 97.1% ¹H NMR (400 MHz, DMSO- d₆): δ9.20-9.12 (m, 3H), 8.92 (s, 1H), 7.87-7.80 (m, 2H), 7.51-7.38 (m, 4H),7.30-7.21 (m, 2H), 5.56 (d, J = 6.6 Hz, 1H), 4.39-4.28 (m, 1H), 3.82-3.65 (m, 2H), 2.31-2.25 (m, 1H), 2.04-1.94 (m, 2H), 1.87-1.75 (m, 1H) 90

520.1 Method E, RT = 2.413 min, 96.7% ¹H NMR (400 MHz, DMSO- d₆): δ 9.24(s, 1H), 7.64- 7.54 (m, 4H), 7.46-7.37 (m, 4H), 6.92-6.82 (m, 2H), 6.71(d, J = 6.8 Hz, 1H), 4.42-4.31 (m, 1H), 3.83 (s, 3H), 3.79-3.67 (m, 2H),2.36-2.25 (m, 1H), 2.06-1.96 (m, 2H), 1.89-1.76 (m, 1H).  91

516.0 Method F, RT = 1.939 min, 97.7% ¹H NMR (400 MHz, DMSO- d₆): δ8.91-8.86 (m, 1H) 8.14-8.08 (m, 1H) 7.82- 7.67 (m, 2H) 7.51-7.34 (m, 5H) 7.32-7.24 (m, 3H) 6.60-6.55 (m, 1H) 4.41-4.31 (m, 1H) 3.75- 3.62 (m,2H) 2.93 (s, 3H) 2.34-2.24 (m, 1H) 2.08- 1.97 (m, 2H) 1.90-1.77 (m, 1H). 92

504.0 Method E, RT = 2.374 min, 95.2% ¹H NMR (400 MHz, DMSO- d₆): δ 8.94(s, 1H), 7.46- 7.38 (m, 5 H), 7.30-7.24 (m, 2H), 6.90-6.83 (m, 2H),6.59-6.54 (m, 1H), 4.38-4.29 (m, 1H), 4.06 (s, 3H), 3.80-3.66 (m, 2H),2.35-2.44 (m, 1H), 2.05-1.96 (m, 2H), 1.88- 1.74 (m, 1H)  93

456.0 Method E, RT = 2.277 min, 93.7% ¹H NMR (400 MHz, DMSO- d₆): δ 8.94(s, 1H), 7.50- 7.48 (m, 1H), 7.46-7.38 (m, 6 H), 7.30-7.24 (m, 2H),6.90-6.83 (m, 2H), 6.59-6.54 (m, 1H), 4.38- 4.29 (m, 1H), 3.80-3.66 (m,2H), 2.35-2.24 (m, 1H), 2.05-1.96 (m, 2H), 1.88-1.74 (m, 1H)  94

451.2 Method D, RT = 1.817 min, 95.7% ¹H NMR (400 MHz, DMSO- d₆): δ 8.96(s, 1H), 8.50 (d, J = 2.5 Hz, 1H), 8.03 (dd, J = 8.5, 2.5 Hz, 1H), 7.72-7.65 (m, 2H), 7.47-7.35 (m, 4H), 7.31-7.22 (m, 2H), 6.94-6.88 (m, 1H),6.60 (d, J = 7.0 Hz, 1H), 4.39-4.28 (m, 1H), 3.90 (s, 3H), 3.79-3.63 (m,2H), 2.32-2.24 (m, 1H), 2.06-1.93 (m, 2H), 1.87- 1.72 (m, 1H)  95

515.3 Method E, RT = 2.185 min, 95.6% ¹H NMR (400 MHz, METHANOL-d₄) δ7.64 (d, J = 8.1 Hz, 1H), 7.60-7.50 (m, 6H), 7.32 (d, J = 8.6 Hz, 2H),6.42 (d, J = 8.1 Hz, 1H), 4.44 (dd, J = 11.2, 6.1 Hz, 1H), 3.95 (d, J =1.5 Hz, 6H), 3.88-3.69 (m, 2H), 2.41 (m, 1H), 2.18- 2.09 (m, 2H),2.05-1.92 (m, 1H)  96

433.2 Method F, RT = 1.784 min, 97.8% ¹H NMR (400 MHz, DMSO- d₆): δ 8.58(d, J = 8.1 Hz, 1H), 7.59-7.51 (m, 3H), 7.49-7.37 (m, 5H), 7.34- 7.26(m, 2H), 6.99 (d, J = 8.3 Hz, 1H), 6.09 (s, 2H), 4.63-4.53 (m, 1H),3.84- 3.63 (m, 2H), 2.15-1.97 (m, 4H)  97

464.2 Method D, RT = 1.938 min, 94.6% ¹H NMR (400 MHz, DMSO- d₆): δ 8.91(s, 1H), 7.65- 7.58 (m, 2H), 7.47-7.39 (m, 2H), 7.38-7.32 (m, 2H),7.30-7.24 (m, 3H), 7.18-7.13 (m, 1H), 7.00 (d, J = 8.0 Hz, 1H), 6.56 (d,J = 7.0 Hz, 1H), 6.06 (s, 2H), 4.39-4.27 (m, 1H), 3.80-3.64 (m, 2H),2.29 (m, 1H), 2.05-1.94 (m, 2H), 1.86-1.74 (m, 1H)  98

457.0 Method F, RT = 1.981 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 8.90(s, 1H), 8.29- 8.25 (m, 1H), 8.23-8.14 (m, 1H), 7.63-7.47 (m, 4H),7.45-7.39 (m, 2H), 7.31-7.22 (m, 2H), 6.61- 6.56 (m, 1H), 4.41-4.30 (m,1H), 3.73-3.61 (m, 2H), 2.35-2.24 (m, 1H), 2.08-1.97 (m, 2H), 1.88- 1.77(m, 1H)  99

522.2 Method E, RT = 2.29 min, 95.8% ¹H NMR (400 MHz, DMSO- d₆): δ 9.48(s, 1H), 8.30- 8.22 (m, 2H), 8.05 (d, J = 8.8 Hz, 2H), 8.01-7.95 (m,2H), 7.91-7.80 (m, 4H), 7.71 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 6.6 Hz,1H), 4.63 (d, J = 12.0 Hz, 1H), 4.12-3.90 (m, 2H), 2.57-2.52 (m, 1H),2.34- 2.22 (m, 2H), 2.11 (m, 1H) 100

502.2 Method F, RT = 2.15 min, 97.4% ¹H NMR (400 MHz, DMSO- d₆): δ 9.48(s, 1H), 7.90- 7.79 (m, 4H), 7.75-7.67 (m, 2H), 7.62-7.55 (m, 3H), 7.28(dd, J = 11.5, 2.4 Hz, 1H), 7.11 (td, J = 8.4, 2.4 Hz, 1H), 6.95 (d, J =6.6 Hz, 1H), 4.61 (dd, J = 11.4, 6.2 Hz, 1H), 4.09-4.02 (m, 3H),4.02-3.91 (m, 2H), 2.58-2.52 (m, 1H), 2.31- 2.21 (m, 2H), 2.08 (m, 1H)101

532.2 Method F, RT = 1.79 min, 99.5% ¹H NMR (400 MHz, DMSO- d₆): δ 9.48(s, 1H), 8.43 (t, J = 1.7 Hz, 1H), 8.31 (dt, J = 8.0, 1.3 Hz, 1H), 8.17(dt, J = 8.2, 1.2 Hz, 1H), 8.10- 7.97 (m, 3H), 7.91-7.79 (m, 4H),7.77-7.69 (m, 2H), 6.96 (d, J = 6.8 Hz, 1H), 4.69-4.57 (m, 1H),4.11-3.90 (m, 2H), 3.56 (s, 3H), 2.63-2.52 (m, 1H), 2.33-2.21 (m, 2H),2.16-2.03 (m, 1H) 102

538.2 Method F, RT = 2.29 min, 98.7% ¹H NMR (400 MHz, DMSO- d₆): δ 9.47(s, 1H), 7.89- 7.80 (m, 5H), 7.79-7.72 (m, 5H), 7.71-7.67 (m, 2H), 6.94(d, J = 7.1 Hz, 1H), 4.66-4.58 (m, 1H), 4.08-3.95 (m, 2H), 2.58- 2.53(m, 1H), 2.31-2.22 (m, 2H), 2.09 (m, 1H) 103

547.2 Method E, RT = 1.8 min, 97.7% ¹H NMR (400 MHz, DMSO- d₆): δ 10.08(br. s., 1H), 9.47 (s, 1H), 7.94-7.80 (m, 6H), 7.76-7.61 (m, 5H), 7.47(dt, J = 7.4, 1.9 Hz, 1H), 6.95 (d, J = 6.8 Hz, 1H), 4.69-4.54 (m, 1H),4.08-3.89 (m, 2H), 3.31-3.25 (m, 3H), 2.58-2.51 (m, 1H), 2.33-2.22 (m,2H), 2.15-2.01 (m, 1H) 104

472.2 Method F, RT = 2.14 min, 96.5% ¹H NMR (400 MHz, DMSO- d₆): δ 9.47(s, 1H), 8.03- 7.96 (m, 2H), 7.95-7.71 (m, 7H), 7.70-7.63 (m, 2H),7.51-7.38 (m, 1H), 6.95 (d, J = 6.8 Hz, 1H), 4.69-4.55 (m, 1H), 4.09-3.89 (m, 2H), 2.58-2.49 (m, 1H), 2.33-2.21 (m, 2H), 2.14-2.02 (m, 1H)105

485.2 Method E, RT = 1.94 min, 99.3% ¹H NMR (400 MHz, DMSO- d₆): δ 9.48(s, 1H), 8.44 (dd, J = 4.9, 2.0 Hz, 1H), 8.03 (dd, J = 7.3, 2.0 Hz, 1H),7.91-7.80 (m, 6H), 7.67-7.58 (m, 2H), 7.36 (dd, J = 7.3, 4.9 Hz, 1H),6.95 (d, J = 6.6 Hz, 1H), 4.67-4.55 (m, 1H), 4.15 (s, 3H), 4.07-3.91 (m,2H), 2.59-2.52 (m, 1H), 2.32-2.21 (m, 2H), 2.17- 2.02 (m, 1H) 106

532.2 Method F, RT = 1.8 min, 99.3% ¹H NMR (400 MHz, DMSO- d₆): δ 9.47(s, 1H), 8.40- 8.33 (m, 1H), 8.02 (dd, J = 7.5, 1.3 Hz, 1H), 7.97-7.90(m, 1H), 7.89-7.80 (m, 4H), 7.74-7.62 (m, 5H), 6.95 (d, J = 6.6 Hz, 1H),4.63 (d, J = 11.7 Hz, 1H), 4.11-3.92 (m, 2H), 3.08 (s, 3H), 2.58 (m,1H), 2.28 (m, 2H), 2.16-2.02 (m, 1H) 107

601.0 Method F, RT = 2.215 min, 97.05%, ¹H NMR (400 MHz, DMSO- d₆): δ9.24-9.19 (m, 1H) 7.64-7.55 (m, 4 H) 7.49- 7.33 (m, 8 H) 6.72-6.66 (m,1H) 4.42-4.31 (m, 1H) 3.81-3.67 (m, 2H) 2.37-2.26 (m, 1H) 2.06- 1.97 (m,2H) 1.89-1.74 (m, 1H) 108

514.1 Method F, RT = 2.022 min, 98.77%, ¹H NMR (400 MHz, DMSO- d₆): δ9.6 (bs, 1H) 8.97- 8.87 (m, 2H) 7.47-7.39 (m, 4 H) 7.31-7.24 (m, 6 H)6.61-6.54 (m, 1H) 4.39- 4.29 (m, 1H) 4.06-4.03 (m, 2H) 3.0 (s, 3H) 2.35-2.26 (m, 1H) 2.03-1.96 (m, 2H) 1.86-1.75 (m, 1H) 109

548.1 Method E, RT = 2.25 min, 96.0% ¹H NMR (400 MHz, DMSO- d₆): δ 9.28(s, 1H), 9.15 (s, 1H), 8.5 (s, 1H), 7.88-7.87 (m, 2H), 7.63-7.57 (m,4H), 7.47-7.39 (m, 4H), 6.73 (d, J = 8 Hz, 1H), 4.53-4.42 (m, 1H), 4.31-4.25 (m, 1H) 3.89-−3.80 (m, 1H), 3.28 (s, 3H), 2.36- 2.31 (m, 1H),2.02-1.96 (m, 2H), 1.79-1.77 (m, 1H) 110

484.2 Method E, RT = 2.11 min, 94.5% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 7.74- 7.66 (m, 2H), 7.65-7.54 (m, 4H), 7.44-7.34 (m, 4H),7.28-7.16 (m, 1H), 6.94 (dt, J = 8.2, 1.3 Hz, 1H), 6.70 (d, J = 6.7 Hz,1H), 4.43-4.29 (m, 1H), 3.83 (s, 3H), 3.81-3.66 (m, 2H), 2.33-2.26 (m,1H), 2.07-1.95 (m, 2H), 1.90-1.76 (m, 1H) 111

561.2 Method E, RT = 1.812 min, 98.1% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 7.73- 7.64 (m, 3H), 7.63-7.53 (m, 6H), 7.49-7.40 (m, 3H), 7.35(d, J = 7.5 Hz, 1H), 6.70 (d, J = 6.6 Hz, 1H), 4.41-4.32 (m, 1H), 4.24(d, J = 6.4 Hz, 2H), 3.83-3.66 (m, 2H), 2.88 (s, 3H), 2.30 (m, 1H),2.07- 1.97 (m, 2H), 1.89-1.76 (m, 1H) 112

585.0 Method F, RT = 1.891 min, 98.6%, ¹H NMR (400 MHz, DMSO- d₆): δ8.89 (s, 1H) 7.49- 7.37 (m, 8 H) 7.33-7.24 (m, 4 H) 6.58 (s, 1H) 4.41-4.31 (m, 1H) 3.66 (d, J = 4.22 Hz, 2H) 2.37-2.28 (m, 1H) 2.08-1.98 (m,2H) 1.88-1.74 (m, 1H) 113

583.0 Method F, RT = 2.022 min, 98.6%, ¹H NMR (400 MHz, DMSO- d₆): δ10.45 (s, 1H) 9.22 (s, 1H) 7.60 (d, J = 5.26 Hz, 4 H) 7.51-7.34 (m, 8 H)6.88-6.56 (m, 2H) 4.45- 4.31 (m, 1H) 3.74 (m, 2H) 2.37-2.26 (m, 1H) 2.02(br. s., 2H) 1.89-1.74 (m, 1H) 114

589.1 Method F, RT = 2.365 min, 99.1%, ¹H NMR (400 MHz, DMSO- d₆): δ9.24-9.2 (m, 1H) 8.97-8.93 (m, 1H) 7.64- 7.55 (m, 4 H) 7.51-7.46 (m, 2H)7.42-7.31 (m, 6 H) 6.72-6.67 (m, 1H) 4.41- 4.30 (m, 1H) 3.79-3.67 (m,2H) 2.69-2.63 (m, 2H) 2.37-2.24 (m, 1H) 2.05-1.89 (m, 3H) 1.87- 1.76 (m,1H) 0.92-0.84 (m, 6H) 115

531.0 Method D, RT = 1.993 min, 97.56%, ¹H NMR (400 MHz, DMSO- d₆): δ9.18-9.08 (m, 1H) 8.88 (s, 1H) 7.51-7.23 (m, 11H) 6.58 (d, J = 6.91 Hz,1H) 4.41-4.34 (m, 1H) 3.83-3.72 (m, 2H) 2.79 (s, 3H) 2.36-2.27 (m, 1H)2.08-1.99 (m, 2H) 1.92- 1.75 (m, 1H). 116

548.1 Method E, RT = 1.91 min, 94.30% ¹H NMR (400 MHz, DMSO- d₆): δ 9.26(s, 1H), 8.50 (d, J = 2.2 Hz, 1H), 7.92-7.84 (m, 2H), 7.67-7.56 (m, 4H),7.50-7.28 (m, 4H), 6.73 (d, J = 6.8 Hz, 1H), 4.55-4.47 (m, 1H), 4.29(dt, J = 12.9, 6.4 Hz, 1H), 3.87-3.78 (m, 1H), 2.80 (s, 3H), 2.05-1.94(m, 1H), 1.89-1.87 (m, 2H). 1.78-1.73 (m, 1H). 117

566.0 Method F, RT = 1.94 min, 96.6% ¹H NMR (400 MHz, DMSO- d₆): δ ppm9.20 (s, 1H) 8.40 (d, J = 0.98 Hz, 1H) 7.91 (dd, J = 10.88, 1.83 Hz, 1H)7.55-7.64 (m, 5 H) 7.42-7.51 (m, 3H) 7.31-7.38 (m, 1H) 6.71 (d, J = 7.09Hz, 1H) 4.42-4.51 (m, 1H) 3.68- 3.77 (m, 2H) 2.84 (s, 3H) 2.27-2.36 (m,1H) 2.01- 2.11 (m, 2H) 1.83-1.95 (m, 1H) 118

553.2 Method F, RT = 1.934 min, 97.8% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 8.15 (t, J = 5.8 Hz, 1H), 7.65-7.55 (m, 4H), 7.54-7.37 (m, 6H),7.32 (d, J = 8.5 Hz, 2H), 6.69 (d, J = 6.5 Hz, 1H), 4.41-4.26 (m, 1H),3.77-3.62 (m, 2H), 2.88 (t, J = 6.5 Hz, 2H), 2.32- 2.25 (m, 1H), 1.99(m, 2H), 1.87-1.74 (m, 1H), 1.68- 1.55 (m, 1H), 0.71 (d, J = 6.5 Hz, 6H)119

562.1 Method E, RT = 1.94 min, 94.30% ¹H NMR (400 MHz, DMSO- d₆): δ 9.25(s, 1H), 8.44 (d, J = 2.0 Hz, 1H), 7.91-7.83 (m, 2H), 7.65-7.56 (m, 5H),7.51-7.38 (m, 3H), 7.29 (d, J = 7.6 Hz, 1H), 6.73 (d, J = 7.1 Hz, 1H),4.55-4.46 (m, 1H), 4.34- 4.25 (m, 2H), 4.11 (d, J = 6.1 Hz, 2H), 2.67(s, 3H), 2.33 (m, 1H), 2.10-1.90 (m, 2H), 1.81-1.72 (m, 1H). 120

610.3 Method F, RT = 1.649 min, 98.1% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 7.95 (d, J = 6.0 Hz, 1H), 7.64-7.55 (m, 4H), 7.49 (d, J = 4.5Hz, 1H), 7.44-7.38 (m, 5H), 7.36-7.29 (m, 2H), 6.69 (d, J = 7.0 Hz, 1H),4.37 (s, 1H), 3.73 (d, J = 5.0 Hz, 2H), 3.55-3.47 (m, 4H), 3.19 (d, J =5.5 Hz, 4H), 2.31-2.20 (m, 5H), 2.00 (m, 2H), 1.89- 1.86 (m, 1H) 121

566.0 Method F, RT = 1.95 min, 96.6% ¹H NMR (400 MHz, DMSO- d₆): δ ppm9.20 (s, 1H) 8.40 (d, J = 0.98 Hz, 1H) 7.91 (dd, J = 10.88, 1.83 Hz, 1H)7.55-7.64 (m, 5 H) 7.42-7.51 (m, 3H) 7.31-7.38 (m, 1H) 6.71 (d, J = 7.09Hz, 1H) 4.42-4.51 (m, 2H) 3.68- 3.77 (m, 1H) 2.84 (s, 3H) 2.27-2.36 (m,1H) 2.01- 2.11 (m, 2H) 1.83-1.95 (m, 1H) 122

545   Method F, RT = 2.096 min, 94.83%, ¹H NMR (400 MHz, DMSO- d₆): δ8.90-8.87 (m, 1H), 7.62-7.57 (m, 1H), 7.49- 7.41 (m, 5H), 7.40-7.32 (m,2H), 7.30-7.24 (m, 4H), 6.60-6.55 (m, 1H), 4.14-4.05 (m, 3H), 3.71- 3.63(m, 2H), 3.19-3.13 (m, 3H), 2.85-2.78 (m, 4H) 123

525.2 Method E, RT = 1.697 min, 99.02% ¹H NMR (400 MHz, DMSO- d₆): δ9.24 (s, 1H), 8.67 (br. s., 1H), 7.71-7.66 (m, 1H), 7.64-7.56 (m, 4H),7.54-7.48 (m, 2H), 7.47- 7.36 (m, 5H), 6.73 (d, J = 6.8 Hz, 1H),4.40-4.32 (m, 1H), 4.10 (br. s., 2H), 3.83-3.68 (m, 2H), 3.22- 3.21 (m,1H), 2.32-2.28 (m, 1H), 2.08-1.98 (m, 2H), 1.91-1.82 (m, 1H), 1.11 (d, J= 6.4 Hz, 6H). 124

485.2 Method E, RT = 2.073 min, 97.8% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 8.12 (d, J = 8.6 Hz, 2H), 7.83-7.75 (m, 1H), 7.66-7.54 (m, 5H),7.44 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.1 Hz, 1H), 6.71 (d, J = 6.8 Hz,1H), 4.43-4.33 (m, 1H), 3.97 (d, J = 6.1 Hz, 3H), 3.85-3.66 (m, 2H),2.31 (m, 1H), 2.07-1.97 (m, 2H), 1.84 (m, 1H) 125

490.2 Method F, RT = 2.167 min, 93.0% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 7.67- 7.55 (m, 6H), 7.46 (d, J = 8.6 Hz, 3H), 7.42-7.27 (m,2H), 6.71 (s, 1H), 4.38 (d, J = 5.1 Hz, 1H), 3.85- 3.68 (m, 2H),2.33-2.26 (m, 1H), 2.02 (m, 2H), 1.84 (m, 1H) 126

532.2 Method F, RT = 1.8 min, 95.8% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 8.17 (t, J = 1.8 Hz, 1H), 8.08-8.03 (m, 1H), 7.92 (dd, J = 9.5,1.0 Hz, 1H), 7.84-7.72 (m, 3H), 7.65-7.55 (m, 4H), 7.50-7.43 (m, 2H),6.70 (d, J = 6.5 Hz, 1H), 4.43-4.32 (m, 1H), 3.84- 3.66 (m, 2H), 3.28(s, 3H), 2.30 (m, 1H), 2.08-1.97 (m, 2H), 1.85 (m, 1H) 127

546.2 Method F, RT = 1.89 min, 95.9 % ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 8.15- 8.05 (m, 2H), 7.89 (br. s., 1H), 7.84-7.74 (m, 3H), 7.60(d, J = 4.6 Hz, 4H), 7.49 (s, 2H), 6.72 (br. s., 1H), 4.40 (m, 1H),3.84- 3.66 (m, 2H), 3.44-3.37 (m, 2H), 2.33-2.27 (m, 1H), 2.03 (m, 2H),1.86 (m, 1H), 1.14 (t, J = 7.2 Hz, 3H) 128

502.2 Method F, RT = 2.103 min, 98.6% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 7.65- 7.52 (m, 6H), 7.45-7.37 (m, 2H), 7.26-7.13 (m, 2H), 7.06(td, J = 7.2, 2.3 Hz, 1H), 6.69 (d, J = 6.5 Hz, 1H), 4.42-4.29 (m, 1H),3.88 (s, 3H), 3.82- 3.66 (m, 2H), 2.31 (d, J = 6.0 Hz, 1H), 2.07-1.96(m, 2H), 1.89-1.76 (m, 1H) 129

499.2 Method E, RT = 2.073 min, 94.9% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 8.16 (dd, J = 4.9, 2.0 Hz, 1H), 7.78 (dd, J = 7.2, 1.8 Hz, 1H),7.65-7.54 (m, 6H), 7.38 (d, J = 8.3 Hz, 2H), 7.09 (dd, J = 7.3, 4.9 Hz,1H), 6.70 (d, J = 6.8 Hz, 1H), 4.44-4.32 (m, 3H), 3.82-3.66 (m, 2H),2.32- 2.27 (m, 1H), 2.07-1.95 (m, 2H), 1.83 (m, 1H), 1.38-1.27 (m, 3H)130

469.0 Method F, RT = 1.96 min, 98.3% ¹H NMR (400 MHz, DMSO- d₆): δ 9.24(s, 1H), 8.68- 8.61 (m, 1H), 8.07-7.95 (m, 1H), 7.66-7.55 (m, 5H), 7.49(d, J = 3.4 Hz, 4H), 6.71 (d, J = 6.6 Hz, 1H), 4.43-4.32 (m, 1H),3.85-3.69 (m, 2H), 2.57 (m, 3H), 2.33-2.27 (m, 1H), 2.03 (m, 2H), 1.92-1.78 (m, 1H) 131

498.1 Method F, RT = 2.48 min, 96.2% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.65-7.56 (m, 4H), 7.43-7.34 (m, 3H),7.26-7.17 (m, 2H), 6.93 (d, J = 8.1 Hz, 1H), 6.70 (d, J = 6.8 Hz, 1H),4.41-4.31 (m, 1H), 4.11 (m, 2H), 3.79 (s, 3H), 2.32- 2.27 (m, 1H),2.06-1.97 (m, 2H), 1.86-1.75 (m, 1H) 132

496.2 Method E, RT = 2.715 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 7.68 (d, J = 8.6 Hz, 2H), 7.65-7.56 (m, 4H), 7.52 (s, 1H), 7.48(d, J = 7.8 Hz, 1H), 7.43- 7.35 (m, 3H), 7.26 (d, J = 7.8 Hz, 1H), 6.71(d, J = 6.8 Hz, 1H), 4.41-4.32 (m, 1H), 3.84-3.65 (m, 2H), 2.98 (dt, J =13.8, 7.0 Hz, 1H), 2.31 (m, 1H), 2.08- 1.97 (m, 2H), 1.89-1.76 (m, 1H),1.31-1.21 (m, 6H) 133

473.2 Method F, RT = 1.95 min, 95.2% ¹H NMR (400 MHz, DMSO- d₆): δ 9.24(s, 1H), 8.10 (s, 3H), 7.97 (br. s., 1H), 7.65- 7.56 (m, 4H), 7.47 (d, J= 9.0 Hz, 2H), 7.15 (br. s., 1H), 6.72 (br. s., 1H), 4.36 (m, 1H),3.84-3.64 (m, 2H), 2.31-2.25 (m, 1H), 2.01 (m, 2H), 1.87-1.78 (m, 1H)134

561.1 Method E, RT = 2.21 min, 94.9% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 8.09- 8.01 (m, 1H), 7.93 (s, 1H), 7.83-7.73 (m, 4H), 7.65- 7.55(m, 4H), 7.47 (d, J = 8.6 Hz, 2H), 6.71 (d, J = 6.6 Hz, 1H), 4.42-4.31(m, 1H), 3.85-3.67 (m, 2H), 2.71-2.64 (m, 6H), 2.32- 2.26 (m, 1H), 2.02(m, 2H), 1.85 (m, 1H) 135

513.1 Method F, RT = 2.47 min, 96.7% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 8.15 (dd, J = 5.0, 2.0 Hz, 1H), 7.76 (dd, J = 7.3, 1.8 Hz, 1H),7.65-7.55 (m, 6H), 7.40-7.34 (m, 2H), 7.09- 7.02 (m, 1H), 6.69 (d, J =6.5 Hz, 1H), 5.37 (quin, J = 6.3 Hz, 1H), 4.41-4.30 (m, 1H), 3.82-3.66(m, 2H), 2.33-2.28 (m, 1H), 2.06- 1.96 (m, 2H), 1.89-1.78 (m, 1H), 1.30(d, J = 6.5 Hz, 6H) 136

501.1 Method F, RT = 1.67 min, 97.8% ¹H NMR (400 MHz, DMSO- d₆): δ 9.25(s, 1H), 7.67- 7.47 (m, 7H), 7.46-7.38 (m, 3H), 7.32-7.24 (m, 1H), 6.73(s, 1H), 4.42- 4.30 (m, 1H), 3.87 (s, 2H), 3.76 (ddt, J = 18.7, 12.3,6.3 Hz, 2H), 2.31 (m, 1H), 2.08-1.97 (m, 2H), 1.88- 1.79 (m, 1H) 137

511.3 Method F, RT = 1.7 min, 97.3% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 7.69 (d, J = 8.5 Hz, 2H), 7.64-7.54 (m, 6H), 7.41 (d, J = 8.5Hz, 3H), 7.31 (s, 1H), 6.69 (d, J = 7.0 Hz, 1H), 4.42- 4.30 (m, 1H),3.81-3.66 (s, 2H), 2.58-2.53 (s, 6H), 2.31-2.15 (m, 3H), 2.01 (m, 2H),1.85 (m, 1H)

Example 138:(R)—N-(3-(4-(2-oxo-3-(3-(4-(trifluoromethyl)phenyl)ureido)piperidin-1-yl)phenyl)pyridin-2-yl)methanesulfonamide

To a solution of Intermediate 4 (0.050 g, 0.099 mmol) in 1,4-dioxane (2mL) were added N-(3-bromopyridin-2-yl)methanesulfonamide (0.025 g, 0.099mmol) and potassium phosphate, tribasic (0.042 g, 0.20 mmol). Thereaction mixture was purged with nitrogen for 5 min and charged withPd(dppf)Cl₂.DCM adduct (8.1 mg, 9.9 μmol). The reaction mixture wasagain purged with nitrogen for 3 min and heated at 60° C. for 16 h. Thereaction mixture was cooled, filtered through a celite pad and thefiltrate was concentrated under reduced pressure. The crude product waspurified by RP-HPLC to afford (19 mg, 0.035 mmol, 35% yield). MS(ESI)m/z: 548 (M+H); ¹H NMR (400 MHz, DMSO-d6): δ 9.67 (s, 1H), 9.26-9.19 (s,1H), 8.41-8.35 (m, 1H), 7.78-7.71 (m, 1H), 7.64-7.55 (m, 6H), 7.54-7.4(m, 2H), 7.31-7.24 (m, 1H), 6.73-6.66 (m, 1H), 4.45-4.31 (m, 1H),3.82-3.7 (m, 2H), 3.0-2.8 (m, 4H), 2.04-1.97 (m, 2H,) 1.90-1.81 (m, 1H).RT=1.859 min (Method F).

The following Examples in Table 3 were made by using analogousprocedures as shown in Example 138 from Intermediates 4 or 5.

TABLE 3 LC HPLC MS Method, (M + RT (min.) Ex Structure H)+ & Purity 1HNMR 139

497.1 Method E, RT = 1.810 min, 97.6% ¹H NMR (400 MHz, DMSO-d₆): δ 9.26-9.20 (m, 1H), 7.72- 7.66 (m, 1H), 7.59 (d, J = 4.95 Hz, 4 H), 7.52- 7.28(m, 9 H), 6.73- 6.66 (m, 1H), 4.40- 4.30 (m, 1H), 3.79- 3.66 (m, 2H),2.37- 2.28 (m, 1H), 2.04- 1.96 (m, 2H), 1.88- 1.75 (m, 1H). 140

480.2 Method F, RT = 1.765 min, 100% ¹H NMR (400 MHz, DMSO-d₆): δ 9.26-9.21 (m, 1H) 8.79- 8.74 (m, 1H) 8.19- 8.10 (m, 1H) 7.86- 7.8 (m, 1H)7.73- 7.67 (m, 2H) 7.64- 7.49 (m, 6 H) 6.73- 6.68 (m, 1H) 4.44- 4.33 (m,1H) 3.86- 3.69 (m, 2H) 2.35- 2.26 (m, 1H) 2.06- 1.97 (m, 2H) 1.91- 1.77(m, 1H) 141

547.0 Method F, RT = 2.106 min, 95.9%, ¹H NMR (400 MHz, DMSO-d₆): δ9.24- 9.19 (s, 1H) 7.67- 7.54 (m, 7 H) 7.32- 7.43 (m, 5 H) 7.0 (bs, 1H)6.65-6.72 (m, 1H) 3.76-3.62 (m, 2H) 2.40-2.35 (m, 4 H) 2.06-1.98 (m, 2H)1.83-1.81 (m, 1H) 142

548.1 Method E, RT = 1.98 min, 98.0% ¹H NMR (400 MHz, DMSO-d₆): δ 9.26(s, 1H), 8.40 (d, J = 2.0 Hz, 1H), 7.90-7.86 (m, 1H), 7.83-7.78 (m, 1H),7.81- 7.78 (m, 1H), 7.74- 7.56 (m, 6H), 7.42 (d, J = 7.3 Hz, 1H), 7.34(d, J = 4.6 Hz, 1H), 6.74 (d, J = 6.8 Hz, 1H), 4.56-4.48 (m, 1H),4.37-4.29 (m, 1H), 3.88-3.80 (m, 1H), 2.40 (d, J = 5.1 Hz, 3H), 2.35-2.31 (m, 1H), 1.99- 1.96 (m, 2H), 1.78- 1.73 (m, 1H). 143

561.1 Method F, RT = 2.059 min, 97.96%, ¹H NMR (400 MHz, DMSO-d₆): δ9.24- 9.18 (m, 1H), 7.64- 7.55 (m, 5H), 7.47- 7.33 (m, 7H), 7.29- 7.21(m, 1H), 6.73- 6.66 (m, 1H), 4.41- 4.31 (m, 1H), 4.16- 4.09 (m, 2H),3.81- 3.66 (m, 2H), 2.76 (s, 3H), 2.36-2.28 (m, 1H), 2.05- 1.95 (m, 2H),1.89- 1.76 (m, 1H) 144

531.0 Method F, RT = 1.99 min, 94.37%, ¹H NMR (400 MHz, DMSO-d₆): δ8.96- 8.88 (m, 1H), 7.95- 7.89 (m, 1H), 7.72- 7.59 (m, 2H), 7.46- 7.38(m, 4H), 7.33- 7.22 (m, 5H), 6.62- 6.55 (m, 1H), 4.41- 4.29 (m, 2H),3.98- 3.91 (m, 1H), 3.64 (s, 3H), 2.36-2.24 (m, 2H), 2.05-1.97 (m, 1H),1.88-1.77 (m, 1H) 145

562.0 Method F, RT = 2.041 min, 97.41%, ¹H NMR (400 MHz, DMSO-d₆): δ9.25- 9.19 (m, 1H), 8.54- 8.49 (m, 1H), 7.97- 7.89 (m, 1H), 7.65- 7.49(m, 7H), 7.46- 7.40 (m, 2H), 6.72- 6.65 (m, 1H), 4.42- 4.31 (m, 1H),3.84- 3.68 (m, 2H), 3.18 (s, 3H), 2.94 (s, 3H), 2.35- 2.28 (m, 1H),2.06- 1.97 (m, 2H), 1.88- 1.77 (m, 1H)

Example 146:(R)-1-(4-chlorophenyl)-3-(1-(5-(2-fluorophenyl)pyridin-2-yl)-2-oxopiperidin-3-yl)urea

Example 146a: tert-butyl(R)-(1-(5-(2-fluorophenyl)pyridin-2-yl)-2-oxopiperidin-3-yl)carbamate

To a solution of Intermediate 7(150 mg, 0.41 mmol) in 1,4-dioxane (5 mL)were added potassium phosphate, tribasic (170 mg, 0.81 mmol) and(2-fluorophenyl)boronic acid (57 mg, 0.41 mmol). The reaction mixturewas purged with nitrogen for 5 min and charged with Pd(dppf)Cl₂.DCMadduct (33 mg, 0.041 mmol). The reaction mixture was again purged withnitrogen for 3 min and heated at 60° C. for 15 h. The reaction mixturewas cooled, filtered through celite pad, and washed with ethyl acetate(20 mL). The filtrate was concentrated under reduced pressure and theresidue was purified by column chromatography afford Example 146a (120mg, 0.31 mmol, 77% yield) as a brown solid. MS(ESI) m/z: 386 (M+H); ¹HNMR (400 MHz, DMSO-d₆): δ 8.61 (s, 1H), 8.00 (d, J=8.0 Hz, 1H), 7.85 (d,J=8.5 Hz, 1H), 7.64-7.59 (m, 1H), 7.43-7.51 (m, 1H), 7.31-7.39 (m, 2H),7.08 (d, J=8.5 Hz, 1H), 4.29-4.21 (m, 1H), 4.25-4.15 (m, 1H), 3.76-3.85(m, 1H), 2.03-2.13 (m, 1H), 1.90-1.99 (m, 2H), 1.89-1.73 (m, 1H), 1.40(s, 9H).

Example 146B:(R)-3-amino-1-(5-(2-fluorophenyl)pyridin-2-yl)piperidin-2-onehydrochloride

To a cooled solution of Example 146A (120 mg, 0.31 mmol) in 1,4-dioxane(10 mL) was added 4N HCl in 1,4-dioxane (1.6 mL) and stirred at RT fortwo hours. The solvent was evaporated and the mixture was trituratedwith diethyl ether (10 ml×2) to afford Example 146B (80 mg, 0.25 mmol,80% yield) as a light brown solid. MS(ESI) m/z: 286.2 (M+H).

Example 146

To a cooled solution of Example 146B (40 mg, 0.12 mmol) in THF (5 mL)were added TEA (0.052 mL, 0.37 mmol) and 1-chloro-4-isocyanatobenzene(19 mg, 0.12 mmol) and reaction mixture was stirred at RT for 15 hours.The solvent was evaporated under reduced pressure and the crude compoundwas purified by RP-HPLC to Example 146 (10 mg, 18% yield). MS(ESI) m/z:439 (M+H); ¹H NMR (400 MHz, DMSO-d6): δ 8.94 (s, 1H), 8.62 (s, 1H),8.03-7.99 (m, 1H), 7.89 (d, J=8.6 Hz, 1H), 7.62 (td, J=7.9, 1.6 Hz, 1H),7.51-7.41 (m, 3H), 7.39-7.32 (m, 2H), 7.30-7.25 (m, 2H), 6.60 (d, J=7.3Hz, 1H), 4.48 (dt, J=12.0, 6.9 Hz, 1H), 4.26 (dt, J=13.0, 6.5 Hz, 1H),3.86-3.78 (m, 1H), 2.36-2.27 (m, 1H), 2.03-1.93 (m, 2H), 1.83-1.71 (m,1H). RT=2.116 min (Method E).

The following Examples in Table 4 were made by using analogousprocedures as shown in Example 146 starting from Intermediate 1a,tert-butyl (R)-(1-(4-bromophenyl)-2-oxopiperidin-3-yl)carbamate(obtained during the synthesis of Intermediate 1a), or Intermediates7-10.

TABLE 4 HPLC LC Method, MS RT (M + (min.) & Ex Structure H)+ Purity 1HNMR 147

472.2 Method F, RT = 2.121 min, 100.0% ¹H NMR (400 MHz, DMSO- d₆): δ9.22 (s, 1H), 7.53- 7.64 (m, 7 H), 7.43 (d, J = 8.56 Hz, 3H), 7.27-7.37(m, 2H), 6.70 (d, J = 6.85 Hz, 1H), 4.31-4.42 (m, 1H), 3.68- 3.83 (m,2H), 2.33 (m, 1H), 1.97-2.06 (m, 2H), 1.76- 1.90 (m, 1H). 148

448.8 Method E, RT = 1.76 min, 96.5% ¹H NMR (400 MHz, DMSO- d₆): δ 8.68(s, 1H), 7.61- 7.52 (m,3H), 7.47-7.39 (m, 3H), 7.36-7.28 (m, 2H), 7.19(d, J = 2.0 Hz, 1H), 6.83- 6.75 (m, 1H), 6.69 (dd, J = 8.3, 2.2 Hz, 1H),6.45 (d, J = 6.6 Hz, 1H), 5.97-5.93 (m, 2H), 4.38-4.29 (m, 1H),3.82-3.66 (m, 2H), 2.33- 2.25 (m, 1H), 2.01 (m, 2H), 1.80 (m, 1H) 149

422.1 Method F, RT = 2.080 min, 95.4% ¹H NMR (400 MHz, DMSO- d₆): δ 8.81(s, 1H), 7.59-7.53 (m, 3H), 7.45-7.37 (m, 5H), 7.34-7.29 (m, 2H),7.08-7.04 (m, 2H), 6.51 (d, J = 6.80 Hz, 1H), 4.36-4.33 (m, 1H), 3.77-3.70 (m, 2H), 2.33-2.29 (m, 1H), 2,02-1.97 (m, 2H), 1.82- 1.78 (m, 1H).150

463.0 Method F, RT = 1.654 min, 98.1% ¹H NMR (400 MHz, DMSO- d₆): δ 8.94(s, 1H), 7.73- 7.69 (m, 1H), 7.51-7.41 (m, 8 H), 7.40-7.33 (m, 3H),7.29-7.26 (m, 2H), 6.60- 6.54 (m, 1H), 4.38-4.29 (m, 1H), 3.78-3.66 (m,2H), 2.34-2.27 (m, 1H), 2.05- 1.96 (m, 2H), 1.85-1.73 (m, 1H) 151

439.0 Method F, RT = 1.900 min, 99.3% ¹H NMR (400 MHz, DMSO- d₆): δ 8.94(s, 1H), 8.25- 8.24 (d, J = 4.89 Hz, 1H), 8.17-8.12 (ddd, J = 10.09,7.76, 1.96 Hz, 1H), 7.66-7.63 (dd, J = 8.56, 1.47 Hz, 2H), 7.51-7.41 (m,5 H), 7.30- 7.25 (m, 2H), 6.58-6.57 (d, J = 6.60 Hz, 1H), 4.39-4.31 (m,1H), 3.82-3.68 (m, 2H), 2.34-2.28 (m, 1H), 2.04- 1.97 (m, 2H), 1.87-1.80(m, 1H). 152

497.1 Method F, RT = 1.813 min, 99.1% ¹H NMR (400 MHz, DMSO- d₆): δ 9.24(s, 1H), 7.73- 7.69 (m, 1H), 7.62-7.60 (dd, J = 4.40 Hz, 4 H), 7.52-7.30(m, 9 H), 6.72-6.67 (m, 1H), 4.40-4.30 (m, 1H), 3.77- 3.69 (m, 2H),2.36-2.28 (m, 1H), 2.04-1.96 (m, 2H), 1.89-1.74 (m, 1H) 154

439.0 Method F, RT = 2.103 min, 98.9% ¹H NMR (400 MHz, DMSO- d₆): δ 8.97(s, 1H), 8.63 (s, 1H), 8.05-7.99 (m, 1H), 7.90 (d, J = 8.80 Hz, 1H),7.66-7.59 (m, 1H), 7.52- 7.42 (m, 3H), 7.40-7.32 (m, 2H), 7.30-7.25 (m,2H), 6.61 (d, J = 7.09 Hz, 1H), 4.53-4.45 (m, 1H), 4.27 (dt, J = 12.72,6.36 Hz, 1H), 3.87- 3.78 (m, 1H), 2.35-2.28 (m, 1H), 2.03-1.94 (m, 2H),1.83-1.73 (m, 1H) 155

472.0 Method F, RT = 2.464 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 8.73(s, 1H), 7.87 (d, J = 8.40 Hz, 2H), 7.66 (d, J = 8.00 Hz, 2H), 7.45 (t,J = 8.00 Hz, 1H), 7.32-7.28 (m, 3H), 7.26-7.20 (m, 2H), 6.67 (d, J =8.40 Hz, 2H), 5.90 (t, J = 5.60 Hz, 1H), 4.33-4.30 (m, 1H), 3.15-3.10(m, 2H), 1.98-1.93 (m, 1H), 1.82- 1.70 (m, 3H). 156

455.2 Method F, RT = 1.665 min, 95.3% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 8.68 (m, 2H), 7.92-7.77 (m, 4H), 7.67-7.56 (m, 4H), 7.49 (d, J= 8.6 Hz, 2H), 6.71 (s, 1H), 4.44-4.31 (m, 1H), 3.85- 3.66 (m, 2H), 2.31(m, 1H), 2.10-1.95 (m, 2H), 1.92- 1.75 (m, 1H). 157

475.1 Method F, RT = 2.126 min, 99.7% ¹H NMR (400 MHz, DMSO- d₆): δ 8.93(s, 1H), 7.60- 7.50 (m, 4H), 7.48-7.40 (m, 4H), 7.36 (dd, J = 8.8, 2.7Hz, 1H), 7.30-7.22 (m, 2H), 6.57 (d, J = 6.8 Hz, 1H), 4.40- 4.27 (m,1H), 3.86 (s, 3H), 3.82?-3.67 (m, 2H), 2.35- 2.24 (m, 1H), 2.05-1.95 (m,2H), 1.82-1.80 (m, 1H) 158

463.0 Method F, RT = 1.668 min, 97.7% ¹H NMR (400 MHz, DMSO- d₆): δ 8.93(s, 1H), 7.69 (s, 1H), 7.53-7.23 (m, 13H), 6.56 (d, J = 6.6 Hz, 1H),4.38- 4.28 (m, 1H), 3.72 (tq, J = 12.5, 6.3 Hz, 2H), 2.30 (m, 1H),2.02-1.94 (m, 2H), 1.86-1.73 (m, 1H). 159

497.2 Method F, RT = 1.590 min, 99.0% ¹H NMR (400 MHz, DMSO- d₆): δ 9.22(s, 1H), 7.69 (s, 1H), 7.64-7.55 (m, 4H), 7.52-7.27 (m, 9H), 6.69 (d, J= 6.6 Hz, 1H), 4.41-4.29 (m, 1H), 3.73 (tq, J = 12.7, 6.2 Hz, 2H),2.37-2.26 (m, 1H), 2.04-1.93 (m, 2H), 1.88- 1.74 (m, 1H). 160

421.2 Method F, RT = 1.506 min, 96.8% ¹H NMR (400 MHz, DMSO- d₆): δ 8.93(s, 1H), 8.69- 8.60 (m, 2H), 7.89-7.80 (m, 2H), 7.77-7.70 (m, 2H),7.51-7.39 (m, 4H), 7.31- 7.22 (m, 2H), 6.57 (d, J = 6.8 Hz, 1H),4.41-4.29 (m, 1H), 3.83-3.63 (m, 2H), 2.37- 2.22 (m, 1H), 2.06-1.94 (m,2H), 1.89-1.73 (m, 1H). 161

443.2 Method F, RT = 1.346 min, 99.8% ¹H NMR (400 MHz, DMSO- d₆): δ 8.65(s, 1H), 7.69 (s, 1H), 7.52-7.23 (m, 11H), 7.03 (d, J = 8.1 Hz, 2H),6.46 (d, J = 6.4 Hz, 1H), 4.38- 4.27 (m, 1H), 3.78-3.66 (m, 2H),2.37-2.25 (m, 1H), 2.22 (s, 3H), 1.98 (m, 2H), 1.78 (m, 1H). 162

448.3 Method F, RT = 1.9 min, 96.9% ¹H NMR (400 MHz, DMSO- d₆): δ 8.55(s, 1H), 7.60- 7.51 (m, 2H), 7.45-7.38 (m, 2H), 7.36-7.25 (m, 3H), 7.00(br. s., 1H), 6.83-6.76 (m, 2H), 6.50 (s, 1H), 6.40 (d, J = 6.5 Hz, 1H),6.26 (s, 1H), 4.39-4.28 (m, 1H), 3.95 (q, J = 7.0 Hz, 2H), 3.81-3.66 (m,2H), 2.31-2.23 (m, 1H), 2.05-1.94 (m, 2H), 1.86- 1.72 (m, 1H), 1.29 (t,J = 7.0 Hz, 3H) 163

448.2 Method F, RT = 1.768 min, 93.22% ¹H NMR (400 MHz, DMSO- d₆): δ8.66 (s, 1H), 7.60- 7.50 (m, 3H), 7.48-7.38 (m, 2H), 7.36-7.27 (m, 2H),7.18 (d, J = 2.5 Hz, 1H), 6.81- 6.75 (m, 1H), 6.68 (dd, J = 8.5, 2.0 Hz,1H), 6.50 (s, 1H), 6.43 (d, J = 6.5 Hz, 1H), 5.93 (s, 2H), 4.38-4.28 (m,1H), 3.82-3.64 (m, 2H), 2.30 (m, 1H), 1.99 (m, 2H), 1.80 (m, 1H) 164

473.1 Method E, RT = 2.292 min, 93.7% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 8.62 (s, 1H), 8.06-7.98 (m, 1H), 7.90 (d, J = 8.8 Hz, 1H),7.67- 7.55 (m, 5H), 7.52-7.43 (m, 1H), 7.39-7.30 (m, 2H), 6.72 (d, J =7.1 Hz, 1H), 4.55- 4.45 (m, 1H), 4.33-4.22 (m, 1H), 3.89-3.79 (m, 1H),2.39-2.29 (m, 1H), 2.05- 1.94 (m, 2H), 1.85-1.72 (m, 1H) 165

506.3 Method F, RT = 1.783 min, 98.3% ¹H NMR (400 MHz, DMSO- d₆): δ 8.93(s, 1H), 8.30 (s, 1H), 7.74 (d, J = 8.6 Hz, 2H), 7.53 (s, 1H), 7.46-7.36(m, 5H), 7.30-7.21 (m, 2H), 6.57 (d, J = 6.8 Hz, 1H), 4.38- 4.28 (m,1H), 3.79-3.62 (m, 6H), 3.29-3.23 (m, 4H), 2.33-2.23 (m, 1H), 2.05- 1.93(m, 2H), 1.82 (m, 1H) 166

540.1 Method F, RT = 1.929 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 8.32 (dd, J = 11.0, 2.2 Hz, 2H), 7.79- 7.72 (m, 2H), 7.64-7.51(m, 5H), 7.42 (d, J = 8.6 Hz, 2H), 6.71 (d, J = 6.6 Hz, 1H), 4.40- 4.31(m, 1H), 3.81-3.66 (m, 6H), 3.30-3.23 (m, 4H), 2.31 (dd, J = 11.9, 6.7Hz, 1H), 2.05-1.96 (m, 2H), 1.90-1.76 (m, 1H) 167

417.1 Method F, RT = 1.485 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 8.90(d, J = 2.00 Hz, 1H), 8.57-8.56 (m, 2H), 8.10- 8.07 (m, 1H), 7.75 (d, J= 8.40 Hz, 2H), 7.51-7.47 (m, 1H), 7.44 (d, J = 8.40 Hz, 2H), 7.31-7.28(m, 2H), 6.83 (d, J = 5.20 Hz, 2H), 6.41 (d, J = 6.80 Hz, 1H), 4.38-4.31(m, 1H), 3.76-3.69 (m, 2H), 3.53 (s, 3H), 2.36-2.20 (m, 1H), 2.06-1.98(m, 2H), 1.74-1.72 (m, 1H). 168

421.1 Method F, RT = 1.739 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ8.93-8.91 (m, 2H), 8.58-8.56 (m, 1H), 8.11-8.08 (m, 1H), 7.76 (d, J =8.40 Hz, 2H), 7.51-7.41 (m, 5H), 7.27 (d, J = 8.80 Hz, 2H), 6.58 (d, J =6.80 Hz, 1H), 4.38-4.33 (m, 1H), 3.71-3.68 (m, 2H), 2.31- 2.29 (m, 1H),2.02-1.97 (m, 2H), 1.83-1.76 (m, 1H). 169

455   Method F, RT = 1.897 min, 98.2% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 8.91 (d, J = 2.00 Hz, 1H), 8.58-8.56 (m, 1H), 8.11-8.08 (m,1H), 7.76 (d, J = 8.40 Hz, 2H), 7.62- 7.57 (m, 4H), 7.51-7.44 (m, 3H),6.70 (d, J = 6.80 Hz, 1H), 4.38-4.35 (m, 1H), 3.74-3.69 (m, 2H),2.33-2.29 (m, 1H), 2.02-2.00 (m, 2H), 1.88-1.85 (m, 1H). 170

422.2 Method E, RT = 1.906 min, 98.4% ¹H NMR (400 MHz, METHANOL-d₄): δ9.04 (br. s., 1H), 8.60 (br. s., 2H), 8.21- 8.09 (m, 2H), 7.63-7.52 (m,2H), 7.48-7.38 (m, 2H), 7.37-7.26 (m, 1H), 7.19 (d, J = 10.0 Hz, 1H),7.13-7.06 (m, 1H), 6.94 (br. s., 1H), 6.53 (s, 1H), 4.39 (m, 1H),3.83-3.66 (m, 2H), 2.30 (m, 1H), 2.01 (m, 2H), 1.80 (m, 1H) 171

439   Method E, RT = 2.116 min, 94.95% ¹H NMR (400 MHz, DMSO- d₆): δ8.94 (s, 1H), 8.62 (s, 1H), 8.03-7.99 (m, 1H), 7.89 (d, J = 8.6 Hz, 1H),7.62 (td, J = 7.9, 1.6 Hz, 1H), 7.51- 7.41 (m, 3H), 7.39-7.32 (m, 2H),7.30-7.25 (m, 2H), 6.60 (d, J = 7.3 Hz, 1H), 4.48 (dt, J = 12.0, 6.9 Hz,1H), 4.26 (dt, J = 13.0, 6.5 Hz, 1H), 3.86-3.78 (m, 1H), 2.36-2.27 (m,1H), 2.03- 1.93 (m, 2H), 1.83-1.71 (m, 1H). 172

434.2 Method F, RT = 1.778 min, 98.8% ¹H NMR (400 MHz, DMSO- d₆): δ 8.55(s, 1H), 7.59-7.53 (m,3H), 7.46-7.41 (m, 3H), 7.34-7.28 (m, 4H), 6.83(d, J = 6.80 Hz, 2H), 6.40 (d, J = 6.80 Hz, 1H), 4.35-4.32 (m, 1H),3.76-3.72 (m, 2H), 3.70 (s, 3H), 2.33-2.29 (m, 1H), 2.01-1.99 (m, 2H),1.81-1.77 (m, 1H). 173

438   Method F, RT = 2.252 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 8.93(s, 1H), 7.59-7.53 (m, 3H), 7.45-7.41 (m, 5H), 7.34-7.26 (m, 4H), 6.57(d, J = 6.80 Hz, 1H), 4.40-4.28 (m, 1H), 3.75-3.72 (m, 2H), 2.34- 2.33(m, 1H), 2.02-1.99 (m, 2H), 1.86-1.75 (m, 1H). 174

447.2 Method E, RT = 1.292 min, 99.3% ¹H NMR (400 MHz, METHANOL-d₄): δ7.59- 7.50 (m, 4H), 7.48-7.41 (m, 2H), 7.40-7.34 (m, 4H), 7.04-6.97 (m,2H), 4.44 (dd, J = 11.5, 6.5 Hz, 1H), 3.90- 3.70 (m, 2H), 2.46-2.36 (m,1H), 2.19-2.08 (m, 2H), 2.01 (m, 1H) 175

457.3 Method E, RT = 1.406 min, 98.6% ¹H NMR (400 MHz, METHANOL-d₄): δ7.60- 7.49 (m, 4H), 7.48-7.41 (m, 2H), 7.40-7.32 (m, 3H), 7.05-6.95 (m,2H), 4.43 (dd, J = 11.3, 6.3 Hz, 1H), 3.88- 3.69 (m, 2H), 2.39 (m, 1H),2.28 (s, 3H), 2.25 (s, 3H), 2.16-2.07 (m, 2H), 2.05- 1.94 (m, 1H) 176

493.2 Method E, RT = 1.384 min, 97.5% ¹H NMR (400 MHz, METHANOL-d₄): δ7.59- 7.49 (m,5H), 7.47-7.41 (m, 2H), 7.40-7.34 (m,2H), 7.21 (dd, J =8.5, 2.5 Hz, 1H), 6.99 (d, J = 9.0 Hz, 1H), 4.43 (dd, J = 11.5, 6.0 Hz,1H), 3.89-3.70 (m, 5H), 2.40 (m, 1H), 2.19-2.07 (m, 2H), 2.05-1.93 (m,1H) 177

469.3 Method E, RT = 1.406 min, 97.3% ¹H NMR (400 MHz, METHANOL-d₄): δ7.60- 7.49 (m, 5H), 7.48-7.41 (m, 2H), 7.41-7.34 (m, 2H), 7.19-7.09 (m,1H), 7.05- 6.98 (m, 1H), 4.43 (dd, J = 11.5, 6.0 Hz, 1H), 3.91-3.70 (m,2H), 2.41 (m, 1H), 2.13 (m, 2H), 1.99 (m, 1H) 178

459.2 Method E, RT = 1.223 min, 98.13% ¹H NMR (400 MHz, METHANOL-d₄): δ7.58- 7.48 (m, 4H), 7.46-7.39 (m, 2H), 7.38-7.33 (m, 2H), 7.28-7.23 (m,2H), 6.87- 6.81 (m, 2H), 4.41 (dd, J = 11.3, 6.8 Hz, 1H), 3.86-3.68 (m,5H), 2.38 (m, 1H), 2.10 (m, 2H), 1.97 (m, 1H) 179

473.3 Method E, RT = 1.221 min, 98.8% ¹H NMR (400 MHz, METHANOL-d₄): δ7.58- 7.48 (m, 4H), 7.46-7.39 (m, 2H), 7.38-7.32 (m, 2H), 7.05 (d, J =1.5 Hz, 1H), 6.73- 6.65 (m, 2H), 5.89 (s, 2H), 4.40 (dd, J = 11.3, 6.3Hz, 1H), 3.86-3.67 (m, 2H), 2.43-2.33 (m, 1H), 2.15- 2.06 (m, 2H),2.02-1.89 (m, 1H) 180

464.0 Method F, RT = 1.570 min, 97.5% ¹H NMR (400 MHz, DMSO- d₆): δ 8.97(s, 1H), 8.47- 8.42 (m, 1H), 7.86-7.80 (m, 2H), 7.77 (br. s., 1H), 7.57-7.42 (m, 4H), 7.37 (br. s., 1H), 7.31-7.24 (m, 2H), 6.61 (d, J = 7.09Hz, 1H) 4.55-4.43 (m, 1H), 4.29 (dd, J = 13.0, 5.9 Hz, 1H), 3.87- 3.75(m, 1H), 2.38-2.25 (m, 1H), 2.10-1.98 (m, 2H), 1.84- 1.74 (m, 1H) 181

451.3 Method F, RT = 2.095 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 8.93(s, 1H), 8.47 (d, J = 1.5 Hz, 1H), 8.38 (d, J = 1.2 Hz, 1H), 7.78 (d, J= 8.3 Hz, 2H), 7.41 (dd, J = 14.1, 8.7 Hz, 4H), 7.27 (d, J = 8.8 Hz,2H), 6.56 (d, J = 6.6 Hz, 1H), 4.40-4.29 (m, 1H), 3.82-3.60 (m, 2H),2.29 (m, 1H), 2.04-1.93 (m, 2H), 1.81 (m, 1H) 182

589.6 Method F, RT = 2.498 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 9.23(s, 1H), 8.05 (dd, J = 8.1, 1.2 Hz, 1H), 7.68-7.53 (m, 6H), 7.45-7.39(m, 2H), 7.38-7.31 (m, 3H), 6.70 (d, J = 6.6 Hz, 1H), 6.54 (s, 1H),4.43-4.30 (m, 1H), 3.82- 3.69 (m, 2H), 2.38-2.27 (m, 1H), 2.06-1.97 (m,2H), 1.88-1.74 (m, 1H), 1.01 (s, 9H) 183

555.5 Method F, RT = 2.105 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 8.93(s, 1H), 8.04 (dd, J = 7.8, 1.2 Hz, 1H), 7.67-7.53 (m, 2H), 7.46-7.39(m, 4H), 7.37-7.31 (m, 3H), 7.30- 7.23 (m, 2H), 6.60-6.49 (m, 2H),4.39-4.29 (m, 1H), 3.83-3.67 (m, 2H), 2.32- 2.25 (m, 1H), 2.04-1.95 (m,2H), 1.85-1.74 (m, 1H), 1.00 (s, 9H) 184

548.0 Method F, RT = 1.96 min, 98.67%, ¹H NMR (400 MHz, DMSO- d₆): δ9.86 (s, 1H), 9.01- 8.96 (m, 1H), 8.58-8.52 (m, 1H), 8.18-8.11 (m, 1H),8.09-8.02 (m, 1H), 7.76- 7.70 (m, 1H), 7.48-7.46 (m, 2H), 7.45-7.32 (m,6H), 4.50-4.40 (m, 1H), 3.85- 3.66 (m, 2H), 2.73 (s, 3H), 2.40-2.31 (m,1H), 2.08- 1.99 (m, 2H), 1.90-1.79 (m, 1H) 185

562.0 Method F, RT = 1.97 min, 96.7% ¹H NMR (400 MHz, DMSO- d₆): δ 9.82(s, 1H) 9.48 (br. s., 1H) 8.56 (s, 1H) 8.18 (br. s., 1H) 8.06 (dd, J =8.80, 2.45 Hz, 1H) 7.95 (s, 1H) 7.72 (d, J = 9.05 Hz, 1H) 7.59 (d, J =7.83 Hz, 1H) 7.29- 7.49 (m, 3H) 7.20-7.27 (m, 1H) 7.03-7.11 (m, 2H)4.40- 4.50 (m, 1H) 4.12 (d, J = 6.36 Hz, 2H) 3.69-3.85 (m, 2H) 2.79 (s,3H) 2.32-2.39 (m, 1H) 1.98-2.08 (m, 2H) 1.78-1.91 (m, 1H) 186

545.0 Method F, RT = 2.01 min, 97.9% ¹H NMR (400 MHz, DMSO- d₆): δ 8.71(s, 1H) 8.16 (t, J = 9.05 Hz, 1H) 7.95 (s, 1H) 7.59 (d, J = 7.83 Hz, 1H)7.30- 7.49 (m, 3H) 7.25 (d, J = 7.58 Hz, 1H) 7.18 (d, J = 9.05 Hz, 1H)7.04-7.14 (m, 4 H) 6.51 (s, 1H) 4.32-4.41 (m, 1H) 4.12 (d, J = 6.11 Hz,2H) 3.67-3.81 (m, 2H) 2.79 (s, 3H) 2.32 (m, 1H) 1.96-2.05 (m, 2H)1.74-1.86 (m, 1H) 187

545.1 Method F, RT = 1.968 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 8.71(s, 1H), 8.16 (t, J = 8.9 Hz, 1H), 7.73-7.63 (m, 3H), 7.59 (d, J = 6.1Hz, 2H), 7.49-7.32 (m, 5H), 7.18 (d, J = 8.6 Hz, 1H), 7.12 (d, J = 6.6Hz, 1H), 4.41-4.31 (m, 1H), 4.24 (d, J = 6.1 Hz, 2H), 3.73 (tt, J =12.4, 6.1 Hz, 2H), 2.88 (s, 3H), 2.31 (m, 1H), 2.06- 1.95 (m, 2H),1.86-1.73 (m, 1H) 188

531.0 Method F, RT = 1.985 min, 96% ¹H NMR (400 MHz, DMSO- d₆): δ 8.99(s, 1H), 8.70 (s, 1H), 8.15 (t, J = 8.8 Hz, 1H), 7.49 (d, J = 8.1 Hz,2H), 7.45- 7.32 (m, 7H), 7.18 (d, J = 8.6 Hz, 1H), 7.11 (d, J = 6.6 Hz,1H), 4.42-4.30 (m, 1H), 3.82-3.64 (m, 2H), 2.75- 2.70 (m, 3H), 2.30 (m,1H), 2.05-1.96 (m, 2H), 1.85- 1.72 (m, 1H) 189

453.1 Method F, RT = 1.728 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 8.32(s, 1H), 8.25 (d, J = 4.6 Hz, 1H), 8.14 (ddd, J = 10.1, 7.8, 1.8 Hz,1H), 7.85 (t, J = 9.2 Hz, 1H), 7.64 (d, J = 7.1 Hz, 2H), 7.51-7.42 (m,3H), 6.90-6.81 (m, 2H), 6.70 (dd, J = 8.4, 2.8 Hz, 1H), 4.40-4.30 (m,1H), 3.82- 3.67 (m, 5H), 2.30 (m, 1H), 2.04-1.94 (m, 2H), 1.85- 1.73 (m,1H) 190

484.0 Method F, RT = 1.607 min, 97% ¹H NMR (400 MHz, DMSO- d₆): δ 9.50(s, 1H), 8.98 (s, 1H), 7.48 (d, J = 8.6 Hz, 2H), 7.44-7.33 (m, 6H), 7.00(d, J = 6.8 Hz, 1H), 6.38 (s, 1H), 4.41-4.30 (m, 1H), 3.80- 3.64 (m,2H), 2.74 -2.68 (m, 3H), 2.35-2.23 (m, 4H), 2.04-1.96 (m, 2H), 1.81 (m,1H) 191

514.0 Method F, RT = 1.677 min, 96% ¹H NMR (400 MHz, DMSO- d₆): δ 9.13(s, 1H), 8.40 (d, J = 2.7 Hz, 1H), 7.93 (dd, J = 8.7, 2.8 Hz, 1H),7.51-7.45 (m, 2H), 7.44-7.32 (m, 8H), 6.73 (d, J = 6.8 Hz, 1H), 4.39-4.29 (m, 1H), 3.80-3.65 (m, 2H), 2.74-2.69 (m, 3H), 2.28 (m, 1H), 2.04-1.96 (m, 2H), 1.84 (m, 1H) 192

516.9 Method F, RT = 1.41 min, 94.7% ¹H NMR (400 MHz, DMSO- d₆): δ 9.14(s, 1H) 8.40 (d, J = 2.69 Hz, 1H) 8.21 (br. s., 1H) 7.93 (dd, J = 8.68,2.81 Hz, 1H) 7.72 (dd, J = 7.34, 1.71 Hz, 1H) 7.54 (d, J = 8.56 Hz, 2H)7.33-7.43 (m, 4 H) 7.12 (br. s., 1H) 6.74 (d, J = 6.85 Hz, 1H) 4.30-4.38(m, 1H) 3.67-3.79 (m, 2H) 3.21 (s, 3H) 2.23-2.35 (m, 1H) 1.95-2.03 (m,2H) 1.75- 1.88 (m, 1H) 193

510.0 Method F, RT = 1.43 min, 99.1% ¹H NMR (400 MHz, DMSO- d₆): δ 9.65(br. s, 1H) 8.55 (s, 1H) 8.33 (br. s., 1H) 7.93 (s, 1H) 7.74 (d, J =7.09 Hz, 1H) 7.52 (d, J = 7.82 Hz, 2H) 7.39 (d, J = 7.82 Hz, 2H) 7.28(d, J = 9.05 Hz, 2H) 6.82 (d, J = 9.05 Hz, 2H) 6.41 (d, J = 6.60 Hz, 1H)4.28-4.37 (m, 1H) 3.70-3.79 (m, 2H) 3.68 (s, 3H) 3.30 (s, 3H) 2.28 (m,1H) 1.95-2.04 (m, 2H) 1.72- 1.84 (m, 1H) 194

532.0 Method F, RT = 1.74 min, 98.2% ¹H NMR (400 MHz, DMSO- d₆): δ 8.70(s, 1H) 8.13 (t, J = 8.93 Hz, 1H) 7.93 (s, 1H) 7.74 (d, J = 7.09 Hz, 1H)7.53 (d, J = 7.83 Hz, 2H) 7.34-7.43 (m, 3H) 7.17 (d, J = 9.29 Hz, 1H)7.10 (d, J = 7.09 Hz, 1H) 4.31- 4.40 (m, 1H) 3.68-3.79 (m, 5 H) 2.30 (m,1H) 1.95-2.04 (m, 2H) 1.73-1.86 (m, 1H) 195

562.0 Method F, RT = 1.928 min, 94% ¹H NMR (400 MHz, DMSO- d₆): δ 9.81(s, 1H), 8.55 (s, 1H), 8.14 (d, J = 5.4 Hz, 1H), 8.06 (dd, J = 9.0, 2.7Hz, 1H), 7.76-7.64 (m, 4H), 7.59 (d, J = 6.4 Hz, 2H), 7.49-7.31 (m, 4H),4.49-4.37 (m, 1H), 4.24 (d, J = 6.4 Hz, 2H), 3.85- 3.65 (m, 2H),2.92-2.85 (m, 3H), 2.40-2.29 (m, 1H), 2.09-1.96 (m, 2H), 1.86 (m, 1H)196

523.1 Method F, RT = 1.665 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 8.56(s, 1H), 7.72- 7.64 (m, 3H), 7.62-7.55 (m, 2H), 7.49-7.25 (m, 6H),6.86-6.77 (m, 2H), 6.41 (d, J = 6.8 Hz, 1H), 4.38-4.28 (m, 1H), 4.24 (d,J = 6.1 Hz, 2H), 3.81-3.66 (m, 5H), 2.88 (s, 3H), 2.30 (m, 1H), 2.04-1.94 (m, 2H), 1.86-1.73 (m, 1H) 197

527.1 Method F, RT = 1.737 min, 95% ¹H NMR (400 MHz, DMSO- d₆): δ 8.99(s, 1H), 8.32 (s, 1H), 7.92-7.80 (m, 1H), 7.49 (d, J = 8.6 Hz, 2H),7.45- 7.32 (m, 6H), 6.89-6.81 (m, 2H), 6.70 (dd, J = 9.5, 2.4 Hz, 1H),4.40-4.30 (m, 1H), 3.81-3.68 (m, 5H), 2.72 (s, 3H), 2.30 (m, 1H), 2.05-1.93 (m, 2H), 1.86-1.72 (m, 1H) 198

528.1 Method F, RT = 1.816 min, 97% ¹H NMR (400 MHz, DMSO- d₆): δ 9.48(s, 1H), 8.22 (d, J = 2.4 Hz, 1H), 7.98 (d, J = 6.4 Hz, 1H), 7.80 (dd, J= 9.0, 2.7 Hz, 1H), 7.72-7.64 (m, 3H), 7.63-7.55 (m, 3H), 7.48- 7.38 (m,3H), 7.35 (d, J = 7.3 Hz, 1H), 4.47-4.38 (m, 1H), 4.24 (d, J = 6.4 Hz,2H), 3.83-3.65 (m, 2H), 2.88 (s, 3H), 2.37-2.27 (m, 1H), 2.06-1.95 (m,2H), 1.90- 1.77 (m, 1H) 199

509.1 Method F, RT = 1.674 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 8.98(br. s., 1H), 8.59 (s, 1H), 7.49 (d, J = 8.3 Hz, 2H), 7.45-7.26 (m, 8H),6.86-6.78 (m, 2H), 6.43 (d, J = 6.8 Hz, 1H), 4.39-4.29 (m, 1H),3.80-3.65 (m, 5H), 2.72 (s, 3H), 2.32-2.25 (m, 1H), 2.05-1.94 (m, 2H),1.85-1.72 (m, 1H) 200

435.0 Method F, RT = 1.647 min, 100% ¹H NMR (400 MHz, DMSO- d₆): δ 8.56(s, 1H), 8.24 (d, J = 4.9 Hz, 1H), 8.14 (dd, J = 10.0, 8.1 Hz, 1H), 7.64(d, J = 7.1 Hz, 2H), 7.51-7.42 (m, 3H), 7.30 (d, J = 9.0 Hz, 2H), 6.82(d, J = 8.8 Hz, 2H), 6.41 (d, J = 6.4 Hz, 1H), 4.39- 4.29 (m, 1H),3.81-3.67 (m, 5H), 2.30 (m, 1H), 2.05- 1.96 (m, 2H), 1.86-1.73 (m, 1H)201

528.0 Method F, RT = 1.69 min, 95.5% ¹H NMR (400 MHz, DMSO- d₆): δ 9.14(s, 1H) 8.41 (d, J = 2.69 Hz, 1H) 7.95 (dd, J = 8.80, 2.69 Hz, 1H) 7.59(d, J = 7.34 Hz, 1H) 7.33-7.48 (m, 8 H) 7.25 (d, J = 7.34 Hz, 1H) 6.74(d, J = 6.85 Hz, 1H) 4.31-4.40 (m, 1H) 4.12 (d, J = 5.87 Hz, 2H)3.69-3.81 (m, 2H) 2.80 (s, 3H) 2.30 (m, 1H) 1.96-2.06 (m, 2H) 1.76- 1.89(m, 1H) 202

528.1 Method F, RT = 1.646 min, 98% ¹H NMR (400 MHz, DMSO- d₆): δ 9.14(s, 1H), 8.41 (d, J =2.9 Hz, 1H), 7.94 (dd, J = 8.9, 2.6 Hz, 1H),7.73-7.63 (m, 3H), 7.59 (d, J = 5.4 Hz, 2H), 7.50-7.30 (m, 5H), 6.74 (d,J = 6.8 Hz, 1H), 4.41- 4.31 (m, 1H), 4.24 (d, J = 6.4 Hz, 2H), 3.82-3.64(m, 2H), 2.88 (s, 3H), 2.30 (m, 1H), 2.00 (m, 2H), 1.84 (m, 1H) 203

539.9 Method F, RT = 1.79 min, 95.46%, ¹H NMR (400 MHz, DMSO- d₆): δ9.86 (s, 1H), 9.01 (s, 1H), 8.58-8.52 (m, 1H), 8.18-8.11 (m, 1H), 8.09-8.02 (m, 1H), 7.76-7.70 (m, 1H), 7.48 (s, 2H), 7.45-7.32 (m, 6H),4.50-4.40 (m, 1H), 3.85-3.66 (m, 2H), 2.73 (s, 3H), 2.40-2.31 (m, 1H),2.08-1.99 (m, 2H), 1.90- 1.79 (m, 1H) 204

562.1 Method E, RT = 1.916 min, 97.167% ¹H NMR (400 MHz, DMSO- d₆): δ9.24 (s, 1H), 8.75 (d, J = 2.4 Hz, 1H), 8.11 (dd, J = 8.6, 2.4 Hz, 1H),7.88 (d, J = 8.6 Hz, 1H), 7.70 (s, 1H), 7.67-7.56 (m, 6H), 7.49 (t, J =7.8 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 6.73 (d, J = 7.1 Hz, 1H),4.54-4.46 (m, 1H), 4.30-4.21 (m, 3H), 3.87- 3.79 (m, 1H), 2.89 (s, 3H),2.37-2.28 (m, 1H), 2.04- 1.94 (m, 2H), 1.85-1.73 (m, 1H). 205

528.1 Method E, RT = 1.761 min, 98.58% ¹H NMR (400 MHz, DMSO- d₆): δ8.95 (s, 1H), 8.75 (d, J = 2.4 Hz, 1H), 8.10 (dd, J = 8.7, 2.6 Hz, 1H),7.88 (d, J = 8.6 Hz, 1H), 7.73-7.57 (m, 3H), 7.51-7.37 (m, 4H), 7.27 (d,J = 8.8 Hz, 2H), 6.61 (d, J = 6.8 Hz, 1H),4.52- 4.44 (m, 1H), 4.29-4.21(m, 3H), 3.86-3.77 (m, 1H), 2.89 (s, 3H), 2.31 (m, 1H), 2.04-1.91 (m,2H), 1.83- 1.71 (m, 1H). 206

528.1 Method E, RT = 1.758 min, 97.024% ¹H NMR (400 MHz, DMSO- d₆): δ8.95 (s, 1H), 8.75 (d, J = 2.2 Hz, 1H), 8.11 (dd, J = 8.6, 2.4 Hz, 1H),7.87 (d, J = 8.6 Hz, 1H), 7.72-7.37 (m, 7H), 7.28 (d, J = 9.0 Hz, 2H),6.60 (d, J = 7.1 Hz, 1H), 4.52- 4.43 (m, 1H), 4.29-4.20 (m, 3H),3.87-3.78 (m, 1H), 2.91-2.86 (m, 3H), 2.31 (m, 1H), 2.03-1.94 (m, 2H),1.83-1.72 (m, 1H). 207

562.1 Method E, RT = 1.914 min, 97.60% ¹H NMR (400 MHz, DMSO- d₆): δ9.24 (s, 1H), 8.75 (d, J = 2.4 Hz, 1H), 8.11 (dd, J = 8.8, 2.4 Hz, 1H),7.88 (d, J = 8.6 Hz, 1H), 7.72-7.55 (m, 7H), 7.49 (t, J = 7.6 Hz, 1H),7.43-7.37 (m, 1H), 6.73 (d, J = 7.1 Hz, 1H), 4.54-4.46 (m, 1H),4.29-4.22 (m, 3H), 3.87-3.78 (m, 1H), 2.89 (s, 3H), 2.37-2.28 (m, 1H),2.04-1.94 (m, 2H), 1.85- 1.73 (m, 1H). 208

528.0 Method F, RT = 1.85 min, 94.9% ¹H NMR (400 MHz, DMSO- d₆): δ 9.49(s, 1H) 8.22 (d, J = 2.45 Hz, 1H) 8.01 (m, 1H) 7.80 (dd, J = 8.93, 2.81Hz, 1H) 7.56-7.63 (m, 2H) 7.33- 7.48 (m, 6 H) 7.25 (d, J = 7.58 Hz, 1H)6.51 (s, 1H) 4.37-4.47 (m, 1H) 4.12 (d, J = 5.87 Hz, 2H) 3.65-3.83 (m,2H) 2.79 (s, 3H) 2.29- 2.38 (m, 1H) 1.97-2.06 (m, 2H) 1.77-1.88 (m, 1H)209

484.0 Method F, RT = 1.606 min, 99% ¹H NMR (400 MHz, DMSO- d₆): δ 10.22(s, 1H), 7.49 (d, J = 8.3 Hz, 2H), 7.44-7.30 (m, 7H), 6.82 (d, J = 6.8Hz, 1H), 5.86 (s, 1H), 4.42-4.29 (m, 1H), 3.82-3.63 (m, 2H), 2.72 (s,3H), 2.30 (m, 1H), 2.13 (s, 3H), 2.05-1.94 (m, 2H), 1.88-1.74 (m, 1H)210

548.0 Method F, RT = 1.875 min, 99% ¹H NMR (400 MHz, DMSO- d₆): δ 9.44(s, 1H), 8.97 (br. s., 1H), 8.68 (d, J = 2.7 Hz, 1H), 8.12 (d, J = 2.4Hz, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.52- 7.44 (m, 2H), 7.43-7.32 (m,6H), 6.85 (d, J = 6.8 Hz, 1H), 4.43-4.30 (m, 1H), 3.81-3.62 (m, 2H),2.72 (s, 3H), 2.35-2.24 (m, 1H), 2.04-1.96 (m, 2H), 1.91- 1.78 (m, 1H)

It will be evident to one skilled in the art that the present disclosureis not limited to the foregoing illustrative examples, and that it canbe embodied in other specific forms without departing from the essentialattributes thereof. It is therefore desired that the examples beconsidered in all respects as illustrative and not restrictive,reference being made to the appended claims, rather than to theforegoing examples, and all changes which come within the meaning andrange of equivalency of the claims are therefore intended to be embracedtherein.

What is claimed is:
 1. A compound of formula I

where: Ar¹ is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl,pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl,imidazolyl, oxazolyl, thiazolyl, triazinyl, oxadiazolyl, thiadiazolyl,or benzodioxyl, and is substituted with 1-3 substituents selected fromcyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, and SO₂R⁶;Ar² is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, or pyrazinyl, and issubstituted with 0-3 substituents selected from cyano, halo, alkyl,haloalkyl, alkoxy, and haloalkoxy; Ar³ is aryl or heteroaryl, and issubstituted with 0-3 substituents selected from cyano, halo, alkyl,haloalkyl, hydroxyalkyl, alkoxyalkyl, (NR¹R²)alkyl, (CO₂R³)alkyl,(CONR⁴R⁵)alkyl, (SO₂R⁶)alkyl, hydroxy, alkoxy, haloalkoxy, cycloalkoxy,NR¹R², CO₂R³, CONR⁴R⁵, SO₂R⁶, oxo, aryl, and heteroaryl; R¹ is hydrogen,alkyl, alkylcarbonyl, alkylsulfonyl, or haloalkylsulfonyl; R² ishydrogen or alkyl; or NR¹R² taken together is selected from azetidinyl,pyrrolidinyl, piperidinyl, piperazinyl, and morpholinyl, and issubstituted with 0-3 substituents selected from halo, alkyl, haloalkyl,alkoxy, and haloalkoxy; and R³ is alkyl or haloalkyl; R⁴ is hydrogen,alkyl, or (R⁷R⁸N)alkyl; R⁵ is hydrogen or alkyl; or NR⁴R⁵ taken togetheris selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, andmorpholinyl, and is substituted with 0-3 substituents selected fromhalo, alkyl, haloalkyl, alkoxy, and haloalkoxy; R⁶ is alkyl or R⁷R⁸N; R⁷is hydrogen or alkyl; R⁸ is hydrogen or alkyl; or NR⁷R⁸ taken togetheris selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, andmorpholinyl, and is substituted with 0-3 substituents selected fromhalo, alkyl, haloalkyl, alkoxy, and haloalkoxy; and X is hydrogen, halo,hydroxy, or alkoxy; or a pharmaceutically acceptable salt thereof.
 2. Acompound of claim 1 where: Ar¹ is phenyl, pyridinyl, pyridazinyl,pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl,isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazinyl,oxadiazolyl, thiadiazolyl, or benzodioxyl, and is substituted with 1-3substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy,haloalkoxy, alkylthio, and SO₂R⁶; Ar² is phenyl or pyridinyl substitutedwith 0-3 substituents selected from cyano, halo, alkyl, haloalkyl,alkoxy, and haloalkoxy; Ar³ is phenyl, pyridinyl, pyridazinyl,pyrimidinyl, pyrazinyl, pyridinonyl, pyrrolyl, furanyl, thienyl,pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl,triazinyl, oxadiazolyl, thiadiazolyl, or benzodioxyl and is substitutedwith 0-3 substituents selected from cyano, halo, alkyl, haloalkyl,hydroxyalkyl, alkoxyalkyl, (NR¹R²)alkyl, hydroxy, alkoxy, haloalkoxy,cycloalkoxy, NR¹R², CO₂R³, CONR⁴R⁵, and SO₂R⁶; R¹ is hydrogen, alkyl,alkylcarbonyl, alkylsulfonyl, or haloalkylsulfonyl; R² is hydrogen oralkyl; or NR¹R² taken together is selected from azetidinyl,pyrrolidinyl, piperidinyl, piperazinyl, and morpholinyl, and issubstituted with 0-3 substituents selected from halo, alkyl, haloalkyl,alkoxy, and haloalkoxy; R³ is hydrogen or alkyl; R⁴ is hydrogen, alkyl,or (R⁷R⁸N)alkyl; R⁵ is hydrogen or alkyl; or NR⁴R⁵ taken together isselected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, andmorpholinyl, and is substituted with 0-3 substituents selected fromhalo, alkyl, haloalkyl, alkoxy, and haloalkoxy; R⁶ is alkyl or R⁷R⁸N; R⁷is hydrogen or alkyl; R⁸ is hydrogen or alkyl; or NR⁷R⁸ taken togetheris selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, andmorpholinyl, and is substituted with 0-3 substituents selected fromhalo, alkyl, haloalkyl, alkoxy, and haloalkoxy; and X is hydrogen, halo,hydroxy, or alkoxy; or a pharmaceutically acceptable salt thereof.
 3. Acompound of claim 2 where Ar¹ is phenyl, pyridinyl, pyridazinyl,thiazolyl, or benzodioxoyl and is substituted with 1-3 substituentsselected from cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, andalkylthio; Ar² is phenyl or pyridinyl and is substituted with 0-3substituents selected from cyano and halo; Ar³ is phenyl, pyridinyl,pyrimidinyl, pyridinonyl, thienyl, pyrazolyl, isoxazolyl, benzodioxoyl,and is substituted with 0-3 substituents selected from cyano, halo,alkyl, haloalkyl, hydroxyalkyl, (NR¹R²)alkyl, alkoxy, haloalkoxy, NR¹R²,CO₂R³, CONR⁴R⁵, and SO₂R⁶.
 4. A compound of claim 1 where Ar¹ is phenylor pyridinyl and is -1,4-substituted with 1 halo, alkyl, haloalkyl,alkoxy, haloalkoxy or alkylthio substituent with respect to the nitrogenattached to Ar¹ and also is substituted with 0-2 fluoro substituents. 5.A compound of claim 1 where Ar² is phenyl or pyridinyl and issubstituted with 0-3 substituents selected from cyano, halo, alkyl,haloalkyl, alkoxy, and haloalkoxy.
 6. A compound of claim 1 where Ar² is-1,4-substituted with respect to the nitrogen and the Ar³ to which it isattached.
 7. A compound of claim 1 where Ar² is phenyl or pyridinyl andis -1,4-substituted with respect to the nitrogen and the Ar³ to which itis attached and is substituted with 0-3 substituents selected fromcyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy.
 8. A compound ofclaim 1 where Ar³ is phenyl, pyridinyl, pyrimidinyl, pyridinonyl,thienyl, pyrazolyl, isoxazolyl, benzodioxoyl, and is substituted with0-3 substituents selected from cyano, halo, alkyl, haloalkyl,hydroxyalkyl, (NR¹R²)alkyl, alkoxy, haloalkoxy, NR¹R², CO₂R³, CONR⁴R⁵,and SO₂R⁶.
 9. A compound of claim 1 where Ar³ is phenyl or pyridinyl andis substituted with 0-3 substituents selected from cyano, halo, alkyl,haloalkyl, hydroxyalkyl, (NR¹R²)alkyl, alkoxy, haloalkoxy, NR¹R², CO₂R³,CONR⁴R⁵, and SO₂R⁶.
 10. A compound of claim 1 where X is hydrogen.
 11. Acompound of claim 1 selected from the group consisting of1-(4-chlorophenyl)-3-[(3R)-1-{2′-methanesulfonamido-[1,1′-biphenyl]-4-yl}-2-oxopiperidin-3-yl]urea;1-[(3R)-1-{2′-methanesulfonamido-[1,1′-biphenyl]-4-yl}-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea;4′-[(3R)-3-{[(4-chlorophenyl)carbamoyl]amino}-2-oxopiperidin-1-yl]-3′-fluoro-[1,1′-biphenyl]-2-carboxamide;1-(4-chlorophenyl)-3-[(3R)-1-{2′-methanesulfonyl-[1,1′-biphenyl]-4-yl}-2-oxopiperidin-3-yl]urea;1-(4-chlorophenyl)-3-[(3R)-1-{3-fluoro-2′-methanesulfonyl-[1,1′-biphenyl]-4-yl}-2-oxopiperidin-3-yl]urea;3-[(3R)-1-[2′-(methanesulfonamidomethyl)-[1,1′-biphenyl]-4-yl]-2-oxopiperidin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea;3-(4-chloro-2-fluorophenyl)-1-[(3R)-1-[3′-(methanesulfonamidomethyl)-[1,1′-biphenyl]-4-yl]-2-oxopiperidin-3-yl]urea;1-(4-chlorophenyl)-3-[(3R)-1-[4-(2-methanesulfonamidopyridin-3-yl)phenyl]-2-oxopiperidin-3-yl]urea;3-(6-chloropyridin-3-yl)-1-[(3R)-1-{2′-methanesulfonamido-[1,1′-biphenyl]-4-yl}-2-oxopiperidin-3-yl]urea;3-(6-chloropyridin-3-yl)-1-[(3R)-1-[3′-(methanesulfonamidomethyl)-[1,1′-biphenyl]-4-yl]-2-oxopiperidin-3-yl]urea;3-[(3R)-1-[4-(2-methanesulfonamidopyridin-3-yl)phenyl]-2-oxopiperidin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea;3-[(3R)-1-[5-(2-methanesulfonamidophenyl)pyridin-2-yl]-2-oxopiperidin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea;3-[(3R)-1-[6-(2-methanesulfonamidophenyl)pyridin-3-yl]-2-oxopiperidin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea;3-[(3R)-1-{2′-methanesulfonamido-[1,1′-biphenyl]-4-yl}-2-oxopiperidin-3-yl]-1-[6-(trifluoromethyl)pyridin-3-yl]urea;1-(4-chloro-2-fluorophenyl)-3-[(3R)-1-[4-(2-methanesulfonamidopyridin-3-yl)phenyl]-2-oxopiperidin-3-yl]urea;1-[(3R)-1-{2′-methanesulfonamido-[1,1′-biphenyl]-4-yl}-2-oxopiperidin-3-yl]-3-(5-methyl-1,2-oxazol-3-yl)urea;3-[(3R)-1-[5-(2-fluorophenyl)pyridin-2-yl]-2-oxopiperidin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea;1-(5-chloropyridin-2-yl)-3-[(3R)-1-[2′-(methanesulfonamidomethyl)-[1,1′-biphenyl]-4-yl]-2-oxopiperidin-3-yl]urea;1-(6-chloropyridin-3-yl)-3-[(3R)-1-[2′-(methanesulfonamidomethyl)-[1,1′-biphenyl]-4-yl]-2-oxopiperidin-3-yl]urea;and3-[(3R)-1-{2′-methanesulfonamido-[1,1′-biphenyl]-4-yl}-2-oxopiperidin-3-yl]-1-[5-(trifluoromethyl)pyridin-2-yl]urea;or a pharmaceutically acceptable salt thereof.
 12. A compositioncomprising a compound of formula I, or a pharmaceutically acceptablesalt thereof, and a pharmaceutically acceptable carrier, diluent, orexcipient.
 13. A method for treating heart disease comprisingadministering a therapeutically effective amount of an FPR2 agonist to apatient in need thereof.
 14. The method of claim 13 wherein the heartdisease is selected from the group consisting of angina pectoris,unstable angina, myocardial infarction, heart failure, acute coronarydisease, acute heart failure, chronic heart failure, and cardiaciatrogenic damage.
 15. The method of claim 13 wherein the treatment ispost myocardial infarction.